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Abstract 
 
The bone morphogenetic proteins (BMPs) are small cystine-knot-containing 
cytokines that serve pivotal functions during the development of a wide range of 
tissues. Consisting of approximately twenty structurally and functionally related 
proteins, the BMP family makes up the largest branch of the transforming growth 
factor beta (TGF-β) superfamily. At least three of the BMPs have the ability to bind to 
heparan sulphate (HS) and heparin, which are highly sulphated, complex 
polysaccharides that are found in abundance on cell surfaces and in the extracellular 
matrix. The functional significance of these interactions remains unclear, but it has 
been demonstrated that BMPs -2 and -4 bind to HS/heparin via a small cluster of basic 
amino acids in their N-terminal regions. BMP-7 has also been shown to interact with 
HS and heparin. However, it belongs to a different BMP sub-group to BMPs -2 and -
4, and it differs from them considerably in this key N-terminal region. This raises the 
question as to where the HS/heparin-binding site of BMP-7 is situated. The aim of this 
study was to answer this question using a combination of predictive computational 
molecular docking calculations, site-directed mutagenesis techniques and heparin-
affinity chromatography. 
The findings from a series of predictive docking calculations suggested that 
BMP-7 binds to HS/heparin through three basic residues close to the C-terminal ends 
of each of its constituent monomers. However, experimental studies have shown that 
this is unlikely, as removing two of these three basic residues from each monomer had 
no affect on the heparin-binding affinity of BMP-7. The same was true when two of 
seven basic residues were removed from the N-terminal regions of each BMP-7 
monomer, both alone and in combination with the C-terminal mutations. Further 
investigation is therefore required in order to resolve this matter. 
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Chapter 1: Introduction 
 
1.1 Bone morphogenetic proteins 
 
1.1.1 Discovery and early work 
 
The study of the bone morphogenetic proteins (BMPs) began in the 1960s 
when Marshall R. Urist first discovered their activity whilst searching for the 
principles that give bone its regenerative capacity. The pioneering work of Urist 
(1965) demonstrated that demineralised bone matrix had the ability to induce de novo 
bone formation when ectopically implanted in subcutaneous and intramuscular 
pockets in a number of host animals, including rats and rabbits. Reddi and Huggins 
(1972) later revealed that the observed matrix-induced bone formation occurred via a 
tightly coordinated sequential cascade of events. The first step in this process was 
chemotaxis, in which the demineralised bone matrix implant was colonised by 
migrating mesenchymal cells. These mesenchymal cells proliferated before 
differentiating into cartilage-forming cells (chondroblasts and chondrocytes). 
Following this, vascular invasion of the site occurred, and differentiated osteoblast 
and osteoclast bone cells began to appear in the area. These bone cells gradually 
removed the cartilage and deposited new bone in its place. This process recapitulated 
all of the events that occur during embryonic skeletogenesis in the limb bud and 
fracture healing in developed bones (Reddi and Huggins, 1972; Reddi, 1981). 
Together, these studies therefore suggested that the demineralised bone matrix 
extracts contained the key signals that are required for bone morphogenesis. 
These early findings demonstrated the importance and considerable 
regenerative potential of the matrix factors, and provoked the interest of both skeletal 
and developmental biologists. However, the identities of the proteins within the matrix 
extracts that were responsible for the bone inductive properties remained unknown 
until the first human BMPs were purified (Sampath et al., 1987; Luyten et al., 1989) 
and cloned (Wozney et al., 1988) many years later. 
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1.1.2 The BMP family 
 
Upon peptide sequencing and gene cloning, the BMPs were found to be 
members of the transforming growth factor beta (TGF-β) protein superfamily 
(Wozney et al., 1988). Whilst the members of this family fulfill an incredibly diverse 
range of functions (reviewed in Kingsley, 1994; Hogan, 1996b; Massague, 2000; 
Attissano and Wrana, 2002; Chang et al., 2002), they are structurally very closely 
related (Lin et al., 2006). TGF-β superfamily proteins display homology in their 
highly conserved pattern of seven characteristically-spaced cysteine residues (Herpin 
et al., 2004), which produces a common cystine-knot fold (Avsian-Kretchmer and 
Hsueh, 2004). They also share sequence similarity within these cystine-knot regions. 
The one exception in the BMP family is BMP-1, a metalloproteinase that is 
structurally unrelated to TGF-β (Mac Sweeney et al., 2008). BMP-1 exercises its pro-
BMP activity during morphogenesis by cleaving the extracellular BMP antagonist 
chordin (Pappano et al., 2003). It also serves to activate GDF-8 and BMP-11 by 
releasing them from their latent pro-protein complexes (Wolfman et al., 2003; Ge et 
al., 2005). 
Work carried out since the initial discovery of the first BMPs has shown that 
the BMP family contains around twenty cytokines, which are highly related both 
structurally and functionally (reviewed by Reddi, 1997; Ducy and Karsenty, 2000). 
Many of the BMP family cytokines were independently characterised prior to them 
being recognised as members of the larger BMP family. As a result, some of the 
BMPs were originally classified as osteogenic proteins (OPs), cartilage-derived 
morphogenetic proteins (CDMPs), or growth and differentiation factors (GDFs) 
(Ducy and Karsenty, 2000). However, it is now apparent that there is a high degree of 
overlap between these nomenclatures, and that these designations do not represent 
separate cytokine lineages. In many cases the terms BMP and GDF are redundant. An 
example of such a case is BMP-13, which is also known as GDF-6. 
Following phylogenetic analyses, a number of the BMPs have been grouped 
into sub-sets based on similarities in the amino acid sequences of their mature protein 
regions. These groupings are: BMPs -2 and -4; BMPs -3 and -3b; BMPs -5 to -8; 
BMPs -9 and -10; BMP-11 and GDF-8; and finally BMPs -12 to -14 (Kingsley, 1994; 
Hogan, 1996; Yamashita et al., 1996; Mehler et al., 1997; Ebendal et al., 1998). The 
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same phylogenetic analyses have also revealed that the BMPs that make up two of 
these sub-sets exhibit close homology to the Drosophila morphogens decapentaplegic, 
Dpp (BMPs -2 and -4) and glass bottom boat, Gbb (BMPs -5 to -8). Comparison of 
their mature protein sequences shows that the most obvious difference between these 
two sub-sets is that the Gbb-type BMPs possess considerably longer amino-terminal 
extensions upstream of their TGF-β-like cystine-knot domains than the Dpp-type 
BMPs. 
 
1.1.3 Synthesis and processing 
 
The BMPs, like other TGF-β family proteins, are initially translated as large 
monomeric pre-pro-proteins that are generally in the region of 400-500 amino acids in 
length (Jones et al., 1994). Following translation, these pre-pro-proteins undergo a 
number of processing events. First, cleavage takes place between the short signal 
peptide sequence and the pro-domain (Jones et al., 1994). Some of the BMPs, 
including BMP-2 and BMP-7 (Israel et al., 1992; Sampath et al., 1992; Jones et al., 
1994), are then glycosylated at a conserved N-glycosylation sequence (NXS/T) before 
dimerisation takes place. BMP dimerisation generally occurs via a covalent inter-
chain disulphide bridge (Griffith et al., 1996), although there are some exceptions to 
this. In the cases of GDFs -3 and -9, and also BMP-15, dimerisation occurs non-
covalently as they lack the fourth conserved cysteine residue that is required to form 
inter-chain disulphide bonds (Liao et al., 2003). Once dimerised, the pro-proteins are 
proteolytically cleaved at a dibasic arginine-X-X-arginine site to release the 30-38 
kiloDalton (kDa) mature BMP dimers from their latent complexes prior to secretion 
(Ozkaynak et al., 1992; Cui et al., 1998). It has been shown that the efficiency of this 
cleavage step is determined by the downstream sequences that lie adjacent to the 
precursor cleavage site (Constam and Robertson, 1999). 
In most instances, the mature BMP dimers are secreted without their pro-
regions, which dissociate after cleavage (Brown et al., 2005). However, there is 
evidence to suggest that the mature GDF-8 and BMP-9 dimers remain non-covalently 
associated with their pro-regions after secretion; for GDF-8, this association inhibits 
the binding of the mature ligand to its receptor (Thies et al., 2001), whereas the 
activities of BMP-9 and the BMP-9 dimer-pro-region complex are equal (Brown et 
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al., 2005). When expressed and characterised in Chinese hamster ovary (CHO) cells 
(Jones et al., 1994) or human embryonic kidney 293 (HEK 293) cells (Gregory et al., 
2005), the majority of the secreted mature BMP-7 dimers were also found to remain 
associated with their pro-regions. In this case, the non-covalent complexes of mature 
BMP-7 dimers and pro-BMP-7 domains had greater solubility in physiological buffers 
than the purified mature dimers alone (Jones et al., 1994). 
The monomeric constituents of the mature BMP dimers each contain around 
100-140 amino acid residues (Jones et al., 1994). Although the BMPs are normally 
homodimeric in nature, natural heterodimers are known to exist. The bioactivity of 
some of these heterodimers has been reported to be equal to, if not greater than, that of 
their homodimeric counterparts (Hazama et al., 1995). 
 
1.1.4 Structure 
 
The three-dimensional structures of a number of BMPs have been resolved to 
high resolution, and their coordinates have been deposited in the Research 
Collaboratory for Structural Bioinformatics (RCSB) Protein Data Bank (PDB) archive 
(http://www.rcsb.org/pdb). These structures include BMPs -1, -2, -3, -6, -7, -9 and 
GDF-5, with their respective PDB identifications being 3EDG, 3BMP, 2QCQ, 2R52, 
1LXI, 1ZKZ and 2BHK. In each of these reported structures, most of the N-terminal 
sequence that lies upstream of the cystine-knot domain remains unresolved and is 
therefore absent. It is likely that this component of the structures was not resolved as a 
result of it being disordered (Griffith et al., 1996; Greenwald et al., 2003). In contrast, 
the N-terminal extensions of TGF-βs -1, -2 and -3 were resolved due to them being 
held in place (close to the cystine-knot domains of the structures) by an additional 
disulphide bond (Daopin et al., 1992; Schlunegger and Grutter, 1992; Hinck et al., 
1996; Mittl et al., 1996). 
The available structures confirm that the BMPs, with the exception of BMP-1, 
possess the cystine-knot structural motif that is characteristic of all the TGF-β 
superfamily members (McDonald and Hendrickson, 1993). Examination of the X-ray 
crystal structure of BMP-7, which was first resolved by Griffith et al. (1996), reveals 
that these knots form the core of each BMP monomer and consist of three intra-chain 
disulphide bonds (Figure 1.1). Two of these bonds, which connect cysteine 2 to 
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cysteine 6, and cysteine 3 to cysteine 7, create a ring through which the third 
disulphide bond passes, linking cysteine 1 and cysteine 5. Emanating from this 
cystine-knot are two elongated, thin and slightly curved finger-like projections. Both 
of these projections are antiparallel beta-sheet structures, and are termed fingers 1 and 
2 (Figure 1.1). On the opposite side of the knot is an alpha-helix. In its monomeric 
form, this fold is often likened to an open left hand, with the beta-sheets making up 
the two fingers, the cystine-knot acting as the palm, and the helix as the wrist/thumb 
(Griffith et al., 1996). 
Upon dimerisation, the wrist/thumb region of one BMP monomer tucks into 
the concave face that is formed by the fingers of the other (Figure 1.2). In most cases 
(see section 1.1.3 for exceptions), a disulphide bond forms between the fourth 
conserved cysteine residues of each monomer to link the two together covalently 
(Figure 1.2). 
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Figure 1.1 The BMP-7 monomer fold 
A schematic (A) and ribbon (B) representation of a BMP-7 monomer. The cystine-
knot forms the core of each BMP monomer and consists of three intra-chain 
disulphide bonds. The first bond connects cysteine 2 to cysteine 6 and the second 
bond connects cysteine 3 to cysteine 7. A ring is created by these two bonds through 
which the third disulphide bond passes, linking cysteine 1 to cysteine 5. Two 
elongated, thin and slightly curved finger-like projections emanate from the cystine-
knot. Both of these projections are antiparallel beta-sheet structures, and are termed 
fingers 1 and 2 (shown in turquoise in B). On the opposite side of the knot is an alpha-
helix (shown in red in B). The side chains of the cysteine residues that partake in 
forming the cystine-knot can be seen in yellow in B. [Figure 1.1A adapted from that 
presented in Griffith et al., (1996). The image shown in Figure 1.1B was generated 
from the PDB file 1LXI using the Accelrys Discovery Studio software package]. 
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Figure 1.2 The BMP-7 dimer 
Views of the BMP-7 dimer shown as ribbon representations from the front (A) and 
top (B). Upon dimerisation, the helix of one BMP monomer tucks into the concave 
face that is formed by the fingers of the other. A disulphide bond forms between the 
fourth conserved cysteine residue of each BMP monomer to link the two together 
covalently. In the case of BMP-7, this residue is cysteine 103 (labeled in B). The side 
chains of the cysteine residues that partake in forming the cystine-knot can be seen in 
yellow. Alpha helices are shown in red and beta sheets are shown in turquoise. The 
images seen in this figure were generated from the PDB file 1LXI using the Accelrys 
Discovery Studio software package. 
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1.1.5 Biological function and clinical applications 
 
The hallmark of the BMPs is their striking ability to induce de novo bone 
formation in both orthotopic and ectopic sites in vivo by promoting osteoblast 
differentiation (Urist, 1965). This remarkable activity can also be demonstrated and 
measured in vitro with a bioassay that utilises the C2C12 myoblastic cell line 
(Katagiri et al., 1994). Following stimulation with BMPs, these cells undergo a 
transformation, transdifferentiating from cells of a myogenic fate into cells with an 
osteogenic phenotype. As the cells transdifferentiate, the expression of muscle-type 
marker proteins such as muscle creatine kinase (MCK) is down-regulated whilst the 
expression of osteoblastic marker proteins such as alkaline phosphatase (ALP) and 
osteocalcin are up-regulated. Given the fact that members of the BMP family have 
such potent bone-inducing abilities (Sampath et al., 1992), it is no surprise that the 
knockout of BMP genes in mice often results in skeletal abnormalities (Kingsley et 
al., 1992). However, due to the level of functional redundancy that exists between the 
numerous members of the BMP family, these abnormalities are often relatively minor. 
Since the discovery of the BMPs, their bone-inducing properties have been the 
subject of extensive research. Much of the research that has been carried out has been 
directed towards developing therapeutic strategies for the treatment of skeletal 
damage/loss that results from trauma, degenerative disease or ablative surgery 
(Warnke et al., 2004). Clinical studies have provided supportive evidence for the use 
of BMPs -2 and -7 in spinal fusion and the treatment of difficult bone fractures, 
nonunions and delayed unions (reviewed by White et al., 2007). A landmark in this 
research was the United States Food and Drug Administration (USFDA) approval 
being granted for the clinical use of BMP-7 (Stryker Corp., Kalamazoo, MI, 2001) 
and BMP-2 (Medtronic Sofamor Danek, Memphis, TN, 2002) for therapeutic 
applications like those described above (White et al., 2007). 
Despite the potent bone-inducing abilities of the BMPs, it has become 
apparent that the historical term ‘bone morphogenetic protein’ is now rather 
unsuitable and somewhat misleading. Although their name might suggest otherwise, 
extensive studies conducted since the BMPs gained their title have shown that BMP 
family members actually have a wide variety of pivotal roles outside skeletal tissue. 
These roles include the establishment of embryonic pattern formation and the 
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development and function of a number of organs (reviewed by Ducy and Karsenty, 
2000). For example, it has been demonstrated that BMP-9 is a regulator of hepatic 
glucose homeostasis (Chen et al., 2003), and that BMP-10 plays a crucial role in 
maintaining the proliferative activity of embryonic cardiomyocytes during the 
development of the heart (Chen et al., 2004). 
 
1.1.5.1 Bone morphogenetic protein-7 (BMP-7) 
 
A particularly interesting member of this protein family is BMP-7, also known 
as osteogenic protein-1 (OP-1). BMP-7 is a 34-38 kDa disulphide-linked homodimeric 
protein. Each of its constituent monomeric units is initially synthesised as a 431 amino 
acid pre-pro-protein, which consists of a 29 residue signal peptide, a 263 residue pro-
protein domain and a 139 residue mature protein domain. Once synthesised, this pre-
pro-protein is cleaved between its signal peptide and pro-domain, glycosylated and 
dimerised. The mature BMP-7 protein is then liberated from its pro-domain by a 
second proteolytic cleavage step before being secreted (Jones et al., 1994). 
BMP-7 was initially discovered in bone matrix based on its bone-inducing 
properties (Celeste et al., 1990; Ozkaynak et al., 1990), but like many of the other 
BMPs it has since been found to be a multifunctional cytokine. The key extraskeletal 
roles of BMP-7 were elucidated using BMP-7-deficient knockout mice (Dudley et al., 
1995; Luo et al., 1995). These studies have shown that the homozygous deletion of 
the BMP-7 gene results in perinatal lethality as a result of severe renal dysplasia, 
marked by the presence of small dysgenic kidneys that are almost completely absent 
of glomeruli (less than 3 glomeruli per histologic section compared with 
approximately 100 in normal mice). Although some functional redundancy is known 
to exist between members of the BMP family, this phenotype is not observed in other 
BMP knockouts. The same studies (Dudley et al., 1995; Luo et al., 1995) also 
revealed that BMP-7 function is essential for normal eye development, with BMP-7-
deficient mice displaying eye defects that originate during lens induction. 
Normal morphogenesis of the kidney is dependent on the specific interactions 
that take place between two early tissue components, known as the epithelial ureteric 
bud and the metanephric mesenchyme (Luo et al., 1995). Further investigation of the 
observed kidney abnormalities in BMP-7-deficient mice revealed that the absence of 
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BMP-7 causes a defect in these interactions, which are associated with mesenchymal-
to-epithelial transition (MET, Vukicevic et al., 1996). As a consequence, the 
metanephric mesenchymal cells fail to differentiate and instead undergo cell death by 
apoptosis. Together, these findings demonstrate that BMP-7 plays a unique and 
critical role during kidney development, acting as a regulator of MET, an early 
inducer of glomeruli formation, and also a mediator of branching morphogenesis 
(Piscione et al., 1997). 
After fulfilling its indispensable role during nephrogenesis, BMP-7 expression 
and activity persists in the adult kidney (Zeisberg et al., 2005; Wetzel et al., 2006) 
where it continues to serve another important function: maintaining tubular 
homeostasis (Kopp, 2002; Kalluri and Zeisberg, 2003). It has long been known that 
TGF-β1 is a mediator of renal fibrosis and that its increased expression is associated 
with the progression of chronic renal disease (Border and Noble, 1994; Sharma et al., 
2000). TGF-β1 acts as the main inducer of epithelial-to-mesenchymal transition 
(EMT) in adult tubular epithelial cells (Zeisberg and Kalluri, 2004), which is a route 
by which fibroblasts may be derived (Iwano et al., 2002). However, there is now 
evidence to suggest that BMP-7 acts as a physiological antagonist of this activity by 
stabilising the epithelial phenotype of tubular cells in vivo and in vitro (Simon et al., 
1999; Zeisberg, Hanai et al., 2003; Wetzel et al., 2006), and reversing TGF-β1-
induced EMT (Zeisberg et al., 2005). 
As discussed previously, the use of BMPs in the treatment of skeletal 
conditions following injury or surgery is well documented (reviewed by Granjeiro et 
al., 2005; White et al., 2007). Of particular interest for the future is the therapeutic 
application of BMPs in the repair of other organs. Using animal models of both acute 
and chronic renal injury, it has been demonstrated that BMP-7 is a prime example of a 
BMP family member that has considerable extraskeletal regenerative potential. In 
these settings, the endogenous expression of BMP-7 is substantially decreased. 
However, studies have shown that administration of exogenous BMP-7 has a 
remarkable effect: enhancing the repair of tubular epithelial injury by inducing MET, 
and significantly improving renal function (Vukicevic et al., 1998; Wang et al., 2001; 
Morrissey et al., 2002; Wang et al., 2003; Zeisberg, Bottiglio et al., 2003; Zeisberg, 
Hanai et al., 2003). BMP-7 is therefore not only a key component of the mechanism 
that gives the adult kidney its intrinsic capacity to repair epithelial damage, but also 
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has the potential for use as a drug in cases where this repair mechanism has failed. 
Notably, at the present time it appears that recombinant BMP-7 is the only agent that 
is able to halt and possibly reverse fibrosis in animal models of chronic kidney 
disease. 
 
1.1.6 Signaling 
 
Members of the BMP family elicit their diverse range of signaling functions 
by forming complexes with various combinations of a type I activin receptor-like 
kinase receptor (ALKs -2 to -7) and a type II BMP or activin receptor (BMPRII; 
ActRIIA and ActRIIB) (reviewed by Shi and Massague, 2003; Mazerbourg and 
Hsueh, 2006). These structurally related dimeric receptors consist of an N-terminal 
extracellular ligand-binding domain, a transmembrane region, and a C-terminal 
intracellular serine/threonine kinase domain (Mathews and Vale, 1991; Greenwald et 
al., 2003). Both the particular BMP ligand and the physiological context in which the 
complexes are formed dictate the combinations of type I and type II receptors that are 
engaged (Lin et al., 2006; Mazerbourg and Hsueh, 2006). However, while there is 
some selectivity as to which receptor combinations individual BMPs will interact 
with, there is also evidence of promiscuity (Mazerbourg and Hsueh, 2006). 
The structures of some of the BMP ligand-receptor complexes have been 
solved by X-ray crystallography and deposited in the RCSB PDB archive. The 
structures that are available at the present time include that of BMP-2 in complex with 
the extracellular domains of BMPRIA, also known as ALK-3 (Kirsch et al., 2000) and 
BMP-7 in complex with the extracellular domains of ActRIIA (Figure 1.3, Greenwald 
et al., 2003). These structural studies have revealed that the type I receptor chains 
interact with a number of amino acids in the wrist regions of the BMP dimers. These 
regions are situated close to the interfaces between the two constituent monomers, and 
each receptor chain can be seen to make contact with both monomers. The type II 
receptor chains each bind to a single BMP monomer, and interact with residues 
located in the knuckle regions on the convex faces of their finger-like protrusions 
(Figure 1.3). While the BMPs make extensive contacts with each of their individual 
receptors in the assembled ternary complexes, it has been shown that the extracellular 
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domains of the type I and type II receptors do not interact with each other (Kirsch et 
al., 2000; Greenwald et al., 2003). 
Unlike the type I receptors, the serine/threonine kinase activity of the type II 
receptors is constitutively active (Wrana et al., 1994; Attisano et al., 1996). Upon 
binding a dimeric BMP ligand, the type II receptor trans-phosphorylates the type I 
receptor at a glycine- and serine-rich sequence (the GS domain) that lies just upstream 
of its C-terminal kinase domain (Wrana et al., 1994). Once activated, the type I kinase 
phosphorylates and activates members of the Smad family of intracellular signal 
transducers, known as receptor-regulated Smad (R-Smad) proteins (Hoodless et al., 
1996; Liu et al., 1996; Kretzschmar et al., 1997; Massague and Wotton, 2000). 
The R-Smad proteins are divided into two sub-sets based on their signaling 
specificities (Smads -1, -5 and -8; Smads -2 and -3) and each set counteracts the 
activities of the other (Shi and Massague, 2003). The particular type I receptor that is 
employed in the signaling complex determines which R-Smad protein is activated; 
ALKs -1, -2, -3 and -6 phosphorylate R-Smads -1, -5 and -8, whereas ALKs -4, -5 and 
-7 phosphorylate Smads -2 and -3 (Mazerbourg and Hsueh, 2006). Following 
activation, the R-Smads interact and form heteromeric complexes with Smad-4, which 
is a common-mediator Smad (Co-Smad) (Lagna et al., 1996). These complexes 
translocate to the nucleus and regulate the transcription of target genes in conjunction 
with other nuclear transcription factors or co-activators (Chen et al., 1996; Liu et al., 
1996; Kretzschmar et al., 1997; Massague and Wotton, 2000). 
 29 
 
 
 
 
 
Figure 1.3 BMP-7 in complex with two ActRII extracellular domains 
Each ActRII type II receptor extracellular domain (ECD, shown in purple) binds to a 
single BMP monomer (shown in red, turquoise and white), interacting with residues 
located in the knuckle and tip regions on the convex faces of their finger-like 
protrusions. This image was generated from the PDB file 1LX5 using the Accelrys 
Discovery Studio software package. 
 
 
 
1.1.7 Regulation and localisation 
 
There are a number of mechanisms in place to ensure that the BMPs act in a 
controlled manner during development and in adult tissues. Firstly, the expression of 
the BMPs and their individual receptors is strictly regulated both spatially and 
temporally. For example, the expression of GDF-9 and BMP-15 is restricted to male 
and female germ cells (McGrath et al., 1995; Nicholls et al., 2009). Secondly, several 
high affinity BMP antagonist proteins are known to exist, and their expression is also 
tightly regulated (Dionne et al., 2001; Kim and Pleasure, 2003; Kusu et al., 2003). 
The activity of a BMP within a particular tissue compartment is therefore not only 
dependent on its own expression and that of its receptors, but also the presence or 
absence of its specific antagonist(s). 
Many of the BMP antagonists contain an identical or very similar cystine-knot 
structural motif to that found in their BMP ligands (Avsian-Kretchmer and Hsueh, 
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2006). They are therefore distant relatives of the TGF-β superfamily proteins and it 
has been suggested that the BMP ligands and such antagonists may have evolved from 
a common ancestor (Groppe et al., 2002). An example of a cystine-knot-containing 
BMP antagonist protein is noggin (Smith and Harland, 1992). The X-ray crystal 
structure of noggin in complex with BMP-7 was the first of any of the antagonist 
structures to be solved (Groppe et al., 2002). This structure revealed that noggin 
antagonises the activity of its BMP ligands by forming a clamp-like structure around 
them (Figure 1.4). In doing so, noggin masks both the type I and type II receptor-
binding epitopes of its BMP ligands, and effectively mimics the binding mode of the 
heterotetrameric receptor assembly. 
Another BMP antagonist protein is sclerostin (Balemans et al., 2001). 
Interestingly, it has been reported that noggin and sclerostin are able to directly 
interact with high affinity and attenuate the BMP antagonistic abilities of each other 
(Winkler et al., 2004). As a result, BMP activity is facilitated rather than being limited 
when these two antagonists are co-localised. This unexpected and remarkable finding 
adds yet another level of complexity to the way in which BMP-driven processes are 
finely controlled. 
Finally, it has been observed that the BMPs function in a highly localised 
autocrine or paracrine manner (Grimsrud et al., 1999; Miller et al., 2000). However, 
after being liberated from their pro-domains by proteolytic cleavage and subsequently 
secreted, the mature BMP proteins are small, soluble and freely diffusible. This 
observation therefore raises a question as to how the distribution of these mature BMP 
proteins is so locally restricted. Because some of the BMPs have been found to bind to 
heparan sulphate (HS) and heparin (Ruppert et al., 1996; Ohkawara et al., 2002; Irie 
et al., 2003; Takada et al., 2003), one possible answer to this question is that the 
BMPs remain localised by interacting with these cell-surface and extracellular matrix 
glycosaminoglycans (GAGs) close to their sites of secretion. 
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Figure 1.4 BMP-7 in complex with noggin 
The X-ray crystal structure of BMP-7 (red, turquoise and white) in complex with its 
antagonist noggin (light brown) shows that noggin antagonises the activity of its BMP 
ligands by forming a clamp-like structure around them. In doing so, noggin masks 
both the type I and type II receptor-binding epitopes of its BMP ligands. Two short 
polyglycine loops (GGGGGAA) in the noggin structure, which link the clamp-like 
noggin dimer to two extended ‘clip’ segments, remain unresolved due to their 
flexibility (Groppe et al., 2002). This image was generated from the PDB file 1M4U 
using the Accelrys Discovery Studio software package.  
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1.2 Heparan sulphate and heparin 
 
1.2.1 What is heparan sulphate? 
 
Heparan sulphate (HS) is a complex sulphated polysaccharide. It is produced 
by nearly every cell type in metazoan organisms and is found almost ubiquitously on 
cell surfaces and in the extracellular matrix (ECM) (Gallagher et al., 1986; Esko and 
Selleck, 2002). HS is a member of the glycosaminoglycan (GAG) family of 
carbohydrates, which are long linear polysaccharides that are composed of a repeating 
disaccharide unit. As shown later in Figure 1.5, in HS, the disaccharide unit consists 
of a uronic acid residue [either β-D-glucuronic acid (GlcA), GlcA O-sulphated at C-2 
(GlcA2S), α-L-iduronic acid (IdoA), or IdoA O-sulphated at C-2 (IdoA2S)] and a 
derivative of the amino sugar glucosamine [either N-acetyl-α-D-glucosamine 
(GlcNAc), N-sulphated-α-D-glucosamine (GlcNS) or unsubstituted α-D-glucosamine 
(GlcNH3)] that is variably O-sulphated (comprehensively reviewed by Lindahl and 
Hook, 1978; Esko and Selleck, 2002). 
 
1.2.2 Heparan sulphate biosynthesis and diversity 
 
Unlike the synthesis of nucleic acids or proteins, the process by which HS 
chains are synthesised does not depend on a template macromolecule that codes for 
the exact sequence of building blocks in a new chain, and that is faithfully replicated 
to produce identical copies of that chain over and over again. Instead, the chains are 
generated by the concerted action of a large repertoire of biosynthetic enzymes whose 
presence and relative activities vary in a tissue-specific fashion (Esko and Lindahl, 
2001). A brief overview of this process is provided below. 
HS chains are assembled in the Golgi apparatus while attached to a 
proteoglycan (PG) core protein, yielding heparan sulphate proteoglycans (HSPGs) 
(Silbert, 1982; Stow et al., 1985; Carlsson et al., 2008). It is in this form that HS is 
found on cell surfaces and in the ECM. Proteoglycans are highly glycosylated 
glycoproteins that have one or more covalently attached GAG chains. A number of 
PG core proteins have been characterised. Amongst these proteins are the four 
members of the membrane-spanning syndecan family (Bernfield et al., 1992), the six 
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members of the glycosylphosphatidylinositol (GPI)-linked glypican family (Filmus 
and Selleck , 2001) and the basement membrane PGs perlecan and agrin (Iozzo et al., 
1994; Cole and Halfter, 1996). 
HS is initially synthesised as an unsulphated precursor polysaccharide known 
as heparan or N-acetylheparosan (Gallagher and Walker, 1985). The heparan chains 
are attached to specific serine residues at the GAG attachment sites on the core 
proteins via an O-linked tetrasaccharide linker (Esko and Zhang, 1996; Sugahara and 
Kitagawa, 2000). This linker is produced by the actions of various xylosyltransferase, 
galactosyltransferase and glucuronosyltransferase enzymes, and consists of a xylose 
residue, two galactose residues and a glucuronic acid residue (Ser-Xyl-Gal-Gal-GlcA) 
(Kitagawa et al., 1998; Almeida et al., 1999; Okajima et al., 1999; Wei et al., 1999; 
Gotting et al., 2000; Bai et al., 2001). Following the formation of the linker, a 
GlcNAc residue is added (Fritz et al., 1994) and the heparan chains are elongated by 
the stepwise addition of alternating GlcA and GlcNAc residues to a final length that is 
generally between 40 and 160 disaccharides (Esko and Selleck, 2002). This chain 
polymerisation process depends on the actions of specific glycosyltransferase 
enzymes, which are members of the exostosin (EXT) family of tumour suppressors 
(McCormick et al., 2000; Senay et al., 2000; Kim et al., 2001). 
While the heparan chains are still undergoing chain extension, the incorporated 
disaccharide units are subjected to a sequential series of complex modification 
reactions. Firstly, the N-acetyl groups of GlcNAc residues may be replaced with N-
sulphate groups (forming GlcNS) by dual-function N-acetylglucosamine N-
deacetylase/N-sulfotransferase (NDST) enzymes (Brandan and Hirschberg, 1988; 
Hashimoto et al., 1992; Wei et al., 1993; Aikawa et al., 2001). This modification not 
only marks the beginning of the transformation of heparan to HS, but also gives rise to 
the basic domain structure of HS (described in section 1.2.3 below). Secondly, 
glucuronic acid (GlcA) residues that are situated immediately adjacent to the reducing 
side of GlcNS moieties may be converted into iduronic acid (IdoA) (Jacobsson et al., 
1984). This epimerisation reaction is catalysed by the glucuronyl C5-epimerase 
enzyme (Malmstrom et al., 1980; Campbell et al., 1994). Thirdly, IdoA residues, and 
occasionally GlcA residues (Bienkowski and Conrad, 1985; Fedarko and Conrad, 
1986), may be modified by sulphation at their C-2 position by heparan sulphate 2-O-
sulphotransferase (HS2ST), producing IdoA2S and GlcA2S (Bai and Esko, 1996; 
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Kobayashi et al., 1996; Kobayashi et al., 1997). Finally, the disaccharides may also be 
sulphated at the C-6 position of the glucosamine residue by a heparan sulphate 6-O-
sulphotransferase (HS6ST) variant (Habuchi et al., 1995, 1998, 2000), and more 
rarely at the C-3 position of glucosamine by an isoform of heparan sulphate 3-O-
sulphotransferase (HS3ST) (Liu et al., 1996; Shworak et al., 1997, 1999). 
A fundamentally important point here is that the modifications described 
above are by no means comprehensive as the reactions do not go to completion 
(Lindahl and Hook, 1978; Kusche and Lindahl, 1990). Therefore, the extent to which 
individual disaccharide units within a HS chain are modified by any of the 
aforementioned enzymes is highly variable, and means that the disaccharides can be 
found in a number of partially modified states. As a result, HS chains exhibit a high 
degree of microsequence diversity. Overall, as many as 48 disaccharide combinations 
could potentially occur, but only 23 have been identified in nature to date (Figure 1.5, 
Esko and Selleck, 2002). It is thought that restrictions on the biosynthetic process may 
account for the absence of the remaining 25 theoretical combinations (Esko and 
Selleck, 2002). These restrictions include the substrate specificities of the biosynthetic 
enzymes and their differing spatial and temporal expression patterns (Esko and 
Lindahl, 2001). Also, all of the enzymes that play a part in HS GAG synthesis [with 
the exception of one intraluminal HS3ST isoenzyme (Shworak et al., 1997)] are type 
II membrane proteins, which span the membranes of the Golgi apparatus (Pinhal et 
al., 2001). This physical arrangement of the enzymes within the Golgi apparatus 
restricts their interactions to two dimensions within a lipid lattice. 
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Figure 1.5 Disaccharide subunits of HS/heparin 
The 23 disaccharide units that have been identified in nature to date in HS/heparin. β-
D-GlcA-containing disaccharides are shown on the left, and those containing α-L-
IdoA are shown on the right. The C-4 hydroxyl groups of the uronic acid residues are 
not shown due to them normally being linked to C-1 of a derivative of α-D-
glucosamine in the preceding disaccharide unit. X = H or SO3-. [Image taken from 
Esko and Selleck (2002)]. 
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Figure 1.5 Disaccharide subunits of HS/heparin 
Please refer to the figure legend on the opposite page. 
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1.2.3 Heparan sulphate domains 
 
Typical HS chains contain relatively short but regularly spaced regions of high 
sulphation [known as N-sulphated (NS)- or S-domains] that are separated by longer 
regions of low modification [known as N-acetylated (NA)- or N-domains]. These N- 
and S-domains are linked by transition zones (T-zones), or NA/NS-domains (Turnbull 
and Gallagher, 1991; Murphy et al., 2004), which are regions that contain a mixture of 
N-acetylated and N-sulphated disaccharide units. A simple representation of this 
domain structure is shown in Figure 1.6. In most variants of HS, the S-domains are 
between 2-9 disaccharide units in length and the stretches of unmodified and partly 
modified sequence that separate them average 16-18 disaccharide units in length 
(Lyon and Gallagher, 1998). In highly sulphated HS chains, the S-domains are longer 
and situated closer together than those that are found in chains containing lower levels 
of sulphate modification (Lyon et al., 1994; Maccarana et al., 1996; Lyon and 
Gallagher, 1998). 
The combination of the variability in its domain organisation and the diversity 
of its disaccharide units results in HS being a highly structurally heterogenous GAG. 
Despite this heterogeneity, the existence of such well-ordered domain patterns 
suggests that the modification of heparan chains takes place in a manner that is at least 
partially organised rather than occurring randomly (Lindahl et al., 1998). 
 
 
 
 
 
 
 
 
Figure 1.6 HS domain structure 
HS chains contain regularly spaced regions of high sulphation (S-domains, blue) that 
are separated by regions of low sulphate modification (N-domains, silver). These N- 
and S-domains are linked by transition zones (T-zones, orange), which are regions 
that contain a mixture of N-acetylated and N-sulphated disaccharide units. This 
diagram is based on that presented by Murphy et al., 2004. 
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1.2.4 Heparin 
 
Heparin is a highly sulphated relative of HS that is primarily found in the 
granules of mast cells (Lindahl and Hook, 1978). Heparin chains are mainly 
composed of trisulphated IdoA2S-GlcNS6S disaccharide units (Dietrich et al., 1973; 
Silva and Dietrich, 1975 and references within). This repeating unit is structurally 
similar to those found within the S-domains of HS chains, albeit with an even higher 
degree of sulphation. It can therefore be said that heparin chains resemble extensively 
modified, extended HS S-domains (Kreuger et al., 2006). Because heparin is so rich in 
sulphate and carboxyl groups, it has the highest negative charge density of any known 
biological macromolecule (Salmivirta et al., 1996). 
The solution conformation of the main repeating structure that is found within 
heparin chains was characterised by Mulloy et al. (1993) using a combination of 
nuclear magnetic resonance (NMR) spectroscopy and molecular modelling 
techniques. This study demonstrated that heparin chains have a right-handed helical 
structure and that each turn of the helix contains approximately four residues. The 
sulphate groups of heparin chains are positioned in clusters on opposite faces of the 
helix in an offset manner (Figure 1.7), and with a periodicity of approximately 17 Å (1 
Å = 0.1 nm). A consequence of the high density of negatively charged groups that are 
found along heparin chains is that intra-chain like-charge repulsions occur between 
them. Because of this, and due to the fact that heparin chains exhibit limited rotation 
about their glycosidic linkages (Mulloy et al., 1994), the heparin helix is relatively 
rigid and straight, although a slight curve in the helical axis is apparent. In addition, 
the heparin helix is quite bulky due to its relatively large hydrodynamic volume. 
Because the S-domains of HS chains closely resemble heparin, it is likely that they 
also adopt a heparin-like structure. However, the unsulphated N-domains of HS differ 
in that they are more flexible and allow for some bending of the chains (Mobli et al., 
2008). 
In typical heparin chains prepared from different sources, it has been 
demonstrated that between 70 % and 100 % of the GlcA moieties are converted to 
IdoA (Hook et al., 1974; Rosenberg et al., 1978; Sudo et al., 2001). These IdoA 
residues (and their 2-O-sulphated IdoA2S counterparts) exhibit a remarkable 
conformational plasticity that is not found in GlcA residues. While the pyranose rings 
 39 
of GlcA residues are stable in the 4C1 chair conformation, those found in the IdoA 
residues of heparin chains (and presumably in the S-domains of HS chains) exist in a 
dynamic equilibrium between two solution conformations. These are the 1C4 chair 
conformation and the 2S0 skew-boat conformation (Ferro et al., 1990). It can be seen 
in Figure 1.7 that this interconversion causes very little disturbance to the glycosidic 
linkages of neighbouring residues, and therefore the overall shape of the 
polysaccharide chain is not greatly affected (Mulloy et al., 1993). However, it does 
add another level of variability and complexity to what are already structurally diverse 
biopolymers. 
Heparin is widely utilised therapeutically as an anticoagulant and it is readily 
commercially available. Due to its resemblance to the S-domains of HS, and the ease 
with which it can be obtained in good quantities, heparin is often used as a model 
compound in both theoretical and experimental studies of interactions that would 
generally involve HS in a physiological context. 
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Figure 1.7 Heparin structure 
Ball and stick (A and C) and space fill (B and D) representations of heparin 
dodecasaccharide NMR structures, in which all of the IdoA2S residues are in either 
the 1C4 (A and B) or 2S0 (C and D) conformations. It can be seen that heparin adopts a 
helical conformation and that its sulphate groups (sulphur atoms coloured yellow and 
oxygen atoms coloured red) are distributed along opposite faces of the helix in an 
offset manner. The images shown were generated from the PDB file 1HPN using the 
Accelrys Discovery Studio software package. 
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1.3 Heparan sulphate/heparin-protein interactions 
 
1.3.1 Nature of the interactions 
 
It is well documented that HS and heparin GAG chains have the ability to 
interact with a number of different proteins (Esko and Selleck, 2002). Such 
HS/heparin-protein binding interactions primarily utilise the most prominent feature 
of these GAG chains: their abundant sulphate groups. These highly acidic, negatively 
charged groups partake in ionic interactions with the side chains of positively charged, 
basic amino acid residues (arginine, lysine, and to a lesser extent, histidine) (Hileman 
et al., 1998). As has already been established, the helices of heparin chains and the S-
domains of HS chains are relatively bulky and rigid (Mulloy et al., 1993). They are 
therefore unable to access crevices or pockets within protein structures. Consequently, 
for an interaction to occur, the basic side chains must be exposed prominently on the 
surface of the protein. They must also be suitably spaced and oriented to match the 
pattern of sulphate groups along the HS/heparin chain. 
Because sulphate groups are present on opposite sides of the helices of heparin 
chains and the S-domains of HS chains, these structures have two faces that proteins 
can potentially bind to (Mulloy et al., 1993). This may permit large protein complexes 
to form on relatively short polysaccharide sequence elements, as is the case in the X-
ray crystal structure of two fibroblast growth factor-1 (FGF-1) ligands in complex 
with a heparin decasaccharide and two FGF receptor-2 (FGFR-2) ectodomains 
(Pellegrini et al., 2000). 
While it is clear that ionic bonds, which connect the sulphate groups of 
HS/heparin chains and the exposed basic side chains on protein surfaces, play an 
important part in HS/heparin-protein interactions, it should be noted that they are not 
the only contributors. In the case of the interaction between basic FGF (also known as 
bFGF or FGF-2) and heparin, Thompson et al. (1994) have demonstrated that a 
combination of hydrogen bonding, van der Waals forces and hydrophobic effects 
predominate, and that pure electrostatic interactions contribute only 30 % of the 
binding free energy. 
 42 
1.3.2 HS/heparin-binding sites on protein surfaces 
 
HS/heparin-binding sites on protein surfaces generally consist of a number of 
basic residues (typically 4-7) that are not interrupted by the presence of residues 
containing acidic side chains (Hileman et al., 1998). These basic residues may form a 
single patch of positive charge or be arranged in a linear fashion along a face of the 
protein or one of its component structural elements, such as an α-helix. Where the 
former is true, the positively charged patch may be present either as a result of the 
basic residues being located in close proximity in the primary protein sequence, or due 
to them having been brought together as a result of folding in the three-dimensional 
tertiary structure of the protein (Hileman et al., 1998 and references within). 
For linear arrays of basic residues, it is particularly important that the side 
chains are in positions that are easily accessible to the sulphates of the GAG chain, 
and that the path of the chain across them is free from any obstruction. This is because 
heparin chains and the S-domains of HS chains are relatively straight and rigid, as 
explained earlier (section 1.2.4). They are therefore unable to bend into crevices or 
around obstacles such as protein surface protrusions, carbohydrate chains that are 
attached to the glycosylation sites of glycoproteins, or even acidic side chains. They 
are also unable to flex sufficiently to wrap around protein surfaces to accommodate 
interactions with basic residues that are situated on different sides of the structures. 
While the S-domains of HS chains are relatively rigid, it was mentioned 
previously (section 1.2.4) that the unsulphated N-domains of HS GAGs offer these 
chains more flexibility and allow for some bending to occur. As noted by Gallagher 
(2001), it has been suggested that the flexibility of these N-acetyl-rich ‘spacer’ regions 
assists the simultaneous interaction of two S-domains within a single HS chain with 
dimeric proteins that possess a separate binding site on each of their subunits. 
Examples of proteins for which this is suggested to be the case include TGF-β (Lyon 
et al., 1997), interferon gamma (IFN-γ; Lortat-Jacob et al., 1995) and interleukin 8 
(IL-8; Spillmann et al., 1998). It has also been proposed that the flexibility of these N-
acetylated regions permits two spaced S-domains on the same HS/heparin chain to 
simultaneously interact with two HS/heparin-binding sites that are situated on 
opposite faces of the platelet factor 4 (PF4) protein (Stringer and Gallagher, 1997). 
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1.3.3 Specificity of HS/heparin-protein interactions 
 
Because heparin chains and the S-domains of HS chains are so negatively 
charged, one could assume that the interactions that take place between these GAGs 
and the exposed positively charged residues on protein surfaces occur simply as a 
result of structurally non-specific electrostatic encounters. While it is possible that this 
may be true in some instances, it is certainly not always the case. Indeed, for some 
proteins, high-affinity binding to HS/heparin GAGs is dependent on the presence of 
very specific saccharide sequences/structures within the chains. An example of such a 
protein is antithrombin III (ATIII), which requires a specific pentasaccharide that 
contains a central (and rare) 3-O-sulphate modification (Choay et al., 1983; Lindahl et 
al., 1984). 
There are also proteins that do not stringently require the presence of a unique 
saccharide sequence in order to bind to HS/heparin but clearly do not interact with 
these GAGs in a non-specific manner. Instead, the binding of these proteins to 
HS/heparin chains is dependent on the occurrence of a limited set of specific structural 
features/modifications. For example, the minimum requirement for the interaction of 
FGF-2 with HS/heparin is a pentasaccharide sequence in which the glucosamine 
moieties are N-sulphated and at least one of the uronic acid entities is a 2-O-sulphated 
IdoA residue (Kreuger et al., 2001 and references within). Based on these findings 
and those from other similar studies it is apparent that the degree of structural 
specificity varies considerably from one HS/heparin-protein interaction to another. 
Therefore, the minimal GAG sequences/modifications that different proteins require 
to be present for them to bind to HS/heparin chains needs to be determined on an 
individual basis. 
 
1.3.4 Biological consequences of HS/heparin-protein interactions 
 
The binding of a protein to HS/heparin GAG chains may serve a number of 
potential purposes. Firstly, such an interaction may protect a protein from proteolytic 
degradation. A fine example of a protein for which this is true is IFN-γ. Studies have 
shown that the carboxyl-terminal domain of IFN-γ is particularly susceptible to 
extensive proteolytic cleavage, and that this process results in the protein being 
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rapidly inactivated (Lortat-Jacob et al., 1996). However, it has also been revealed that 
IFN-γ is able to bind to HS/heparin with high affinity through sequences within the 
same carboxyl-terminal domain (Lortat-Jacob et al., 1991; Lortat-Jacob and Grimaud, 
1992). Further investigation of these interactions has demonstrated that the binding of 
IFN-γ to HS/heparin serves to limit the extent to which the carboxyl-terminal domain 
of IFN-γ is degraded, which in turn results in a substantial increase in IFN-γ activity 
by as much as six-fold due to its prolonged circulatory half-life (Lortat-Jacob et al., 
1996). 
Secondly, the interaction of a protein with HS/heparin GAGs may serve to 
restrict its diffusion following secretion. This is a particularly important function in 
the case of some small, soluble cytokines that would normally be readily diffusible 
but have a role that requires their distribution to be tightly controlled. A good example 
of such a protein is decapentaplegic (Dpp), the Drosophila morphogen that has close 
homology with BMPs -2 and -4. During development of the Drosophila wing, Dpp is 
produced by a stripe of cells along the anterior-posterior (A-P) compartment boundary 
(Posakony et al., 1990; Capdevila and Guerrero, 1994). Following secretion, Dpp 
forms an extracellular concentration and activity gradient, which is required for it to 
direct the anteroposterior patterning of the wing in a concentration-dependent manner 
(Belenkaya et al., 2004 and references within). Belenkaya et al. (2004) have provided 
evidence to support the idea that both the formation and maintenance of this gradient 
is dependent on the interaction of Dpp with dally and dally-like (dly), which are two 
Drosophila homologues of the glypican family of HS proteoglycans. They propose 
that Dpp moves across the cell surfaces by a process of restricted extracellular 
diffusion involving these glypican homologues. 
Thirdly, HS/heparin GAGs may act as catalysts of protein-protein interactions. 
A notable example of an instance in which HS/heparin oligosaccharides serve such a 
purpose is during the binding of the serine protease inhibitor antithrombin III to factor 
Xa, which is an interaction that plays a key part in helping to maintain normal blood 
flow by inhibiting the coagulation cascade (Chuang et al., 2001 and references 
within). Although antithrombin III circulates at a high concentration, it only becomes 
capable of efficiently antagonising the coagulating activity of factor Xa upon binding 
with high affinity to HS/heparin GAG chains that contain a specific pentasaccharide 
sequence (Choay et al., 1983; Lindahl et al., 1984). It has been demonstrated that 
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HS/heparin promotes this inhibition by inducing a conformational change in the 
structure of antithrombin III (Olson et al., 1981; Gettins et al., 1993). HS/heparin 
GAGs have also been shown to greatly enhance the rate at which antithrombin III 
inhibits the coagulating activity of thrombin by forming ternary complexes with these 
two proteins (Danielsson et al., 1986; Li et al., 2004). After promoting the initial 
encounter that takes place between antithrombin III and thrombin, the HS/heparin 
GAGs dissociate before the tightly bound inhibitor-protease complexes are rapidly 
cleared from circulation (Bourin and Lindahl, 1993; Kounnas et al., 1996). 
A different example of HS/heparin promoting protein-protein interactions 
arises from X-ray crystallographic studies that have been carried out on FGF-FGFR-
heparin complexes (where FGF is fibroblast growth factor and FGFR is FGF 
receptor). These studies have provided evidence to suggest that HS/heparin chains 
assist with the assembly and/or stabilisation of FGF-FGFR signaling complexes. In 
the X-ray crystal structure of a 2:2:1 FGF-1-FGFR-2-heparin complex (Pellegrini et 
al., 2000), one heparin decasaccharide links two FGF-1 ligands, each of which is 
bound to a FGFR-2 ectodomain. The FGF-1 ligands are shown to bind to opposite 
sides of the heparin oligosaccharide, highlighting the importance of the two-sided 
arrangement of the sulphate groups along the chain. While the heparin oligosaccharide 
can be seen to interact with both FGF-1 ligands, it only comes into contact with one of 
the FGFR-2 ectodomains due to its asymmetric arrangement within the core of the 
complex. Because there is little protein-protein interface between the two halves of the 
FGF-1-FGFR-2-heparin complex, Pellegrini et al. (2000) propose that the heparin 
oligosaccharide plays a critical role in FGF receptor dimerisation. 
By carrying out high-resolution size-exclusion chromatography (SEC) studies 
on FGF-1-FGFR-2-heparin complexes in solution, Robinson et al. (2005) have shed 
some light on a potential mode of assembly for the structure resolved by Pellegrini et 
al. (2000). The findings of Robinson et al. (2005) suggest that the first step in the 
assembly process involves the cooperative binding of two FGF-1 molecules to a 
single heparin oligosaccharide to produce a FGF-1 dimer. Based on the X-ray crystal 
structure displayed in Pellegrini et al. (2000), it is likely that this FGF-1 dimer lacks 
any inter-molecule protein-protein contacts. Once dimerised, FGF-1 recruits two 
FGFR-2 ectodomains to form a stable signaling complex. In the absence of heparin, 
Robinson et al. (2005) demonstrated that FGF-1 had no detectable affinity for FGFR-
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2. This may indicate that in addition to its role in dimerising FGF-1, heparin also 
induces a conformational change in FGF-1 that increases its affinity for FGFR-2 
(Gallagher, 2006). From these studies, it appears that heparin-protein interactions play 
a critical role in dictating both the mode of assembly and overall arrangement of the 
FGF-1-FGFR-2-heparin signaling complex. It may therefore be said that HS/heparin 
GAGs have a co-receptor function in this context. 
In an alternative X-ray crystallographic study, Schlessinger et al. (2000) 
resolved the structure of a 2:2:2 FGF-2-FGFR-1-heparin complex. This complex is 
symmetrical and consists of two identical 1:1:1 FGF-2-FGFR-1-heparin units. The 
two heparin decasaccharides are arranged non-reducing end to non-reducing end in a 
basic canyon that is situated at the membrane-distal end of the structure. Schlessinger 
et al. (2000) demonstrated that the heparin decasaccharides make numerous contacts 
with both FGF-2 and FGFR-1 within each 1:1:1 FGF-2-FGFR-1-heparin unit, and 
therefore augment the ligand-receptor interactions. They also showed that each 
heparin decasaccharide interacts with the FGFR-1 component of the adjoining 1:1:1 
FGF-2-FGFR-1-heparin unit to promote FGFR-1 dimerisation. However, in contrast 
to the structure published by Pellegrini et al. (2000), the two halves of the 
Schlessinger structure are held together by a number of protein-protein contacts. It 
therefore appears that the heparin oligosaccharides play a part in stabilising the 
complex rather than dictating its arrangement or mode of assembly. 
In the time since the two X-ray crystal structures described above were 
published (Pellegrini et al., 2000; Schlessinger et al., 2000), there has been much 
debate over which of them best represents the physiological FGF-FGFR-HS/heparin 
signaling complex. Although a considerable amount of time and effort has been 
invested in resolving this matter, there is still not a conclusive answer. Even so, it is 
clear that heparin-related GAGs play an important part in the FGF signaling process. 
While the heparin-binding properties of a number of proteins have been well 
studied (including those discussed above), there are other proteins that have been 
shown to bind to HS/heparin but have received much less attention in this context. 
The role of HS/heparin-binding for these proteins therefore remains unclear. A large 
and interesting family of proteins for which this is particularly true is the BMPs. 
 47 
1.4 HS/heparin-binding in the BMP family 
 
The first indication that members of the BMP family may have HS/heparin-
binding abilities came from the demonstration that both osteogenin (BMP-3) and 
BMP-2 bound to the heparin-affinity chromatography columns that were employed 
for their purification from demineralised bone matrix preparations (Sampath et al., 
1987; Wang et al., 1990). Since this time, the heparin-binding properties of the BMPs 
have been investigated a little further, with a particular focus on the Dpp-type BMPs 
(BMPs -2 and -4). By conducting a series of biosensor experiments at physiological 
pH and salt concentration, Ruppert et al. (1996) confirmed the heparin-binding ability 
of recombinant BMP-2, showing that it binds to immobilised heparin chains (Mr of 
around 16,000) with a dissociation constant (Kd) of approximately 20 nM. Using an 
embryonic chicken limb bud cell system, Ruppert et al. (1996) also showed that the 
addition of exogenous heparin potentiated the activity of recombinant BMP-2 in a 
dose dependent manner. 
Upon examining the effect that heparin and HS polysaccharides have on the 
activity of the BMPs in C2C12 mouse myoblast cells, Takada et al. (2003) reported 
similar findings to Ruppert et al. (1996). As discussed previously in section 1.1.5, the 
stimulation of C2C12 myoblast cells with BMPs causes them to transdifferentiate and 
begin to express osteoblastic markers such as alkaline phosphatase (Katagiri et al., 
1994). This is therefore an excellent in vitro cellular model system for the well-
established in vivo activity of the BMPs, due to the fact that injection or implantation 
of BMPs into muscle results in the initiation of new bone formation (Urist, 1965). 
Takada et al. (2003) demonstrated that the addition of exogenous heparin dose-
dependently potentiates the transdifferentiation of C2C12 cells when stimulated with 
BMPs -2 or -4. The same potentiating effect, albeit weaker, was observed when HS 
was used in place of heparin. However, chemically desulphated derivatives of heparin 
were shown to have lost their stimulatory capacity. 
While the studies described above have provided evidence to support the idea 
that HS/heparin GAGs are able to bind to the Dpp-type BMP family members and 
enhance their biological activity, the exact role that these sulphated GAGs play in 
BMP-mediated processes in vivo remains unclear. To date, the best insight into the 
potential function of HS/heparin GAGs in these processes comes from the study of 
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Drosophila Dpp itself. As explained in more detail in section 1.3.4, the correct 
patterning of the Drosophila wing requires the establishment of an extracellular Dpp 
concentration and activity gradient. Belenkaya et al. (2004) demonstrated that the 
formation and maintenance of this gradient occurs via a process of restricted 
extracellular diffusion, which is dependent on the interaction of Dpp with two 
Drosophila homologues of the mammalian glypican family of HS proteoglycans 
(dally and dly). Due to the high degree of homology between Dpp and BMPs -2 and -
4, it is possible that the patterning of vertebrate limbs and tissues by the Dpp-type 
BMPs is directed by a similar HS/heparin-dependent mechanism to that in 
Drosophila. Some early evidence to support this theory and suggest that the binding 
of the Dpp-type BMPs to HS/heparin may serve to restrict their diffusion in vivo can 
be found in a study published by Ohkawara et al. (2002). Ohkawara and colleagues 
demonstrated that in Xenopus embryos, a non-heparin-binding mutant of Xenopus 
BMP-4 exhibited a long-range signaling activity rather than the short-range action that 
was observed for the wildtype Xenopus BMP-4 protein. 
Although the HS/heparin-binding properties of the Gbb-type BMPs (BMPs -5 
to -8) have been little studied, work conducted in both our own laboratory 
(unpublished data) and that of Irie et al. (2003) has demonstrated that BMP-7 also has 
the ability to bind to HS/heparin GAGs. In addition to this, using rat osteosarcoma 
(ROS) 17/2.8 osteoblast-like cells, Irie et al. (2003) showed that the stripping of cell-
surface HS by digestion with heparitinase markedly reduced the phosphorylation of 
the R-Smads (Smads -1, -5 and -8) in response to BMP-7 stimulation. They also found 
that inhibiting the sulphation of cell-surface HS chains by growing the cells in the 
presence of chlorate resulted in the same outcome, as did adding exogenous heparin to 
the cell culture media. The same pattern of results was obtained when a similar study 
was carried out in our own laboratory using mouse C2C12 myoblast cells 
(unpublished data). Together, these studies suggest that cell-surface HS chains also 
play an important part in BMP-7-mediated cellular processes, although their function 
is once again unclear. Because the Gbb-type BMPs share close homology with each 
other, it is likely that HS also plays a part in the cellular processes that take place 
under the direction of BMPs -5, -6 and -8. 
Interestingly, in the functional studies described above, the addition of 
exogenous heparin to the cell culture media had the opposite effect on BMP-7 activity 
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to the effect it had on the activities of the Dpp-type BMPs at similar concentrations of 
GAG. In the cases of the Dpp-type BMPs, exogenous heparin potentiated their 
activity (Ruppert et al., 1996; Takada et al., 2003) whereas it was reported to decrease 
the activity of BMP-7 (Irie et al., 2003). This finding opens up the possibility that the 
function of heparin-related GAGs in BMP-mediated processes may differ from one 
BMP sub-group to another. 
Despite the present uncertainty surrounding the functional role that HS/heparin 
GAGs play in BMP-mediated processes, one thing that is now clear are the locations 
of the key HS/heparin-binding residues of BMPs -2 and -4. As shown in Figure 1.8, it 
has been demonstrated that these Dpp-type BMPs (and Dpp itself) bind to HS/heparin 
polysaccharides via a small cluster of basic arginine and lysine residues in their short 
N-terminal extensions, situated immediately upstream of the first of seven conserved 
cysteine residues that form their cystine-knot domains (Ruppert et al., 1996; 
Ohkawara et al., 2002; Akiyama et al., 2008). Because the BMPs are homodimeric 
proteins, BMPs -2 and -4 both possess two of these key basic residue clusters, one on 
each monomer. As a result, these proteins may either contain two independent 
HS/heparin-binding sites, or the clusters on each of the constituent monomers may 
cooperate to bind a single sulphated GAG chain between them. However, at the 
present time it is not yet understood which of these two binding site configurations is 
adopted by BMPs -2 and -4. 
It was mentioned briefly in section 1.1.2 that the most obvious difference 
between the Dpp-type and Gbb-type BMPs is in the length of their N-terminal 
extensions. At 36-37 residues in length, the N-terminal sequences of the Gbb-type 
BMPs are considerably longer than the 13-15 residue sequences that are found in their 
Dpp-type counterparts (Figure 1.8). However, an inspection of their protein sequences 
reveals that the distribution of basic residues also differs between the Dpp-type and 
Gbb-type BMPs (Figure 1.8). One notable difference is that unlike the Dpp-type 
BMPs, the Gbb-type BMPs exhibit an almost complete absence of basic amino acids 
in the region of their N-terminal extensions that lies immediately upstream of their 
first cysteine residue. As outlined above, the presence of a group of basic amino acids 
within this region of the protein has been shown to be an important requirement in 
order for HS/heparin-binding to take place in the cases of the Dpp-type BMPs. 
Regardless of the fact that BMP-7 is missing a number of key basic residues from this 
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particular section of its N-terminal extension, the aforementioned findings from the 
studies that were carried out in our own laboratory (unpublished data) and that of Irie 
et al. (2003) clearly show that it has the ability to interact with HS/heparin GAGs. 
This collection of observations and experimental findings therefore raises the question 
as to where the HS/heparin-binding site of BMP-7 is situated. 
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Figure 1.8 BMP N- and C-terminal sequences 
A comparison of the N- and C-terminal mature protein sequences of human BMP-2, 
Xenopus BMP-4 and human BMP-7. It can be seen that BMP-7, a gbb-type BMP, has 
a considerably longer N-terminal extension than the dpp-type BMPs (BMPs -2 and -
4). It is also apparent that the distribution of basic arginine and lysine residues differs 
between these two BMP sub-groups. Arginine and lysine residues that have been 
experimentally shown to play an important part in HS/heparin-binding in human 
BMP-2 and Xenopus BMP-4 are highlighted in red. Other arginine and lysine residues 
are highlighted in blue, and the conserved cysteine residues that form the cystine-knot 
are highlighted in yellow and numbered. The three basic residue clusters of BMP-7 
are labeled accordingly. 
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Figure 1.8 BMP N- and C-terminal sequences 
Please refer to the figure legend on the opposite page. 
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The mature human BMP-7 protein possesses a total of fifteen arginine and 
lysine residues. All but one of these basic residues lies within three short stretches of 
its amino acid sequence (Figure 1.8). The first stretch contains a cluster of six basic 
residues and can be found close to the beginning of the long N-terminal extension of 
BMP-7, upstream of the section of sequence that contains the key heparin-binding 
residues in BMPs -2 and -4. The second stretch contains a cluster of four basic 
residues and encompasses the region of sequence immediately upstream and 
downstream of the first cysteine residue. The third and final stretch contains a tight 
cluster of four basic residues and is located at the opposite end of the BMP-7 protein, 
in close proximity to its C-terminus. As can be seen in Figure 1.8, this C-terminal 
stretch of sequence is another example of a region in which the distribution of basic 
amino acids differs between BMP-7 and BMPs -2 and -4. Not only does BMP-7 
contain an additional basic residue within this region, but the four basic residues it 
contains are also clustered tighter together. Like the other two clusters of basic 
residues described here, this C-terminal basic cluster is conserved throughout the 
Gbb-type BMP family. To date, there is no evidence to suggest that basic residues in 
the C-terminal ends of BMPs -2 and -4 are involved in the interaction of these proteins 
with HS/heparin. However, because both the number and arrangement of the basic 
residues within this region differs between the Dpp-type and Gbb-type BMPs, one 
cannot rule out the possibility that C-terminal arginine and lysine residues may play a 
part in the binding of BMP-7 to these sulphated GAGs. 
Because the BMP-7 protein contains three basic residue clusters, there are a 
number of potential ways in which it may interact with HS/heparin GAGs. Firstly, any 
of the basic residue clusters described above could form a binding site on their own. 
Secondly, basic residues from different clusters on the same monomer may cooperate 
to form a binding site. Thirdly, basic residues from clusters in the same or different 
position on different covalently-linked monomers may cooperate to form a binding 
site. Due to the fact that these three options could potentially give rise to a multitude 
of different types of binding site, it is not possible to determine where the HS/heparin-
binding site of BMP-7 is situated based only on primary sequence data or an 
inspection of the published BMP-7 X-ray crystal structures. Therefore, further 
investigation is required in order to resolve this matter, which brings us to the aim of 
this study. 
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1.5 Aim 
 
The aim of this study is to determine the location of the HS/heparin-binding 
site of human BMP-7. To accomplish this goal, the locations of the key HS/heparin-
binding residues will first be predicted by carrying out a series of computational 
molecular docking calculations using published BMP-7 and heparin structures. Based 
on the results that are obtained from these docking calculations, site-directed 
mutagenesis techniques will be employed to produce mutant BMP-7 DNA expression 
constructs in which the predicted key basic residues will be substituted for alanine 
residues. These DNA constructs will subsequently be transfected into cultured cells to 
express mutant BMP-7 proteins. Once expressed, the heparin-binding abilities of these 
mutant proteins will be determined by subjecting them to heparin-affinity 
chromatography. Mutants that are found to lack the ability to bind to heparin, or 
whose heparin-binding affinity has been markedly reduced compared to that of the 
wildtype protein, will indicate the location of the HS/heparin-binding site of BMP-7. 
Comparison of the location of the HS/heparin-binding site of BMP-7 with that 
of BMPs -2 and -4 will provide insight into the extent to which members of the Gbb- 
and Dpp-type BMP sub-groups of this structurally homologous protein family differ 
in the way that they interact with HS/heparin. Moreover, any muteins that exhibit 
either a complete absence of or a marked reduction in heparin-binding affinity will be 
ideal for use in future functional studies to investigate the role that HS/heparin-
binding plays in BMP mediated processes. With recombinant BMP-7 already being 
licensed for clinical use for the treatment of skeletal damage/loss, and with further 
potential clinical applications, such studies may provide information that could help to 
determine whether or not heparin mimetics would be a useful ancillary in therapeutic 
products containing recombinant BMP-7. These studies might also help to determine 
whether heparin mimetics could be utilised to create an optimal extracellular 
environment for endogenous BMP-7 to function, thereby potentially avoiding the 
necessity to use exogenous BMP-7. 
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Chapter 2: Materials and methods 
 
2.1 Molecular docking studies 
 
Molecular docking studies were carried out according to the method described 
in Forster and Mulloy (2006) and Mulloy and Forster (2008). A brief outline of this 
method can be found below, with a more detailed account being provided in section 
3.2.1. 
Coordinates for the experimentally determined protein and oligosaccharide 
structures were derived from PDB files deposited in the Research Collaboratory for 
Structural Bioinformatics (RCSB) Protein Data Bank (PDB) archive 
(http://www.rcsb.org/pdb). The structural coordinates for the human BMP-7 protein 
monomer and dimer were taken from the files 1LXI (Greenwald et al., 2003) and 
1M4U (Groppe et al., 2002) respectively. Three heparin oligosaccharide ligands were 
used, one of which was an endecasaccharide [(GlcNS6S-IdoA2S)5-GlcNS6S] whilst 
the other two were pentasaccharides. As explained in section 3.2.1, the two iduronate 
residues in one of these pentasaccharides were both fixed in the 1C4 conformation. For 
the other, they were both fixed in the 2S0 conformation. All of the heparin ligands 
were derived from the PDB file 1HPN (Mulloy et al., 1993). 
The docking of heparin oligosaccharide ligand models to human BMP-7 
protein structures was performed in an 84 x 84 x 84 Å grid using Autodock version 
2.4 (Morris et al., 1996). The Autodock version of the AMBER force field was used 
to provide partial charges for protein atoms (Weiner et al., 1984). To generate models 
of mutant BMP-7 proteins, in silico amino acid substitution mutations were 
introduced using the Biopolymer module of the Insight II software package (Accelrys, 
San Diego, CA, USA) on a 300 MHz SGI Octane workstation running the IRIX 
operating system (Silicon Graphics Inc, Fremont, CA, USA). Protein structural 
coordinates were visualised and figures were prepared using The PyMOL Molecular 
Graphics System (DeLano Scientific LLC, San Carlos, CA, USA) and the Accelrys 
Insight II and Discovery Studio software packages. 
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2.2 BMP-7 cDNA clone 
 
A 1814 base pair complementary deoxyribonucleic acid (cDNA) clone 
containing the complete coding sequence of Homo sapiens BMP-7 (I.M.A.G.E ID: 
4183402, GenBank accession: BC008584) was purchased as a stab colony from 
Geneservice Limited (Cambridge, UK). This clone was handled as advised in the 
documentation provided by the supplier. 
 
2.3 Plasmid DNA extraction and purification 
 
2.3.1 Plasmid DNA miniprep 
 
A 5 ml volume of Luria-Bertani (LB) medium [1 % (w/v) bacto-tryptone, 0.5 
% (w/v) yeast extract, 171 mM NaCl, pH 7.2] containing an appropriate selective 
antibiotic was inoculated with a single colony from an agar plate of E. coli cells that 
had been transformed with a DNA plasmid of interest. The culture was grown by 
shaking at 225 rpm in a 37 °C incubator overnight (approximately 16 hours). A 1.5 ml 
aliquot of the culture was transferred to a microcentrifuge tube and the cells were 
pelletted by centrifugation at 10,000 rpm for 3 minutes in a MiniSpin microcentrifuge 
(Eppendorf, Hamburg, Germany). The supernatant was removed and this step was 
repeated once more before the DNA was extracted using the QIAprep Spin Miniprep 
Kit (Qiagen Inc, Valencia, CA, USA) according to the manufacturers instructions. 
Purified plasmid DNA was eluted from the silica membrane of the supplied QIAprep 
spin column with 50 µl of sterile distilled water. 
 
2.3.2 Endotoxin-free plasmid DNA maxiprep 
 
A starter culture was prepared by inoculating a 2 ml volume of LB medium 
containing an appropriate selective antibiotic with a single colony from an agar plate 
of E. coli cells transformed with a DNA plasmid of interest. The culture was grown by 
shaking at 225 rpm in a 37 °C incubator for approximately 8 hours. The starter culture 
was then diluted 1:500 in a 100 ml volume of selective LB medium, and this culture 
was grown overnight in a 37 ºC incubator while shaking at 225 rpm. Following this, 
 57 
the cells were pelletted by centrifugation at 6000 x g for 15 minutes at 4 ºC before 
DNA was extracted using the EndoFree Plasmid Maxi Kit (Qiagen) according to the 
manufacturers instructions. 
 
2.3.3 DNA clean-up following modification, restriction digestion and 
polymerase chain reaction (PCR) 
 
Following restriction digests and PCR reactions, DNA clean-up and 
concentration was performed using the QIAquick PCR Purification Kit (Qiagen) 
according to the supplied protocol. The purified DNA was eluted from the silica 
membrane of the supplied QIAquick spin column with 30 µl of sterile distilled water. 
 
2.3.4 Extraction and purification of DNA from agarose gels 
 
An ultraviolet (UV) light box was used to visualise DNA bands on agarose 
gels, and a sterile scalpel was used to quickly but carefully excise bands and trim off 
excess agarose. DNA bands were purified from the gel slice using the QIAquick Gel 
Extraction Kit (Qiagen) according to the supplied protocol. The purified DNA was 
eluted from the silica membrane of the supplied QIAquick spin column with 30 µl of 
sterile distilled water. 
 
2.4 Quantification of DNA and RNA 
 
The quantification of DNA and RNA was carried out using a SmartSpec 3000 
spectrophotometer (Bio-Rad Laboratories, Hercules, CA, USA), and absorbance 
readings were carried out using the pre-programmed methods according to the 
manufacturers instructions. 
 
2.5 DNA sequencing 
 
DNA sequencing was performed by The Sequencing Service (College of Life 
Sciences, University of Dundee, Scotland, http://www.dnaseq.co.uk) using Applied 
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Biosystems Big-Dye Ver 3.1 chemistry, on an Applied Biosystems model 3730 
automated capillary DNA sequencer. 
 
2.6 Digestion of DNA with restriction endonuclease 
(RE) enzymes 
 
Restriction endonucleases and their accompanying buffers were purchased 
from either Promega Corporation (Madison, WI, USA) or Fermentas International Inc 
(Burlington, Ontario, Canada). Digestion mixtures were set-up in 0.5 ml thin-walled 
Eppendorf PCR tubes containing the following components: 
 
1x final concentration of the appropriate reaction buffer (supplied) 
1-4 µg DNA 
2 µg acetylated bovine serum albumin (BSA) 
5-10 units of each restriction enzyme  
Sterile distilled water to a suitable reaction volume (typically 20 µl) 
 
Mixtures were incubated in a water bath at the appropriate temperature (as 
indicated by the enclosed data sheet and generally 37 ºC) for 2 hours. When carrying 
out tandem digestions with restriction enzymes that required buffers that were 
incompatible with one another, and there was no suitable alternative, the reactions 
were carried out in two stages to optimise enzyme activity. Following the first 
digestion, the mixture was diluted 1:1 with sterile distilled water and a suitable 
volume of the second supplied 10x buffer and restriction enzyme were added prior to 
a further 2 hour incubation. 
 
2.7 DNA PCR primers 
 
DNA oligonucleotide primers for PCR were designed according to 
requirements and purchased from Invitrogen (Carlsbad, CA, USA). Upon receipt, the 
lyophilised primers were resuspended in sterile distilled water to a stock concentration 
of 100 µM. The sequences of the primers that were used during this study can be 
found in Table 2.1. 
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Primer name Primer sequence (5’ to 3’) 
BMP7WT1-S ATAGGATCCGCCCGGAGCCCGGAGCCCGGGTAC 
BMP7WT2-S ATAGGATCCGCCGCCACCATGGACGTGCGCTCACTGCGAGCT 
BMP7WT-A ATTGGATCCCTAGTGGCAGCCACAGGCCCG 
BMP7K419A/R421A-S CTCCAACGTCATCCTGAAGGCATACGCAAACATGGTGGTCCGGGCC 
BMP7K419A/R421A-A GGCCCGGACCACCATGTTTGCGTATGCCTTCAGGATGACGTTGGAG 
BMP7ΔS296-R327-S TTCCGCAGCATCCGGTCCACGGGGCAGGCCTGTAAGAAGCACGAGCTG 
BMP7ΔS296-R327-A CAGCTCGTGCTTCTTACAGGCCTGCCCCGTGGACCGGATGCTGCGGAA 
pIRESbla-S CGACTCACTATAGGGAGACC 
pIRESbla-A CTGACAATCTTAGCGCAGAAGTC 
T7 TAATACGACTCACTATAGGG 
SP6 AGCTATTTAGGTGACACTATAG 
pFastBac1-S TATTCCGGATTATTCATACCGTC 
pFastBac1-A GTATGGCTGATTATGATCCTC 
Actin-S GGCCACGGCTGCTTC 
Actin-A GTTGGCGTACAGGTCTTTGC 
 
 
Table 2.1 PCR primers 
The names and sequences, in the 5’ to 3’ orientation, of the DNA PCR primers that 
were used during this study. All primers were purchased from Invitrogen. 
 
 
 
2.8 Polymerase chain reaction (PCR) 
 
2.8.1 PCR using Platinum Pfx DNA Polymerase 
 
For applications that required PCR products with high fidelity, such as 
cloning, PCR amplifications were carried out using Platinum Pfx DNA Polymerase 
(Invitrogen). Unlike Taq polymerase, this recombinant polymerase (derived from 
Thermococcus sp. strain KOD) possesses a proofreading 3’ to 5’ exonuclease activity. 
This enables it to correct nucleotide mis-incorporation errors. Reaction mixtures were 
assembled on ice as follows in 0.5 ml thin-walled Eppendorf PCR tubes: 
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1x final concentration of Pfx Amplification Buffer (supplied) 
Deoxynucleotide triphosphate (dNTP) mixture (0.3 mM each) 
1 mM MgSO4 
0.3 µM 5’ sense primer 
0.3 µM 3’ antisense primer 
20-50 ng template DNA 
1 unit Platinum Pfx DNA Polymerase 
Sterile distilled water to a final volume of 50 µl 
 
The components were mixed well and centrifuged briefly to collect the 
contents at the bottom of the tubes before cycling using the following parameters in a 
Progene thermal cycler (Techne Ltd, Cambridge, UK): 
 
Initial denaturation: 94 ºC 2 minutes 
 
Denaturation:  94 ºC 30 seconds 
Annealing:  55 ºC 30 seconds                 30 cycles 
Extension:  68 ºC 1 minute per kb 
 
Final extension: 68 ºC 5 minutes 
 
PCR products were stored at -20 ºC. 
 
2.8.2 PCR using BIOTAQ DNA Polymerase 
 
For routine PCR applications where the fidelity of the PCR product was less 
important, amplifications were carried out using BIOTAQ DNA Polymerase (Bioline 
Ltd, London, UK), which is a purified enzyme from Thermus aquaticus. Reaction 
mixtures were assembled on ice in 0.5 ml thin-walled Eppendorf PCR tubes 
containing the following components: 
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1x final concentration of NH4 Buffer (supplied) 
dNTP mixture (0.3 mM each) 
1.5 mM MgCl2 
0.3 µM 5’ sense primer 
0.3 µM 3’ antisense primer 
20-50 ng template DNA 
1 unit BIOTAQ DNA Polymerase 
Sterile distilled water to a final volume of 50 µl 
 
The components were mixed well and centrifuged briefly to collect the 
contents at the bottom of the tubes before cycling using the following parameters in a 
Progene thermal cycler (Techne): 
 
Initial denaturation: 94 ºC 2 minutes 
 
Denaturation:  94 ºC 30 seconds 
Annealing:  55 ºC 30 seconds                 30 cycles 
Extension:  72 ºC 1 minute per kb 
 
Final extension: 72 ºC 5 minutes 
 
PCR products were stored at -20 ºC. 
 
2.8.3 Colony PCR 
 
Colony PCR was carried out according to the protocol described in section 
2.8.2 above with one amendment. Colonies were picked carefully using a sterile 
pipette tip and re-streaked on to a divided and labelled fresh LB-agar plate containing 
an appropriate selective antibiotic. The remainder of the colony was added to 10 µl 
sterile distilled water, mixed well by pipetting, and 1 µl of this solution was added to 
the PCR reaction mixture in place of the template DNA. PCR products were analysed 
on agarose gels. 
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2.9 Agarose gel electrophoresis 
 
DNA size analysis was carried out on 1 % (w/v) agarose gels, which were 
prepared by melting molecular biology grade agarose (Helena BioSciences Europe, 
Tyne & Wear, UK) in Tris-acetate-EDTA (TAE) buffer [40 mM Tris-acetate, 1 mM 
ethylenediaminetetraacetic acid (EDTA)]. The solution was heated until the agarose 
had completely dissolved using a microwave oven on the low power setting. Once the 
agarose solution had cooled, 0.5 µg/ml ethidium bromide was added and the solution 
was poured into a gel-tray. A comb was placed in the tray to form wells and the gel 
was allowed to set at room temperature. The gel was then placed in a horizontal 
electrophoresis tank (Bio-Rad) filled with TAE buffer. The DNA samples were mixed 
with an appropriate volume of 5x DNA loading buffer (Bioline), and were loaded into 
the wells alongside a DNA molecular weight marker that contained bands of a suitable 
size range, typically HyperLadder I (Bioline). Gel electrophoresis was performed at 
80 V for an appropriate time for the size of gel being used, and DNA bands were 
visualised using a Doc-It UV transilluminator and camera (UVP, Upland, CA, USA). 
 
2.10 Cloning PCR products using the pGEM-T vector 
system 
 
The pGEM-T vector system (Promega) provides a convenient way to clone 
PCR products. The vectors are prepared by cutting with EcoRV, a blunt cutter, and 
adding a 3’ terminal thymidine to both ends of the insertion site. The single 3’-T 
overhangs improve the efficiency of ligation by providing a compatible overhang for 
PCR products generated using some thermostable polymerases that add a single 3’-A 
overhang. However, proofreading thermostable DNA polymerases generate blunt-
ended PCR fragments, and 3’-A overhangs must be added to these fragments prior to 
them being ligated in to the pGEM-T vector. 
 
2.10.1 Addition of 3’-A overhangs to PCR fragments 
 
3’-A overhangs were added to purified PCR fragments using GoTaq DNA 
Polymerase (Promega). Mixtures were set up containing the following components: 
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1x final concentration of GoTaq reaction buffer with MgCl2 (supplied) 
1-6 µl of purified blunt-ended PCR fragment (0.5-1.0 µg total amount) 
0.2 mM dATP 
5 units GoTaq DNA Polymerase 
Sterile deionised water to a final reaction volume of 10 µl 
 
Mixtures were incubated at 72 ºC for 30 minutes in a Progene thermal cycler 
(Techne), and 1-2 µl of the mixture was then used in a ligation reaction with the 
pGEM-T vector according to the supplied instructions. 
 
2.11 Transformation of competent E. coli cells with 
plasmid DNA 
 
Library Efficiency competent DH5α E. coli cells, MAX Efficiency competent 
DH10Bac E. coli cells (both Invitrogen) and XL-1 Blue supercompetent E.coli cells 
(Stratagene, La Jolla, CA, USA) were stored at -80 °C, and were thawed on ice 
immediately before use. A 100 µl aliquot of cells was transferred to a chilled 14 ml 
BD Falcon polypropylene round-bottom tube (BD Biosciences, San Jose, CA, USA) 
containing 1-5 µl of DNA, mixed very gently by swirling, and incubated for 30 
minutes on ice. The cells were then heat-shocked in a water bath at 42 ºC for 45 
seconds before a further 2 minute incubation on ice. 0.9 ml room temperature Super 
optimal broth with catabolite repression (SOC) medium [2 % (w/v) bacto-tryptone, 
0.5 % (w/v) yeast extract, 8.56 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 20 mM 
glucose, pH 7.0] was added to the solution of cells and DNA, mixed gently by 
swirling, and incubated at 37 °C whilst shaking vigorously at 225 rpm for 1 hour. A 
suitable volume of the culture was then spread out on to pre-warmed LB-agar plates 
containing the appropriate antibiotic for selection (generally 50 µg/ml ampicillin), 
with 80 µg/ml X-gal (5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside) and 20 
mM IPTG (Isopropyl-β-D-1-thiogalactopyranoside) where required. Plates were 
incubated at 37 °C overnight. 
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2.12 pIRESbla vector 
 
The pIRESbla mammalian expression vector was a kind gift received from 
Chris Ball at the National Institute for Biological Standards and Control (NIBSC), 
Potters Bar, Herts, UK. The vector was produced at NIBSC (Thorpe et al., 2008) as a 
modification of the pIRESneo vector (Clontech Laboratories Inc, Mountain View, 
CA, USA). Briefly, the neomycin phosphotransferase (NPT II) gene and the bovine 
growth hormone polyadenylation signal were removed from pIRESneo, and replaced 
with the Blasticidin resistance gene (Bsdr) and SV40 early polyadenylation signal 
from the pcDNA 6.2/V5-DEST vector (Invitrogen). This enabled stable cell lines to 
be selected using Blasticidin S HCl. 
 
2.13 Alkaline phosphatase treatment of DNA 
 
When being digested prior to use in a ligation reaction, vector DNA was 
treated with Shrimp alkaline phosphatase (SAP, Promega) to remove 5’ phosphates, 
therefore preventing recircularisation and religation of the linearised DNA. 10 units 
SAP / µg vector DNA was added in a final volume of 30-50 µl, and incubated at 37 ºC 
in a water bath for 15 minutes. SAP was then heat-inactivated at 65 ºC for 15 minutes. 
 
2.14 DNA ligation 
 
DNA ligation reactions were carried out using T4 DNA Ligase (Promega). 
Ligation mixtures were set up on ice in 0.5 ml thin-walled Eppendorf PCR tubes 
containing the following components: 
 
1x final concentration of ligation buffer (supplied) 
50-100 ng vector 
An appropriate quantity of insert DNA to give either a 1:1 or 3:1 insert:vector 
molar ratio 
1 unit T4 DNA Ligase 
Sterile distilled water to a total volume of 20 µl 
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Ligation mixtures were incubated overnight at 16 ºC in a Progene thermal 
cycler (Techne), and 5 µl was then used to transform competent E. coli cells. 
 
2.15 Site-directed mutagenesis 
 
Site-directed mutagenesis was carried out using the QuikChange II Site-
Directed Mutagenesis Kit (Stratagene), generally according to the enclosed 
instructions and including the appropriate controls. The double-stranded plasmid 
template DNA used in the experiments was purified from Library Efficiency DH5α 
cells (Invitrogen) by carrying out a DNA miniprep or maxiprep. Mutagenic primers 
were designed using Stratagene’s web-based QuikChange Primer Design Program. 
 
2.15.1 Mutant strand synthesis reaction 
 
Mutant DNA strands were synthesised in reactions containing the following 
components in 0.5 ml thin-walled Eppendorf PCR tubes: 
 
5 µl of 10x reaction buffer 
20 ng of double stranded DNA template 
125 ng of oligonucleotide primer #1 
125 ng of oligonucleotide primer #2 
1 µl of supplied dNTP mix 
Distilled water to a final volume of 50 µl 
1 µl of PfuUltra HF DNA polymerase (2.5 U/µl) 
 
The components were mixed well and centrifuged briefly to collect the 
contents at the bottom of the tubes before cycling using the following parameters in a 
Progene thermal cycler (Techne): 
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Initial denaturation: 95 ºC 30 seconds 
 
Denaturation:  95 ºC 30 seconds 
Annealing:  55 ºC 1 minute                                             18 cycles 
Extension:  68 ºC 1 minute / kb of plasmid length 
 
Following temperature cycling, tubes were placed on ice for 2-3 minutes to 
cool reactions to ≤37 °C. 
 
2.15.2 DpnI digestion of template plasmid DNA 
 
Following the synthesis of mutant DNA strands, the restriction enzyme DpnI 
was used to digest the parental (i.e. non-mutated) template DNA. DpnI cleaves only 
when its recognition sites are methylated, which is the case when the template DNA is 
purified from a dam+ E. coli strain such as DH5α (a requirement of the procedure). 
Because the newly-synthesised mutant strands are not methylated, the enzyme can 
distinguish between the two DNA forms and leave the mutant strands intact. 
1 µl of the supplied DpnI restriction enzyme (10 units/µl) was added directly 
to each mutant strand synthesis reaction, and the contents of the tubes were mixed 
gently but thoroughly by pipetting up and down several times. The reaction mixtures 
were spun down briefly in a microcentrifuge and immediately incubated in a water 
bath at 37 ºC for 2 hours to digest the parental DNA. Following this, 1-2 µl of the 
mixture (containing mutated plasmid DNA) was used to transform the supplied XL-1 
Blue supercompetent cells according to the method described in section 2.11. Single 
colonies were picked from transformation plates, and plasmid DNA was isolated by 
carrying out DNA minipreps (section 2.3.1). The presence of the desired mutations 
was confirmed by sending purified plasmid DNA for sequencing (section 2.5). 
 
2.16 Detection of BMP-7 by enzyme-linked 
immunosorbent assay (ELISA) 
 
Detection of the BMP-7 protein in samples by ELISA was carried out using 
the human BMP-7 DuoSet sandwich ELISA development kit (R&D Systems Inc, 
 67 
Minneapolis, MN, USA). Wells of a Nunc Maxisorp 96-well plate (Fisher Scientific 
UK Ltd, Loughborough, Leics, UK) were coated overnight at room temperature with 
100 µl phosphate buffered saline (PBS, 137 mM NaCl, 2.7 mM KCl, 10 mM 
Na2HPO4, 1.76 mM KH2PO4, pH 7.4) containing 2 µg/ml of mouse anti-human BMP-
7 monoclonal capture antibody. The wells were then washed three times by filling 
with 400 µl PBS containing 0.05 % (v/v) Tween 20 (PBS-Tween 20). The wells were 
blocked for 1 hour at room temperature on a rotating platform, with 300 µl PBS 
containing 1 % (w/v) Probumin Diagnostic Grade Bovine Serum Albumin (BSA) 
(Millipore UK Ltd, Watford, Herts, UK), before washing three times with PBS-Tween 
20. 100 µl volumes of samples, or recombinant human BMP-7 standards (R&D 
Systems) diluted in PBS containing 1 % (w/v) BSA, were added to the wells and 
incubated at room temperature for 2 hours. After washing the wells three times with 
PBS-Tween 20, 100 µl of biotinylated mouse anti-human BMP-7 monoclonal 
detection antibody was added at a concentration of 0.5 µg/ml diluted in PBS / 1 % 
(w/v) BSA, and incubated at room temperature for 2 hours. Following this, the wells 
were washed three times with PBS-Tween 20, and 100 µl PBS / 1 % (w/v) BSA 
containing 1:200 diluted streptavidin-horseradish peroxidase (HRP) conjugate was 
added. After 20 minutes at room temperature, the wells were washed three times with 
PBS-Tween 20. 100 µl of substrate solution [1:1 mixture of Colour Reagent A (H2O2) 
and Colour Reagent B (Tetramethylbenzidine), R&D Systems] was added to each 
well, and after allowing a further 20 minutes in the dark at room temperature for 
colour development, 50 µl of stop solution (2 N H2SO4) was added. The optical 
density of each well was determined immediately using an Emax plate reader 
(Molecular Devices, Sunnyvale, CA, USA) set to 450 nm, with wavelength correction 
set at 595 nm to correct for any optical imperfections in the plate. 
 
2.17 Sample preparation 
 
2.17.1 Preparation of supernatant samples for sodium dodecyl 
sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
 
Laemmli sample buffer [62.5 mM Tris-HCl pH 6.8, containing 20 % (v/v) 
glycerol, 2 % (v/v) ß-mercaptoethanol and 2 % (w/v) SDS] was added to each sample 
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at a 1:1 ratio as described by Laemmli (1970), to give a final concentration of 1 % 
(v/v) ß-mercaptoethanol and 1 % (w/v) SDS. In addition, 5 µl of bromophenol blue 
[0.1 % (w/v) in 10 mM Tris] was added per 100 µl of sample to enable visualisation 
of the dye front during protein separation. Samples were boiled for 5 minutes in a 100 
ºC water bath to denature the proteins prior to loading on polyacrylamide gels. 
 
2.17.2 Preparation of whole cell lysates for SDS-PAGE and ELISA 
 
Cells were pelleted by centrifugation at 1000 x g for 5 minutes, the supernatant 
was aspirated completely and the pellet was washed once gently with PBS. For SDS-
PAGE, the pellets were resuspended in 200 µl of Laemmli sample buffer, and boiled 
for 5 minutes in a 100 ºC water bath to denature the proteins. For use in ELISA, the 
pellets were resuspended in 200 µl of PBS, frozen in a dry ice and isopropanol bath 
for 10 minutes, and the suspension was thawed in a 37 ºC water bath. This freeze/thaw 
cycle was repeated 3 times. 
 
2.18 SDS-PAGE and Western blotting 
 
2.18.1 SDS-PAGE 
 
SDS-polyacrylamide gel electrophoresis was carried out as described by 
Laemmli (1970) using the Bio-Rad Mini-PROTEAN III mini-gel apparatus, according 
to the manufacturers instructions. 1 mm thick 15 % (w/v) polyacrylamide gels were 
used, which were cast using the same apparatus and were made up with 3.6 ml of 
deionised water, 3.75 ml of 1.5 M Tris-HCl pH 8.8, 150 µl of 10 % SDS and 7.5 ml of 
30 % (w/v) acrylamide solution containing 0.8 % (w/v) bis-acrylamide (BDH 
Scientific, VWR International, Dublin, Ireland), with 150 µl 10 % (w/v) ammonium 
persulphate (APS) and 10 µl tetramethylethylenediamine (TEMED) to catalyse 
polymerisation. The stacking gel [5.5 % (w/v) acrylamide] contained 2.9 ml of 
deionised water, 1.25 ml of 0.5 M Tris-HCl pH 6.8, 0.95 ml of 30 % (w/v) acrylamide 
solution containing 0.8 % (w/v) bis-acrylamide and 50 µl of 10 % SDS, with 31.5 µl 
10 % (w/v) APS and 7.5 µl TEMED. 
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Gels were clamped in to the tank and the inner chamber was filled to the top 
(above the level of the gel) with reservoir buffer [25 mM Tris, 192 mM glycine, 0.1 % 
(w/v) SDS, pH 8.3]. The buffer was also used to fill the outer chamber of the tank to a 
depth of approximately 5 centimetres. Protein samples were prepared as stated in 
section 2.17 above, and were loaded in 5 mm wide tracks. Gels were run at 200 V 
constant voltage until the dye front reached the end of the gel (approximately 45 
minutes). Pre-stained molecular weight markers (SeeBlue Plus2, Invitrogen) were 
used on all gels. 
 
2.18.2 Western blotting 
 
Following gel electrophoresis, the proteins separated by SDS-PAGE were 
transferred onto a nitrocellulose transfer membrane with a pore size of 0.45 µm 
(Schleicher & Schuell Protran, Whatman plc, Maidstone, Kent, UK). A wet Western 
blotting technique was developed (modified from Towbin et al., 1979) using the Bio-
Rad Mini Trans-Blot cell in combination with the Mini-PROTEAN III electrophoresis 
system. The nitrocellulose membrane was pre-equilibrated in blotting buffer [25 mM 
Tris, 192 mM glycine, 20 % (v/v) methanol, 0.1 % (w/v) SDS, pH 8.3] for 1 hour 
prior to blotting, and electrophoretic transfer was carried out in the same buffer for 1 
hour at 100 V constant voltage. 
 
2.18.3 Development of Western blots 
 
Following Western blotting, membranes were washed three times for 15 
minutes each on a rotating platform with Tris buffered saline (TBS, 50 mM Tris, 150 
mM NaCl, pH 7.6) containing 0.05 % (v/v) Tween 20 (TBS-Tween 20), and blocked 
for 1 hour in blocking solution [5 % (w/v) Marvel low fat milk powder in TBS-Tween 
20]. The blots were then incubated overnight with primary antibody dissolved in 
blocking solution (0.5 µg/ml goat polyclonal anti-human BMP-7, R&D Systems) on a 
rotating platform at 4˚C. Following this, membranes were washed three times for 15 
mins with TBS-Tween 20, before a 1 hour incubation at room temperature with 
secondary antibody [horseradish peroxidase (HRP) conjugated rabbit anti-goat IgG 
(Sigma-Aldrich Company Ltd, Dorset, UK)] at a dilution of 1:2000 in blocking 
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solution. After washing three times for 5 minutes each, blots were developed using 
SuperSignal West Pico or Femto Chemiluminescent Substrate (Pierce Biotechnology 
Inc, Rockford, IL, USA) according to the manufacturers instructions. An 
appropriately sized piece of photographic film (Hyperfilm ECL, GE Healthcare UK 
Ltd, Chalfont St Giles, Bucks, UK) was placed over blots wrapped in cling-film and 
exposed for a suitable amount of time (initially 20 seconds but varied depending on 
the intensity of chemiluminescence). After exposure, the film was placed in developer 
for 1-2 minutes, rinsed thoroughly with water, and placed in fixer for 2 minutes. 
 
2.19 Cell culture 
 
2.19.1 Adherent Chinese Hamster Ovary-K1 (CHO-K1) cells 
 
CHO-K1 cells were purchased from the European Collection of Cell Cultures 
(ECACC, Health Protection Agency, Salisbury, UK) and were cultured as a 
monolayer in a 37 ºC incubator with 5 % CO2 and 95 % relative humidity. The cells 
were routinely maintained in 25 cm2 flasks with vented caps (Orange Scientific, B-
1420 Braine-l’Alleud, Belgium), and were seeded at a density of 0.25 x 106 cells/25 
cm2 flask in a total volume of 8 ml F-12 Nutrient Mixture (Ham) containing 2 mM L-
glutamine and 10 % (v/v) foetal bovine serum (FBS) (both Gibco, Invitrogen). Once 
the cells reached 70-80 % confluence, the maintenance media was aspirated and the 
monolayer was washed briefly with 2 ml 0.25 % Trypsin-EDTA solution (Sigma), 
which was then removed. The cells were detached from the flask by adding 0.5 ml of 
fresh 0.25 % Trypsin-EDTA solution, incubating the flask at 37 ºC for 1 minute and 
gently tapping the sides of the flask. Once detached, the cell suspension was diluted 
by adding 9.5 ml of maintenance media to the flask, and pipetted up and down with a 
10 ml pipette to break up cell clumps. Before re-seeding, the cells were counted using 
an Improved Neubauer Hemocytometer, and their viability was determined by 
carrying out a Trypan Blue dye exclusion assay (section 2.20). When scaling-up was 
required, the cells were cultured in 75 cm2 or 150 cm2 flasks. The cell numbers and all 
volumes stated above were increased proportionally to the surface area of the flask. 
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2.19.2 Adherent Spodoptera frugiperda (Sf9) insect cells 
 
Spodoptera frugiperda (Sf9) insect cells were purchased from Invitrogen for 
use with the Bac-to-Bac Baculovirus Expression System, and were cultured as a 
monolayer in a 27 ºC incubator according to the supplied manual. Sf9 cells were 
routinely maintained in Supplemented Grace’s Insect Medium (Gibco, Invitrogen) 
containing 10 % FBS. 
 
2.19.3 Suspension FreeStyle Chinese Hamster Ovary (CHO-S) 
cells 
 
FreeStyle CHO-S cells were purchased from Invitrogen as part of the 
FreeStyle MAX CHO Expression System. FreeStyle CHO-S cells are derived from 
the CHO cell line, and are adapted to suspension culture in FreeStyle CHO Expression 
Medium supplemented with 8 mM L-glutamine. The cells were cultured as described 
in the supplied manual in 125 ml, 250 ml or 1 litre polycarbonate sterile Erlenmeyer 
shaker flasks with vented caps (VWR International, Dublin, Ireland). Cells were 
grown in a 37 ºC incubator containing a humidified atmosphere of 8 % CO2 in air on 
an orbital shaker platform rotating at 135 rpm. 
 
2.20 Trypan Blue dye exclusion assay for determining 
cell viability 
 
A 5 µl volume of 0.4 % Trypan Blue dye solution (Sigma) was added to 95 µl 
cell suspension and mixed thoroughly. 20 µl of this solution was applied to each side 
of an Improved Neubauer Hemocytometer by allowing drops held at the end of a 
pipette tip to be taken under the coverslip by capillary action. The percentage cell 
viability was determined by comparing the number of unstained viable cells to the 
number of dead cells that stained blue. 
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2.21 Transfection of cells 
 
2.21.1 Stable transfection of adherent CHO-K1 cells 
 
Prior to being used in transfections, the CHO-K1 cells were grown in 25 cm2 
or 75 cm2 flasks until they reached approximately 90 % confluency. They were then 
trypsinised, counted, and their viability was determined (as described in section 2.20) 
to ensure that they were >95 % viable and therefore in optimum condition to be 
transfected. 
Approximately 24 hours before transfection, the cells were seeded in to 6-well 
plates (Orange Scientific) at a density of 3 x 105 cells/well in 3 ml maintenance 
medium. Duplicate wells were prepared for each plasmid to be transfected, and the 
necessary control transfections (vector only and a sham transfection without DNA). 
Plates were placed in a 37 ºC incubator containing 5 % CO2 overnight. The next day, 
the following components were assembled in a sterile 1.5 ml tube: 
 
100 µl F-12 Nutrient Mixture (no FBS) 
3 µl GeneJuice Transfection Reagent (Novagen, Merck Chemicals Ltd, Notts, 
UK) 
 
The contents of the tube were mixed well by vortexing and incubated for 5 
minutes at room temperature. Following this, 1 µl of endotoxin-free plasmid DNA (1 
mg/ml) was added to the mixture, mixed by gently pipetting, and incubated at room 
temperature for 15 minutes. The plasmid DNA / GeneJuice mixture was then added to 
the plated cells dropwise in different areas of the well and the plate was rocked gently 
from side to side before being incubated for approximately 24 hours at 37 ºC with 5 % 
CO2. 
The day after transfection when the cells were approximately 90 % confluent, 
stably transfected cells were selected for resistance to the antibiotic Blasticidin S HCl 
(Invitrogen). The media was aspirated from the wells and the cell monolayer was 
washed with 1 ml 0.25 % Trypsin-EDTA solution. After this solution was removed, 
another 0.25 ml of the same solution was used to detach the cells from the surface of 
the wells. The detached cells were resuspended in 2 ml transfection medium 
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(maintenance medium containing 10 µg/ml Blasticidin S HCl) and added to 23 ml 
transfection medium in 75 cm2 flasks. The flasks were incubated at 37 ºC with 5 % 
CO2 and the transfection medium was replaced every 3-4 days until the cells were 80-
90 % confluent and required passaging (approximately 7-10 days). The same 
procedure was followed for the control transfections. 
 
2.21.2 Transfection of Sf9 insect cells 
 
In each well of a 6-well plate, 9 x 105 Sf9 cells were seeded in 2 ml of growth 
medium and allowed to attach at 27 ºC for 1 hour. For each transfection, 1 µg of 
purified bacmid DNA was diluted in 100 µl of unsupplemented Grace’s Medium 
(Invitrogen). 6 µl of Cellfectin transfection reagent (Invitrogen) was also diluted in 
100 µl of unsupplemented Grace’s Medium. The diluted bacmid DNA was then 
combined with the diluted Cellfectin reagent, mixed gently, and incubated at room 
temperature for 45 minutes. The media was removed from the cells and the cells were 
washed once with 2 ml of unsupplemented Grace’s Medium, which was then 
removed. 0.8 ml of unsupplemented Grace’s Medium was added to each tube 
containing the DNA-Cellfectin complexes and mixed gently before being added to 
each well containing the cells to be transfected. The cells were then incubated at 27 ºC 
for 5 hours, after which time the media containing the DNA-Cellfectin complexes was 
removed and replaced with 2 ml of fresh growth media. The cells were once again 
incubated in a 27 ºC humidified incubator for approximately 72 hours until signs of 
viral infection were seen. After this time, the medium containing the P1 baculoviral 
stock was collected from each well, clarified by centrifugation at 500 x g for 5 
minutes and stored at 4 ºC protected from light. 
 
2.21.3 Transfection of FreeStyle CHO-S cells 
 
Approximately 24 hours before transfection, FreeStyle CHO-S cells 
(Invitrogen) were passaged at 5 x 105 cells/ml, and placed on an orbital shaker 
platform rotating at 135 rpm in a 37 ºC incubator containing 8 % CO2. On the day of 
transfection, the cells were counted and their viability was determined to ensure that 
they were >95 % viable, and therefore in optimum condition for t
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cells were then diluted to a density of 1 x 106 cells/ml in FreeStyle CHO Expression 
Medium (Invitrogen) and 30 ml of cell suspension was transferred into each 125 ml 
shake flask (VWR) ready for transfection. 37.5 µg of plasmid DNA was diluted into 
OptiPro SFM (Invitrogen) to a total volume of 600 µl and mixed. In another tube, 37.5 
µl of FreeStyle MAX Transfection Reagent (Invitrogen) was also diluted in OptiPro 
SFM to a total volume of 600 µl, and mixed gently by inverting the tube. The diluted 
FreeStyle MAX Transfection Reagent was then immediately added to the diluted 
DNA solution, and the 1.2 ml total volume was mixed gently and incubated at room 
temperature for 10 minutes to allow DNA-FreeStyle MAX Reagent complexes to 
form. After this time, the 1.2 ml volume containing the DNA-FreeStyle MAX 
complex was slowly added into the 125 ml flask containing FreeStyle CHO-S cells 
while slowly swirling the flask. Transfected cell cultures were incubated at 37 ºC with 
8 % CO2 on an orbital shaker platform rotating at 135 rpm. 
 
2.21.4 Transfection of adherent CHO-K1 cells with the Centocor 
mutant DNA constructs 
 
Approximately 24 hours prior to transfection, CHO-K1 cells were seeded in to 
150 cm2 flasks (Orange Scientific) at a density of 1 x 107 cells/flask in 30 ml 
maintenance medium (DMEM/F-12 containing 10 % FBS). The flasks were placed in 
a 37 ºC incubator containing 5 % CO2 overnight. The next day, for each transfection, 
1 ml of Opti-MEM (Invitrogen) was added to each of two sterile 15 ml tubes. To one 
of these tubes, 30 µg of plasmid DNA was added. To the other, 90 µl of 
Lipofectamine 2000 transfection reagent (Invitrogen) was added. The tubes were 
incubated at room temperature for 5 minutes, before the contents of the tubes were 
combined and mixed gently. Following a further 20 minute incubation at room 
temperature, the 2 ml mixtures were added directly to the flasks containing cells and 
the culture media was gently swirled. The flasks were again incubated at 37 ºC 
overnight. Approximately 24 hours later, the media containing the DNA complex was 
aspirated from the flasks and the cell monolayer was washed with PBS. 30 ml of fresh 
CD CHO medium containing 4 mM L-glutamine and 5 mM sodium butyrate (all 
Invitrogen) was then added to each flask, and the flasks were incubated at 37 ºC for 4 
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days. After this time, the conditioned supernatants were collected from the transfected 
cells, clarified by centrifugation and assayed for BMP-7 content by ELISA. 
 
2.22 Viral plaque assay 
 
Viral plaque assays to determine the titer of baculoviral stocks were carried 
out as described in Invitrogen’s Bac to Bac Baculovirus Expression System manual, in 
a 6-well plate format. Briefly, on the day of infection the Sf9 cells were harvested and 
a cell suspension was prepared at 5 x 105 cells/ml in Sf-900 II SFM medium 
(Invitrogen). 2 ml of the cell suspension was aliquoted into each well, and the cells 
were allowed to settle and attach to the bottom of the plate for 1 hour at room 
temperature. After this time, an 8-log serial dilution (10-1 to 10-8) of the baculoviral 
stock was prepared in Sf-900 II SFM medium. The medium was removed from each 
well and immediately replaced with 1 ml of the appropriate virus dilution. The cells 
were then incubated with the virus for 1 hour at room temperature, after which time 
the virus-containing medium was removed and replaced with 2 ml of Sf-900 plaquing 
medium (60 ml of Sf-900 medium (1.3X) plus 20 ml of 4 % melted agarose gel 
solution). The agarose gel overlay was allowed to set for 20 minutes at room 
temperature, and the cells were placed in a 27 ºC humidified incubator for 7 days until 
plaques were visible and ready to count after staining with neutral red. 
 
2.23 Clarification of cell culture supernatants 
 
After harvesting cell culture supernatants, cell debris was removed by 
centrifugation at 4500 x g for 5 minutes. 
 
2.24 Protease inhibitors 
 
A cocktail of protease inhibitors for general use (Sigma) was added to 
harvested cell culture supernatants and cell lysates from a 100x concentrated stock, 
which was prepared as described in the included datasheet. 
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2.25 Protein concentration 
 
Protein concentration was carried out using Vivaspin 2 sample concentrators 
with a 10 kDa molecular weight cut-off (GE Healthcare UK Ltd) according to the 
manufacturers instructions. 
 
2.26 Protein assay 
 
Samples were assayed to determine their total protein concentration using the 
Bio-Rad Protein Assay Dye Reagent Concentrate kit, according to the microtitre plate 
protocol in the enclosed manual. Briefly, the dye reagent was prepared by diluting 1 
part Dye Reagent Concentrate with 4 parts distilled and deionised water, and the BSA 
protein standard and samples were diluted as appropriate. 10 µl of each standard or 
sample solution were pipetted into separate wells of a 96-well microtitre plate, and 
200 µl of diluted dye reagent was added per well. The sample and reagent were mixed 
thoroughly using a Wellwarm 1 microplate mixer (Labsystems, Cambridge, UK), 
incubated for 5 minutes at room temperature, and the absorbance was measured at 595 
nm using an Emax plate reader (Molecular Devices). 
 
2.27 Ion exchange chromatography 
 
2.27.1 Cation exchange chromatography 
 
Cation exchange chromatography was carried out mainly according to the 
method described by Sampath et al. (1992). Briefly, conditioned supernatants were 
clarified and dialysed against 20 mM HEPES buffer pH 7.0, containing 20 mM NaCl. 
Volumes of the dialysed supernatants (20-100 ml) were then applied at a flow rate of 
5 ml/hour to columns containing a 2 ml bed volume of SP-Trisacryl beads (Sigma), 
which had been equilibrated in the same buffer and packed according to the 
manufacturers instructions. Columns were washed with 5 bed volumes of buffer, and 
a 16 ml linear gradient of NaCl, up to a final concentration of 1.3 M, was applied at 
the same flow rate. The column pass-through was pooled and 1 ml fractions were 
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collected throughout the wash and NaCl gradient steps. This entire procedure was 
carried out at 4 ºC. Fractions were assayed for BMP-7 content by ELISA. 
 
2.27.2 Anion exchange chromatography 
 
Anion exchange chromatography was carried out as described for cation 
exchange chromatography except that 20 mM Tris-Cl pH 8.5 containing 100 mM 
NaCl was used as the buffer, and Q-Sepharose beads (GE Healthcare UK Ltd) as the 
column matrix. 
 
2.28 RNA extraction and purification 
 
CHO-K1 cells were grown in 75 cm2 flasks until 80-90 % confluent and 
harvested as described in section 2.19.1. 7.5 x 106 cells were pelleted by 
centrifugation at 300 x g for 5 minutes in 15 ml RNase-free polypropylene tubes (BD 
Biosciences). The cell culture medium was completely aspirated, and RNA was 
extracted and purified using the RNeasy Mini Kit (Qiagen) according to the supplied 
protocol for the purification of total RNA from animal cells. During the RNA 
purification process, any residual genomic DNA was eliminated by carrying out an 
on-column DNase digestion using the RNase-Free DNase Set (Qiagen) containing 
DNase I. Purified RNA was eluted from the silica membrane of the supplied RNeasy 
spin column in two steps with 30 µl volumes of the supplied RNase-free water. 
 
2.29 Reverse transcription polymerase chain reaction 
(RT-PCR) 
 
cDNA was synthesised from purified total RNA by carrying out reverse 
transcription using SuperScript II Reverse Transcriptase (Invitrogen). Reaction 
mixtures were set up as follows in 0.5 ml thin-walled PCR tubes: 
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150 ng random primers (Invitrogen) 
1 µg purified total RNA 
1 µl dNTP mix (10 mM each) 
Sterile distilled water to a final volume of 12 µl 
 
The mixture was heated to 65 ºC for 5 minutes in a thermal cycler, and quickly 
chilled on ice. The contents of the tubes were collected by briefly centrifuging, and 
the following components were added: 
 
4 µl 5x first-strand buffer (supplied) 
2 µl 0.1 M 1,4-Dithiothreitol (DTT) 
1 µl RNaseOUT (40 units /µl, Invitrogen) 
 
The contents of the tubes were mixed gently and incubated at 25 ºC for 2 
minutes. 1 µl (200 units) of SuperScript II Reverse Transcriptase was added, mixed 
gently by pipetting up and down, and the tubes were incubated at 25 ºC for a further 
10 minutes. cDNA first strand synthesis was carried out by incubating the tubes at 42 
ºC for 50 minutes, before the reaction was inactivated by heating at 70 ºC for 15 
minutes. Newly synthesised cDNA was used as a template for PCR amplification as 
described in section 2.8.2. 
 
2.30 Heparin affinity chromatography 
 
Clarified cell culture supernatants containing recombinant BMP-7 proteins 
were dialysed against 100 volumes of PBS for 4 hours at 4 ºC. Prior to sample 
application, 1 ml Heparin HiTrap HP columns (GE Healthcare UK Ltd) were 
equilibrated with 20 ml PBS. Unless otherwise stated, a volume of dialysed 
supernatant containing 500 ng of BMP-7 protein (approximately 5 - 8 ml determined 
by ELISA) was applied to the columns at a flow rate of 0.5 ml/min using a peristaltic 
pump. After columns were washed with 5 ml of PBS containing 25 µg/ml BSA, a 20 
ml linear gradient of NaCl in PBS was applied at the same flow rate up to a final 
concentration of 1.5 M, also containing 25 µg/ml BSA. The whole procedure was 
carried out at 4 ºC and 1 ml fractions were collected throughout. The NaCl 
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concentration of the fractions was determined by carrying out conductivity 
measurements and standardising against a series of solutions of known concentration. 
 
2.31 Digestion of BMP-7 with Endoproteinase Lys-C 
 
Reaction mixtures containing 50 ng of recombinant human BMP-7 (R&D 
Systems) in 25 µl volumes of 100 mM Tris-Cl pH 8.5, in the presence and absence of 
5 µg/ml heparin (Sigma), were assembled in thin-walled 0.5 ml PCR tubes on ice. The 
mixtures were incubated for 30 minutes at room temperature before 1 ng 
Endoproteinase Lys-C (Sigma) was added to each tube with the exception of the zero 
time samples, to which Laemmli sample buffer was added and the tubes contents were 
immediately boiled for 5 minutes in a 100 ºC water bath. The remaining digestion 
mixtures were incubated in a 37 ºC water bath for the specified time, after which 
Laemmli sample buffer was added and they were also boiled immediately for 5 
minutes in a 100 ºC water bath. Following digestion, samples were stored at -20 ºC 
until they were analysed by carrying out SDS-PAGE and Western blotting (section 
2.18). 
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Chapter 3: Molecular docking 
calculations 
 
3.1 Introduction 
 
During the drug discovery process, high throughput computer-based 
simulation techniques, known as docking calculations, are widely used to identify 
small molecule drug candidates that will interact with a specific protein target 
(Kitchen et al., 2004). Using high-resolution experimental structural information, 
these docking calculations can be used to predict the optimal way to accommodate a 
particular ligand in the binding site of the protein. The most favourable mutual 
orientation of the protein and its ligand in the theoretical complex is that with the 
lowest interaction energy, which is used as a scoring function. 
Since the solution conformation of the main repeating structure in the heparin 
polysaccharide was characterised (Mulloy et al., 1993), it has been possible to apply 
similar methods to those described above for the prediction of heparin/HS-binding 
sites on proteins. However, before doing so, some modification of the methods was 
required. This is because in general, the nature of protein-heparin/HS interactions 
differs from other protein-ligand binding interactions. Firstly, due to the level of 
structural complexity and heterogeneity, no single structure of heparin/HS exists 
(section 1.2.2). Secondly, rather than binding tightly to deep clefts in the structure of 
the protein, HS and heparin bind primarily electrostatically to sites on the surfaces of 
proteins (sections 1.3.1 and 1.3.2). Although the above complications exist, the nature 
of the binding interactions - being dependent on a combination of charge and 
geometry - make them particularly suitable for modeling using adapted docking 
calculation techniques. Therefore, similar equally successful methods were 
simultaneously but independently developed and validated by Forster and Mulloy 
(described in Forster and Mulloy, 2006; Mulloy and Forster, 2008) and by Bitomsky 
and Wade (1999) to enable such studies to be carried out. Since then, another 
alternative approach has also been successfully implemented (Ricard-Blum et al., 
2004). As outlined in this chapter, the strategy that was adopted for use in this 
investigation was that of Forster and Mulloy. Docking calculations were performed to 
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predict the location of potential HS/heparin-binding sites on the surface of the BMP-7 
protein, and the results of these calculations were used to assist in the design of the 
site-directed mutagenesis experiments described in Chapter 4. 
 
3.2 Results and discussion 
 
3.2.1 The Forster and Mulloy docking strategy 
 
As mentioned above, the docking calculations carried out in this chapter to 
predict the location of the BMP-7 HS/heparin-binding site were conducted using a 
method developed by Forster and Mulloy. A full detailed explanation of this strategy 
is provided in Forster and Mulloy (2006) and Mulloy and Forster (2008), but what 
follows is a summary account covering the key aspects. 
The method that was developed is a relatively simple one, which utilises a 
software application called Autodock, version 2.4 (Morris et al., 1996). This software 
enables the automated docking of heparin oligosaccharide ligands to experimentally 
derived protein structures. In this particular scenario, Autodock achieves this by 
screening the entire protein surface for clusters of basic residues that have suitable 
shape and charge profiles to complement the pattern of acidic sulphate groups along 
the heparin chain. The coordinates for these structures are obtained from PDB files 
deposited in the Research Collaboratory for Structural Bioinformatics (RCSB) Protein 
Data Bank (PDB) archive (http://www.rcsb.org/pdb). The Autodock version of the 
AMBER force field (Weiner et al., 1984) is used to provide the required partial 
charges for protein atoms, whilst the Jaguar program (Schrodinger, Portland, OR, 
USA) is used to provide the partial atomic charges for the heparin oligosaccharide 
ligands, based on ab initio calculations using 1-OMe, 4-OMe substituted 
monosaccharides. 
Using this strategy, the calculation of probe atom interaction energies is 
carried out on a grid of 120 x 120 x 120 points. A central grid point is also added, and 
the grid is centred on the mean of the coordinates of the protein. A grid spacing of 0.7 
Å (1 Å = 0.1 nm) is used, producing a total grid size of 84 x 84 x 84 Å. Consequently, 
this is also the maximum size of protein that can be studied using this method. 
Docking is performed using a Monte Carlo simulated annealing procedure (128 runs 
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of 300 cycles are generally performed), in which the protein remains stationary while 
the oligosaccharide ligand performs a random walk in space around it. In doing so, the 
position, orientation and allowed rotatable torsion angles of the ligand structure are 
optimised to find the fit with the lowest intermolecular interaction energy. The five or 
ten lowest energy coordinate sets can then be extracted and visualized using a suitable 
molecular graphics viewer, such as the Discovery Studio software package (Accelrys, 
San Diego, CA, USA). In these coordinate sets, the amino acid residues that contain 
atoms that lie within 3.5 Å of the oligosaccharide ligand are generally recorded. 
Although the accurate computation of interaction energies is not the focus of 
this method, complexes with predicted energies of less than -1000 kcal/mol are 
considered to have the potential to represent a feasible protein-heparin interaction. 
Where the predicted interaction energy is greater than zero, the protein is regarded as 
having no ability to bind heparin. The reported energies are the result of a scoring 
function only, and have no significance in absolute terms. The reason for this is that 
the predictions made by the docking calculations are based upon a simulation of 
binding in a hard vacuum rather than in aqueous solution. As a result, the docking 
calculations exaggerate binding affinity, and the predicted interaction energies that 
result from these calculations are therefore larger than would be expected in aqueous 
solution. 
Three different heparin oligosaccharide model ligands are commonly used, 
which are all derived from the NMR structure of the disaccharide repeat of heparin, 
named 1HPN (Mulloy et al., 1993). These ligands include two pentasaccharide 
structures that both contain three GlcNS6S (N-sulpho-D-glucosamine 6-O-sulphate) 
residues, separated by IdoA2S (L-iduronic acid 2-O-sulphate) residues. This results in 
sequences of OMe-GlcNS6S-IdoA2S-GlcNS6S-IdoA2S-GlcNS6S-OMe. However, 
because the IdoA2S residues are able to adopt two different ring formations, the two 
pentasaccharides differ in that one of them contains all of the IdoA2S residues in the 
1C4 conformation, whilst in the other they are all in the 2S0 conformation. Although 
this a simplistic way of incorporating conformational mobility of the IdoA2S residue, 
there have been no previous cases in which the difference between the two 
conformations has produced considerably different predictions. The remaining heparin 
model ligand that is often used is an endecasaccharide [(GlcNS6S-IdoA2S)5-
GlcNS6S]. 
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During the docking process, Autodock conducts a docking approximation that 
treats the protein entity as a rigid body. Although this results in a decrease in the 
calculation time, it prevents the successful modelling of interactions in which the 
conformation of the protein is changed to achieve a fit. However, some 
oligosaccharide ligand flexibility is permitted but is limited by Autodock, which 
allows a maximum of 32 rotatable bonds. For the pentasaccharide ligand structures, 
this means that all of the exocyclic torsion angles can be flexible with the exception of 
the glycosidic linkages. For the larger endecasaccharide model ligand, all bonds have 
fixed torsion angles. The results from docking calculations carried out using the small 
pentasaccharide ligands (with their flexible sulphate groups) can be useful for 
predicting the location of the core of the heparin-binding site of a protein. Use of the 
longer and completely rigid endecasaccharide ligand in such calculations can assist in 
confirming the location of the predicted heparin-binding site. It may also give an 
indication of extensions to the binding site and the preferred orientation of the bound 
heparin fragment. 
Although the Forster and Mulloy method is an effective one for generating 
predictions and aiding the design of site-directed mutagenesis experiments, it does 
have certain limitations in addition to those mentioned above. For example, it does not 
provide any details of interactions that may occur between specific atoms in either the 
protein or oligosaccharide ligand structures, or give any information about the mode 
of binding. Furthermore, the specific sulphate groups that play a key role in a 
particular interaction cannot be precisely identified. This method is also unable to 
determine the preferred direction, if any, of the bound heparin chain. This is due to the 
fact that the pattern of sulphates along a fully sulphated heparin chain appears very 
similar in either direction, irrespective of the directionality of the carbohydrate 
backbone. 
 
3.2.2 Human BMP-7 X-ray crystal structures 
 
To date, four human BMP-7 X-ray crystal structures have been published and 
their coordinates have been deposited as pdb files in the RCSB protein data bank 
(http://www.rcsb.org/pdb). These structures are identified as 1BMP (Griffith et al., 
1996), 1M4U (Groppe et al., 2002), 1LXI (Greenwald et al., 2003) and 1LX5 
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(Greenwald et al., 2003). Whilst the pdb files for 1BMP and the higher resolution 
1LXI contain the coordinates for the BMP-7 protein structure alone, the other two 
available files contain the coordinates for the BMP-7 protein in complex with either 
its antagonist Noggin (1M4U), or the extracellular domain of its receptor ActRII 
(1LX5). 
The availability of these structures enabled docking calculations to be 
performed to predict the location of the HS/heparin-binding site of BMP-7 prior to 
conducting site-directed mutagenesis experiments. However, an important limitation 
of all the structures is that they are missing the first 27 to 35 amino acids out of a total 
of 37 residues in their N-terminal extensions, upstream of the first cysteine residue. As 
a result, either 6 or 7 (depending on the structure used) of the 15 basic residues found 
within the mature BMP-7 protein are absent from these structures. It is likely that this 
region of the protein remains unresolved as a result of it being disordered (Griffith et 
al., 1996; Greenwald et al., 2003). 
Before carrying out any docking calculations, close attention was paid to 
ensuring that suitable BMP-7 structures were selected for study, using files that 
contained the appropriate coordinates for either the BMP-7 monomer or dimer. The 
required coordinates were extracted and the structures were checked to ensure that 
there were no missing atoms or residues, other than those that were situated in the 
unresolved N-terminal region. Docking calculations based on the BMP-7 monomer 
and dimer were conducted using the 1LXI and 1M4U structures respectively. 
 
3.2.3 Prediction of the heparin-binding site of human BMP-7 using 
molecular docking calculations 
 
As mentioned previously, BMP-7 is a homodimeric protein. Because of this, it 
was unclear whether it possesses two independent heparin-binding sites - one on each 
monomer - or a single cooperative binding site that requires the involvement of both 
its constituent monomers. It was therefore necessary to conduct any docking 
calculations to predict the heparin-binding site of human BMP-7 using both 
monomeric and dimeric BMP-7 structures. It was thought that a comparison of the 
resulting predictions might provide some insight into the nature of the binding 
interaction. 
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3.2.3.1 Docking of the heparin pentasaccharide ligands to the BMP-7 protein 
monomer 
 
When the heparin pentasaccharides were docked to the BMP-7 monomer, the 
resulting predictions were almost identical to one another. This was expected as fixing 
all the IdoA2S residues in either the 1C4 or 2S0 conformation has never previously 
produced considerably different predictions (Forster and Mulloy, 2006). As displayed 
in Figure 3.1 and summarised in Table 3.1, the pentasaccharide structures docked very 
consistently across the lower face of a region of the BMP-7 protein known as finger 2. 
This region of the protein lies close to the C-terminus of BMP-7 and consists of two 
antiparallel beta-sheets, formed by two pairs of antiparallel beta-strands (β5 and β8, 
β6 and β7) (Griffith et al., 1996). 
More specifically, the docking calculations that were performed predicted that 
the core of the heparin-binding site of BMP-7 may be localised to a small C-terminal 
cluster of basic amino acids situated in beta-strands 7 and 8, and the connecting region 
between them. In total, three basic residues were in close contact (≤ 3.5 Å) with the 
heparin ligands and therefore predicted to be involved in the interaction. These 
residues were lysine 419, arginine 421 and arginine 426 (coloured purple in Figure 3.1 
and labeled in the absence of any heparin ligands for clarity in Figure 3.2B). Although 
lysine 418 is also present in this region (coloured purple in Figure 3.1 and labeled in 
Figure 3.2B), the orientation of its basic side chain was not conducive to its 
participation in the interaction. Another three residues upstream of the basic cluster 
were also predicted to come into close contact with the heparin ligands. These were 
asparagine 402, alanine 403 and serine 405, which are located at the C-terminal end of 
beta-strand 5, the region between beta-strands 5 and 6, and in beta-strand 6 
respectively. However, as these residues are all neutral at physiological pH, it is likely 
that they would play a lesser role in any interaction of the protein with heparin. For 
example, the polar side chains of asparagine 402 and serine 405 could assist in 
stabilising the complex by forming hydrogen bonds with the heparin chain. More 
importantly, the close proximity of these residues would not destabilise the complex 
like the presence of a negatively charged aspartic or glutamic acidic residue might do 
via like-charge repulsion. 
It can be seen in Figure 3.1A that when overlaid, the five lowest energy 
arrangements for the docked IdoA2S 1C4
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agreement. This is a good indication that Autodock has been able to positively 
discriminate between a region that it considers to possess the theoretical 
characteristics of a suitable heparin-binding site, and other regions that do not. A very 
small amount of variation was observed in the predicted orientations of the IdoA2S 
2S0 pentasaccharide (Figure 3.1B). However, this variation did not alter the protein 
region or particular selection of amino acid residues that came into close contact with 
the oligosaccharide. 
The lowest predicted intermolecular interaction energies calculated for the two 
heparin pentasaccharide ligands were very similar. Values of -1098.04 kcal/mol 
(IdoA2S 1C4) and -1055.62 kcal/mol (IdoA2S 2S0) were reported. Both of these values 
were slightly below the -1000 kcal/mol threshold that is generally regarded as being 
indicative of a protein that has the capacity to bind heparin. Therefore, it can be said 
that these docking outcomes have the potential to be representative of physiologically 
possible BMP-7-heparin complexes. Even still, the results of any docking calculations 
may be taken only as predictions. This is especially true in this case and it is not only 
due to the limitation of the unresolved N-terminus. It is also because these predictions 
were based on a BMP-7 monomer, which is not the physiological state of the protein. 
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Figure 3.1 Molecular docking of two heparin pentasaccharides to a BMP-7 
monomer 
Molecular docking calculations were performed using Autodock (version 2.4) to 
determine if/how two different heparin pentasaccharide ligands would interact with a 
BMP-7 monomer. In these ligands, all of the IdoA2S residues were fixed in either the 
1C4 conformation (A) or the 2S0 conformation (B). It can be seen that the heparin 
pentasaccharides both docked across the bottom face of finger 2 on the BMP-7 
monomer, coming into close contact with K419, R421 and R426. The side chains of 
these residues (and K418) are shown in stick form and coloured purple. For clarity, 
they have also been shown and labeled in Figure 3.2B in the absence of any heparin 
ligands. In each case, the five lowest energy arrangements of the heparin ligands are 
overlaid and are in close agreement with each other, with the exception of one IdoA2S 
2S0 pentasaccharide ligand shown in (B). The N-linked glycan stub (containing two 
GlcNAc residues) that is present in the BMP-7 structure is represented in stick form 
and is also labeled ‘Carb.’ in Figure 3.2B. 
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Figure 3.1 Molecular docking of two heparin pentasaccharides to a BMP-7 
monomer 
Please refer to the figure legend on the opposite page. 
 89 
3.2.3.2 Docking of the heparin endecasaccharide ligand to the BMP-7 protein 
monomer 
 
When the heparin endecasaccharide ligand was docked to the BMP-7 
monomer, the prediction of the protein contact site made by Autodock firmly 
supported those obtained for the pentasaccharide ligands. It can be seen in Figure 
3.2A that the endecasaccharide model ligand docked diagonally across the same 
region in finger 2 of the monomeric BMP-7 protein that the pentasaccharides had 
before. As a result, the individual amino acid residues that were pinpointed as being in 
close proximity of the heparin chain were also largely the same. Asparagine 402, 
lysine 419, arginine 421 and arginine 426 once again contained atoms that were 
located within 3.5 Å of the ligand structure. In addition to these previously mentioned 
residues, the increased length of the endecasaccharide ligand compared to the two 
pentasaccharides also brought it in to close contact with lysine 332, glutamine 400 and 
alanine 427 (Table 3.1). 
A consequence of the electrostatic attraction of the heparin endecasaccharide 
to lysine 332 was that it docked across the only N-linked glycosylation site that is 
utilised out of the three potential sites located within the mature BMP-7 protein (Jones 
et al., 1994). Two GlcNAc residues from the N-linked glycan chain that is attached to 
asparagine 372 of BMP-7 are visible in the available BMP-7 X-ray crystal structures 
and can be seen in Figure 3.2A and B. Due to the steric obstruction that would most 
likely be caused by the presence of the carbohydrate entity in this particular region, it 
is doubtful that this complex arrangement would be feasible. It also remained to be 
seen if this type of arrangement would be favoured, or even possible, when the BMP-
7 protein was in its physiological dimeric form. 
Figure 3.2A shows that the five lowest energy orientations of the docked 
endecasaccharide were again in very close agreement. The predicted intermolecular 
interaction energy for the best-fit arrangement was -1362.17 kcal/mol. Although no 
flexibility was allowed for in the heparin endecasaccharide ligand structure, this value 
was lower than those reported for the pentasaccharides. Theoretically, the BMP-7 
monomer therefore interacted more favourably with the longer heparin 
endecasaccharide than with the pentasaccharides. However, it is possible that this 
reduction in energy occurred largely as a result of the additional basic residue contact 
with lysine 332. Because the described arrrangement of the BMP-7 monomer-
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endecasaccharide complex would be unlikely to assemble in practice, such a 
comparison in interaction energies has little value in this instance. 
As previously discussed, it is the basic lysine and arginine residues that are 
generally of particular interest when investigating the location of the heparin-binding 
site of any given protein. All of the docking calculations to this point supported each 
another in suggesting that the C-terminal residues lysine 419, arginine 421 and 
arginine 426 might all be of key importance for the binding of BMP-7 to heparin. 
Although the particular complex arrangement that is displayed in Figure 3.2A 
appeared to be unfeasible, the close proximity of lysine 332 to the endecasaccharide 
ligand also provoked some thought into the possibility that the N- and C-termini of the 
BMP-7 protein could perhaps form a cooperative heparin-binding site. The major 
component of the N-terminus of BMP-7 is likely to be flexible, intimated by the fact 
that it is unresolved in the available crystal structures. Therefore, one can imagine that 
a number of additional N-terminal residues might also have the capacity to be 
appropriately oriented to interact with a heparin chain. Unfortunately, the absence of 
the N-terminus in the available crystal structures prevented further investigation of 
this possibility using these methods. 
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Figure 3.2 Molecular docking of a heparin endecasaccharide to a BMP-7 
monomer 
A molecular docking calculation was performed using Autodock (version 2.4) to 
determine if/how a heparin endecasaccharide ligand would interact with a BMP-7 
monomer. (A) It can be seen that the heparin endecasaccharide docked across the 
bottom face of finger 2 on the BMP-7 monomer, coming into close contact with 
K419, R421 and R426. The side chains of these residues (and K418) are shown in 
stick form, coloured purple, and have been labeled in (B) in the absence of any 
heparin ligands for clarity. The five lowest energy arrangements of the heparin ligand 
are overlaid and are in close agreement with each other. The N-linked glycan stub 
(containing two GlcNAc residues) that is present in the BMP-7 structure is 
represented in stick form and labeled ‘Carb.’ in (B). 
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Figure 3.2 Molecular docking of a heparin endecasaccharide to a BMP-7 
monomer 
Please refer to the figure legend on the opposite page. 
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3.2.3.3 Docking of the heparin pentasaccharide ligands to the BMP-7 protein 
dimer 
 
It can be seen in Figure 3.3 (and Table 3.1) that when the IdoA2S 1C4 and 2S0 
heparin pentasaccharide structures were independently docked to the BMP-7 protein 
dimer, amino acid residues in the same region of finger 2 as found for the BMP-7 
monomer before (section 3.2.3.1) were once again consistently predicted to be 
important for heparin-binding. However, due to the presence of both overlapping 
BMP-7 monomers, the results of the docking calculations differed from those seen 
before. Rather than docking across the lower face of a single monomer, both of the 
pentasaccharide ligands were predicted to bridge between the lower faces of the two 
disulphide-linked monomeric structures. In doing so, the ligands came in to contact 
with amino acids lying within the same region on both monomers. 
As before, the results from both docking calculations predicted the 
involvement of the basic residues lysine 419, arginine 421 and arginine 426 in the 
heparin-binding site of BMP-7 (coloured purple in Figure 3.3 and labeled in the 
absence of any heparin ligands for clarity in Figure 3.4B). The contact of the heparin 
ligands with these residues also brought them into close proximity with a small 
number of additional amino acids, which were located in the same protein region. In 
the case of the IdoA2S 1C4 pentasaccharide, these additional residues were asparagine 
402 and alanine 403. As well as these two residues, the IdoA2S 2S0 pentasaccharide 
also came into contact with threonine 399, glutamine 400, leucine 401 and asparagine 
422. 
The interaction energies that were reported for the lowest energy arrangements 
of the BMP-7 dimer-pentasaccharide complexes were -1142.32 kcal/mol (IdoA2S 
1C4) and -1148.03 kcal/mol (IdoA2S 2S0). It can be seen in Table 3.1 that these values 
were slightly lower than those obtained for the monomer-pentasaccharide complexes, 
which were -1098.04 kcal/mol (IdoA2S 1C4) and -1055.62 kcal/mol (IdoA2S 2S0). As 
explained previously, this docking method places no emphasis on the accurate 
calculation of interaction energies. Despite this, relative to each other these results 
would appear to suggest that the docking of the pentasaccharide ligands between the 
two monomers of the BMP-7 dimer would be a little more energetically favourable. 
The bridged dimer-pentasaccharide arrangements shown in Figure 3.3 had the 
potential to allow for twice the number of basic residue-heparin contacts that the 
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monomer-pentasaccharide complexes did. Therefore, one might have expected the 
dimer-pentasaccharide complexes to have been greatly preferred, and that this would 
have been demonstrated by these particular complex arrangements having 
considerably lower theoretical interaction energies than the monomer-pentasaccharide 
complexes. However, this was not the case as the energies reported were in fact quite 
similar. 
Upon inspection of the docking calculation predictions, the likely reasons for 
the lack of a considerable difference between the interaction energies of the BMP-7 
dimer-pentasaccharide and monomer-pentasaccharide complexes became apparent. 
Due to the limited length of the two pentasaccharide ligands employed, neither ligand 
was able to make contact with all of the previously mentioned predicted key basic 
residues on both monomers at the same time. Therefore, a preference was still 
displayed for making a greater number of contacts with one of the monomers than the 
other. This resulted in fewer basic residue-pentasaccharide contacts being made 
overall than it would first appear. Also, to accommodate the interaction with the 
additional BMP-7 monomer, the orientation of the docked pentasaccharides was 
altered from that preferred previously in the monomer-pentasaccharide complexes. 
Any considerable reduction in the theoretical interaction energy, which might have 
resulted from docking the pentasaccharide ligands to basic residues on both of the 
consituent monomers of BMP-7, may have been counteracted by this change in 
orientation. 
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Figure 3.3 Molecular docking of two heparin pentasaccharides to a BMP-7 dimer 
Molecular docking calculations were performed using Autodock (version 2.4) to 
determine if/how two different heparin pentasaccharide ligands would interact with a 
BMP-7 dimer. In these ligands, all of the IdoA2S residues were fixed in either the 1C4 
conformation (A) or the 2S0 conformation (B). It can be seen that the heparin 
pentasaccharides both docked between the bottom faces of the two constituent BMP-7 
monomers, coming into close contact with K419, R421 and R426 on each subunit. 
The side chains of these residues (and K418) are shown in stick form and coloured 
purple. For clarity, they have also been shown and labeled in Figure 3.4B in the 
absence of any heparin ligands. In each case, the five lowest energy arrangements of 
the heparin ligands are overlaid and are in close agreement with each other, with the 
exception of one IdoA2S 2S0 pentasaccharide ligand shown in (B). The N-linked 
glycan stub (containing two GlcNAc residues) that is present in the BMP-7 structure 
is represented in stick form and is also labeled ‘Carb.’ in Figure 3.4B. 
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Figure 3.3 Molecular docking of two heparin pentasaccharides to a BMP-7 dimer 
Please refer to the figure legend on the opposite page. 
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3.2.3.4 Docking of the heparin endecasaccharide ligand to the BMP-7 protein 
dimer 
 
When the heparin endecasaccharide ligand was docked to the BMP-7 protein 
dimer, the heparin-binding site of BMP-7 was once again predicted to be localised to 
the same specific region of finger 2 that was described in section 3.2.3.1. In support of 
all three of the previous docking calculations, lysine 419, arginine 421 and arginine 
426 were also predicted to be the key contributors of the basic charges that are 
necessary for binding to heparin/HS. Table 3.1 shows that in addition to these three 
basic residues, the orientation of the docked endecasaccharide ligand also brought it 
into close proximity with asparagine 402, alanine 403 and serine 405. 
It can be seen in Figure 3.4A that the heparin endecasaccharide consistently 
docked to identical sites on both constituent monomers of the BMP-7 dimer, forming 
a bridge between them. As explained before in section 3.2.3.3, this was also the case 
when the pentasaccharide ligands were docked to the BMP-7 protein in its native 
dimeric form. However, unlike the pentasaccharide ligand structures, the heparin 
endecasaccharide was not so restricted in its chain length. Therefore, a single chain 
was able to make contact with most of the amino acid residues mentioned above on 
both monomers at the same time. As a result, the predicted interaction energy for the 
best-fit BMP-7 dimer-endecasaccharide complex arrangement, at -1925.43 kcal/mol, 
was substantially lower than those of the dimer-pentasaccharide complexes, which 
were -1142.32 kcal/mol (IdoA2S 1C4) and -1148.03 kcal/mol (IdoA2S 2S0). 
In the predicted BMP-7 dimer-heparin endecasaccharide complex shown in 
Figure 3.4A, the heparin ligand docked across the lower face of the BMP-7 protein 
dimer in such a way that it passed through the middle of the two occupied 
glycosylation sites. The two present N-linked glycan stubs (each consisting of two 
GlcNAc residues) extended outwards and away from the docked ligand from opposite 
sides of the structure. Therefore, it would appear from this prediction that such a 
complex would be both energetically and sterically feasible, and that the presence of 
the attached glycan chains would not provide an obstruction and prevent its formation. 
Overall, the docking calculations described in this chapter predicted that the C-
terminal basic residues lysine 419, arginine 421 and arginine 426 would be most 
likely to form the core component of the heparin-binding site of BMP-7. This 
suggested that these residues would be ideal initial targets for mutagenesis 
 98 
experiments. The docking calculations also suggested that the dimer-endecasaccharide 
complex shown in Figure 3.4A, in which the two monomers formed a cooperative 
heparin-binding site, would be the most energetically favourable BMP-7-heparin 
ligand arrangement. 
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Figure 3.4 Molecular docking of a heparin endecasaccharide to a BMP-7 dimer 
A molecular docking calculation was performed using Autodock (version 2.4) to 
determine if/how a heparin endecasaccharide ligand would interact with a BMP-7 
dimer. (A) It can be seen that the heparin endecasaccharide docked across the bottom 
faces of the two constituent BMP-7 monomers, coming into close contact with K419, 
R421 and R426 on each subunit. The side chains of these residues (and K418) are 
shown in stick form, coloured purple, and have been labeled in (B) in the absence of 
any heparin ligands for clarity. The five lowest energy arrangements of the heparin 
ligand are overlaid and are in close agreement with each other. The N-linked glycan 
stub (containing two GlcNAc residues) that is present in the BMP-7 structure is 
represented in stick form and labeled ‘Carb.’ in (B). 
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Figure 3.4 Molecular docking of a heparin endecasaccharide to a BMP-7 dimer 
Please refer to the figure legend on the opposite page. 
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3.2.3.5 Docking of the heparin endecasaccharide ligand to a BMP-7 mutant 
protein created in silico 
 
As mentioned above in section 3.2.3.4, the docking calculations that were 
previously carried out pinpointed lysine 419, arginine 421 and arginine 426 as being 
ideal targets for site-directed mutagenesis experiments. Prior to carrying out such 
experiments, docking calculations were performed to predict the effect that 
substituting these C-terminal basic residues, which are situated in finger 2 of BMP-7, 
would have on its heparin-binding ability. However, before doing so, it was first 
necessary to plan and create a suitable BMP-7 mutant protein in silico. 
The predictions that were made by the previous docking calculations 
suggested that as many as 6 basic residues (3 on each monomer) might take part in the 
binding interaction between BMP-7 and heparin/HS. To maximise the chance of 
reducing the heparin/HS-binding affinity of BMP-7, whilst hopefully maintaining the 
structural integrity of the protein, the decision was made to make substitutions of 
these predicted key residues in pairs. This would result in a reduction of the number of 
predicted basic contact residues in the C-terminal region by two-thirds. Only one of 
the predicted key basic residues would remain on each monomer, which would be 
insufficient to form a heparin/HS-binding site even if the protein monomers were to 
bind cooperatively to a single oligosaccharide chain. Alanine residues were selected 
as replacement residues due to them possessing small methyl groups as side chains, 
which are both structurally and chemically simple. With such properties, it was 
thought that the introduction of these residues would not disrupt the BMP-7 protein 
structure, which is constrained by three intra-chain disulphide bridges. The docking 
calculations described previously suggested that atoms from lysine 419 and arginine 
421 would make the highest number of contacts with the heparin oligosaccharide 
ligands (data not shown). Therefore, this was the first pair of basic amino acids 
selected for substitution to alanine both theoretically and experimentally. These amino 
acid substitutions were made in the human BMP-7 structure 1M4U (Groppe et al., 
2002), using the Biopolymer module of the Insight II software package (Accelrys, San 
Diego, CA, USA). 
Having produced the BMP-7 K419A/R421A mutant protein in silico, the 
heparin endecasaccharide ligand was docked to it to predict the effect that the double 
substitution would have on the heparin-binding ability of BMP-7. The protein-
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oligosaccharide complex that resulted from this docking calculation is shown in 
Figure 3.5A. It can be seen that the heparin endecasaccharide consistently docked to 
and formed a bridge between identical regions of finger 2 on each monomer. This was 
also true when the same ligand was docked to the wildtype BMP-7 protein dimer 
(section 3.2.3.4). However, due to the absence of lysine 419 and arginine 421 from the 
mutant protein, arginine 426 was the only suitably oriented basic contact residue on 
each monomer. As a consequence, the angle of the docked endecasaccharide ligand 
was altered to enable close contact to be made with both of the available basic 
arginine 426 residues. The orientation of the docked ligand also brought it into close 
proximity with glutamine 400, leucine 401 and asparagine 402. More importantly, the 
reduction in the number of basic residues by two-thirds resulted in a substantial 
increase in the value of the predicted interaction energy for the best-fit complex 
arrangement, from the previous -1925.43 kcal/mol to +273.73 kcal/mol. As the 
interaction energy of this complex was predicted to be greater than zero kcal/mol, its 
formation would be highly unfavourable. The results that were obtained when the 
heparin pentasaccharide ligands were docked to the same BMP-7 mutant structure 
were also very similar (data not shown). Based on these predictions, it would appear 
unlikely that a BMP-7 K419A/R421A mutant protein would be capable of binding to 
heparin/HS. Therefore, lysine 419 and arginine 421 were deemed to be suitable initial 
targets for substitution in experimental site-directed mutagenesis studies. 
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Figure 3.5 Molecular docking of a heparin endecasaccharide to a BMP-7 
K419A/R421A mutant dimer 
To predict the effect that the removal of K419 and R421 would have on the 
HS/heparin-binding ability of BMP-7, a mutant BMP-7 protein was produced in silico 
using the Biopolymer module of the Accelyrys Insight II software package. In this 
mutant, the K419 and R421 residues on each monomer were substituted for alanine 
residues. A molecular docking calculation was then performed using Autodock 
(version 2.4) to determine if/how a heparin endecasaccharide ligand would interact 
with the BMP-7 K419A/R421A mutant dimer. (A) It can be seen that despite the 
absence of K419 and R421, the heparin endecasaccharide continued to dock across the 
bottom faces of the two constituent mutant BMP-7 monomers, albeit in a different 
orientation in order to accommodate contact with R426 on each subunit. Even so, the 
results from the docking calculation suggest such an interaction would be 
energetically unfavourable. The five lowest energy arrangements of the heparin ligand 
are overlaid and are in close agreement with each other. The side chains of K418 and 
R426 are shown in stick form and coloured purple. The side chains of A419 and A421 
are shown in stick form and coloured pink. For clarity, these residues have also been 
labeled in (B) in the absence of any heparin ligands. 
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Figure 3.5 Molecular docking of a heparin endecasaccharide to a BMP-7 
K419A/R421A mutant dimer 
Please refer to the figure legend on the opposite page. 
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Table 3.1 Docking calculation summary 
A summary of the residues on monomeric and dimeric BMP-7 protein structures that 
were predicted to come into closest contact with the heparin pentasaccharide and 
endecasaccharide ligands. The predicted interaction energies are also provided. 
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Table 3.1 Docking calculation summary 
Please refer to the table legend on the opposite page. 
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Overall, the results obtained from this predictive study suggested that a C-
terminal cluster of basic lysine 419, argine 421 and argine 426 residues in each 
monomeric unit of the BMP-7 protein may play a key part in its interaction with 
HS/heparin. These results also suggested that in the absence of some of these basic 
residues, the mature BMP-7 protein does not contain any alternative residue clusters 
with the necessary characteristics to bind heparin/HS. However, there is an important 
caveat to this conclusion. As mentioned previously, the N-terminal extension of the 
mature BMP-7 protein was unresolved in all of the available X-ray crystal structures. 
Consequently, this protein region and the cluster of basic residues located within it 
(Figure 1.8) were absent from the structures that were used to carry out the docking 
calculations. This was a limitation of all the predictive calculations that were 
conducted. Therefore, the possibility that the unresolved N-terminal region may also 
have the capacity to bind heparin/HS could not be disregarded based on the outcome 
of docking calculations alone and required experimental investigation. 
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Chapter 4: The expression of 
recombinant human BMP-7 and 
mutant variants thereof 
 
4.1 Introduction 
 
The results obtained from the molecular docking calculations that were 
discussed in Chapter 3 predicted that BMP-7 binds to HS/heparin GAGs through three 
basic residues that are situated close to the C-terminal ends of each of its constituent 
monomers (K419, R421 and R426). These docking calculations also predicted that 
BMP-7 would not be able to bind to HS/heparin in the absence of both K419 and 
R421. In order to test the validity of these predictions experimentally using a site-
directed mutagenesis approach, it was necessary to express mutant BMP-7 variants. 
However, despite the wildtype BMP-7 protein being commercially available, the 
decision was made to express this protein first to optimise the expression conditions. 
It was also thought that expressing the wildtype BMP-7 protein as a control alongside 
mutant variants would provide an indication as to whether or not the mutations that 
were made had any effect on the expression levels of these proteins. Such insight can 
be especially informative in the event that difficulties are encountered when 
attempting to express particular muteins. 
Prior to commencing these expression experiments, it was necessary to select a 
suitable cell line to use to express the required recombinant BMP-7 proteins. In 
previous studies, much success was had when the wildtype BMP-7 protein was 
expressed in stably transfected Chinese hamster ovary (CHO) cells (Sampath et al., 
1992; Jones et al., 1994). Upon characterising the expressed BMP-7 protein, it was 
found that it was glycosylated, dimerised, processed and secreted correctly. The 
protein was also demonstrated to be functional and was consequently deemed to be 
correctly folded. This has since been confirmed by X-ray crystallography (Griffith et 
al., 1996; Groppe et al., 2002; Greenwald et al., 2003). Therefore, it was decided that 
the same cell line and expression approach would be adopted for use during this 
investigation. Once this decision had been made, a BMP-7 cDNA clone was sourced 
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and inserted into an appropriate mammalian expression vector using PCR (polymerase 
chain reaction) and a number of DNA manipulation techniques. This newly 
constructed expression cassette was then transfected into CHO cells to express the 
recombinant wildtype BMP-7 protein. To produce mutant BMP-7 variants, the BMP-7 
cDNA sequence was modified accordingly. A detailed account of this work and the 
procedures involved is provided within this Chapter. 
 
4.2 Results and discussion 
 
4.2.1 Commercial BMP-7 cDNA clone 
 
A 1814 base pair (bp) cDNA clone of human BMP-7 (I.M.A.G.E ID: 4183402, 
GenBank accession: BC008584), was purchased from Geneservice Limited 
(Cambridge, UK). This cDNA clone contained the complete coding sequence of 
human BMP-7 (1296 bp), along with a 41 bp untranslated region upstream (5’ UTR) 
of the start codon and a 477 bp untranslated region downstream (3’ UTR) of the stop 
codon (Figure 4.1). The clone was provided as a 5’-SalI / 3’-NotI oriented insert in the 
4396 bp pCMV-SPORT6 vector (Invitrogen, Figure 4.3), in the form of a bacterial 
stab culture. Upon receipt, the culture was streaked onto a fresh agar plate containing 
ampicillin and incubated overnight at 37 ºC to obtain single colonies. A colony was 
picked, grown up as a liquid culture, and the DNA was isolated and purified by 
carrying out a DNA maxi-prep. 
 
 
 
 
 
 
Figure 4.1 Commercial BMP-7 cDNA clone 
A BMP-7 cDNA clone (GenBank accession: BC008584) was purchased from 
Geneservice Limited containing the full coding sequence of human BMP-7 (1296 bp), 
a 41 bp 5’ UTR and a 477 bp 3’ UTR. The cDNA was provided in the pCMV-
SPORT6 vector, inserted via the SalI (5’) and NotI (3’) restriction sites in its multiple 
cloning site. 
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4.2.2 Characterisation of the BMP-7 cDNA clone 
 
To confirm that the purchased BMP-7 cDNA clone was the correct size, 1 µg 
of the maxi-prep DNA was tandem digested with the restriction enzymes NotI and 
SalI. Agarose gel electrophoresis of the digestion products revealed that the liberated 
BMP-7 cDNA clone was of the expected 1814 bp size, with the 4396 bp pCMV-
SPORT6 vector band also present in the expected size region (Figure 4.2). 
The purchased construct was also sent for DNA sequence analysis using T7 
and SP6 primers (all primer sequences provided in Chapter 2, Table 2.1) that annealed 
to promoter sequences found within the pCMV-SPORT6 vector. A ClustalW 
sequence alignment was then carried out to compare the sequencing results against a 
human BMP-7 cDNA reference sequence (GenBank accession: NM_001719). This 
confirmed that the supplied BMP-7 cDNA was identical to the reference sequence and 
was therefore absent of any errors. 
 
 
 
 
 
 
Figure 4.2 Restriction digestion of the BMP-7 cDNA clone 
1 µg of the plasmid maxi-prep DNA, containing the human BMP-7 cDNA clone in 
the pCMV-SPORT6 vector, was restriction digested with the NotI and SalI enzymes. 
The digestion products were analysed by agarose gel electrophoresis, revealing two 
bands of the appropriate size corresponding to the 1814 bp cDNA insert and 4396 bp 
pCMV-SPORT6 vector. 
 
 
 
4.2.3 Cloning strategy 
 
The purchased BMP-7 cDNA was provided in the pCMV-SPORT6 
mammalian expression vector (Figure 4.3A). This vector does not contain an 
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antibiotic resistance gene that could be used for the selection of mammalian cells 
following transfection, therefore making it unsuitable for the generation of stable cell 
lines. In order to confer antibiotic resistance to cells expressing the BMP-7 protein, 
the cDNA was cloned into pIRESbla (Figure 4.3B) using the procedures described 
below. pIRESbla is a mammalian expression vector that contains the gene for 
blasticidin resistance. pIRESbla also contains an internal ribosome entry site (IRES) 
sequence from the Encephalomyocarditis virus (ECMV). This allows the ribosomes to 
initiate translation in the middle of a bicistronic messenger RNA (mRNA) sequence 
during protein synthesis, rather than just at the 5’ end where 5’ cap recognition is 
usually required. This has the benefit of permitting the translation of two open reading 
frames from a single mRNA sequence. In this case, it enabled the expression of both 
the inserted cDNA and the resistance gene to be driven from the same constitutively 
active human cytomegalovirus (CMV) major immediate-early promoter/enhancer 
sequence. Having both genes present on the same mRNA transcript allows the 
antibiotic to exert selective pressure on the whole expression cassette. Therefore, a 
high dose of antibiotic will select only the cells that are expressing a high level of the 
gene of interest. This helps to ensure that nearly all of the surviving cells will stably 
express the BMP-7 gene following selection with blasticidin without having to isolate 
and characterise clonal cell lines. 
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Figure 4.3 pCMV-SPORT6 and pIRESbla expression vectors 
pCMV-SPORT6 (A) and pIRESbla (B) both contain multiple cloning sites (MCS) into 
which cDNA coding sequences can be inserted to express proteins under the control 
of the CMV promoter, as well as a gene encoding for ampicillin resistance for the 
selection of bacterial transformants. pIRESbla also contains a blasticidin resistance 
gene to enable the generation of stable mammalian cell lines. (pCMV-SPORT6 image 
taken from the Invitrogen pCMV-SPORT6 product manual, pIRESbla image adapted 
from a vector map produced by Chris Ball, NIBSC). 
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4.2.3.1 PCR amplification of the BMP-7 cDNA 
 
The first cloning step entailed PCR amplifying the required regions of the 
BMP-7 cDNA, including the full 1296 bp coding sequence and the 41 bp 5’ 
untranslated region (5’ UTR). The 5’ UTR was included as it contains the native 
ribosomal binding site immediately upstream of the start codon, which is required for 
the initiation of protein translation. The 3’ UTR was excluded as these regions often 
contain regulatory sequences (Mazumder et al., 2003; Sampath et al., 2003) that could 
function to counteract efforts to overexpress the BMP-7 protein. 3’ UTRs also have a 
role in mRNA stability and contain polyadenylation signals. However, the pIRESbla 
vector already has an incorporated synthetic intron that is known to enhance mRNA 
stability, and it also includes the Simian vacuolating virus 40 (SV40) polyadenylation 
signal. Therefore, it was not necessary to include these components in the amplified 
and cloned cDNA insert. 
As shown in Figure 4.4, the BMP-7 cDNA was PCR amplified with the 
BMP7WT1-S and BMP7WT-A sense and antisense primers respectively. This 
amplification was performed using the proofreading Platinum Pfx DNA polymerase 
(Invitrogen) to ensure that high sequence fidelity was obtained in the amplification 
product. To facilitate the insertion of the amplified cDNA sequence into the multiple 
cloning site of the pIRESbla vector, BamHI restriction sites were included in short 
non-annealing sequences at the 5’ ends of the primers. Agarose gel electrophoresis of 
the PCR product showed that the amplification was successful, producing a single 
band in the region of 1.35 kilobase (kb) pairs in size as expected (Figure 4.4). This 
product was purified using a PCR product purification kit (Qiagen). 
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Figure 4.4 PCR amplification of the BMP-7 cDNA 
The 1296 bp coding sequence and 41 bp of the 5’ UTR of human BMP-7 were PCR 
amplified using the BMP7WT1-S and BMP7WT-A primers (A), to produce a 1.35 kb 
PCR amplification product, with BamHI sites introduced by the primers at both the 5’ 
and 3’ ends (B). (C) Agarose gel electrophoresis of the PCR product confirmed that 
the amplification was successful, producing a single band in the region of 1.35 kb in 
size (lane 1). In the absence of template DNA, no band was produced in the negative 
control reaction (lane 2). 
 
 
 
4.2.3.2 Cloning PCR products using the pGEM-T Vector System 
 
As restriction endonuclease enzymes generally cut PCR products directly with 
low efficiency when their specific recognition sites are located close to the termini of 
the DNA sequences, the newly synthesised DNA was sub-cloned using the pGEM-T 
Vector System (Promega, Figure 4.5) prior to being ligated into the pIRESbla vector. 
Inserting PCR products into the pGEM-T vector serves to increase the efficiency of 
digestion and also provides a convenient way to sequence the PCR product, and to 
grow it up if required at a later date without risking the introduction of PCR errors. 
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Figure 4.5 pGEM-T sub-cloning vector 
With its single 3’-T overhangs, the pGEM-T vector provides a convenient way to sub-
clone PCR products that possess a compatible 3’-A overhang. (Image taken from the 
Promega pGEM-T product manual). 
 
 
 
The 3 kb pGEM-T vector is supplied linearised, with 3’ terminal thymidines 
added to each end. The single 3’-T overhangs at the DNA insertion site provide a 
compatible overhang for the ligation of PCR products generated using DNA 
polymerases that add a single 3’ deoxyadenosine in a template-independent manner. 
However, because the BMP-7 cDNA was amplified using a proofreading DNA 
polymerase, which produce blunt-ended PCR fragments without the required 3’-A 
overhangs, these overhangs were added in another reaction using GoTaq DNA 
Polymerase (Promega) and dATP. The PCR product was then ligated into the pGEM-
T vector (Figure 4.6) and transformed into competent DH5α E. coli cells. Four white 
colonies were picked from the agar plate, grown up in liquid cultures, and 
recombinant plasmid DNA was isolated by carrying out DNA mini-preps. To confirm 
the presence of the BMP-7 cDNA insert, the purified plasmid DNA from each of the 
four liquid cultures was digested with BamHI and analysed by carrying out agarose 
gel electrophoresis (Figure 4.7). The presence of both a 3 kb vector band and a 1.35 
kb insert band was indicative of a successful ligation. The recombinant pGEM-T 
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plasmid DNA containing the BMP-7 insert was sent for sequence verification using its 
incorporated T7 and SP6 primer sites, which confirmed that the insert was absent of 
any sequence errors. 
 
 
 
 
 
Figure 4.6 Cloning the BMP-7 cDNA into pGEM-T 
A-overhangs were added to the 3’ ends of the amplified BMP-7 cDNA, and a ligation 
reaction was carried out to insert the BMP-7 cDNA into the pGEM-T vector via its 
single T-overhangs. 
 
 
 
 
 
 
 
Figure 4.7 Confirming the presence of the BMP-7 cDNA insert in pGEM-T 
2 µg of mini-prep DNA from each of four liquid DH5α E. coli cultures was digested 
with BamHI to confirm the presence of a BMP-7 cDNA insert within the pGEM-T 
vector. The digestion products were analysed by agarose gel electrophoresis (lanes 1-
4). The presence of two bands at 3 kb and 1.35 kb in size in each lane, corresponding 
to the pGEM-T vector and BMP-7 insert respectively, indicated that the ligation was 
successful with each clone containing the BMP-7 cDNA. 
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4.2.3.3 Cloning the BMP-7 cDNA into pIRESbla 
 
The amplified BMP-7 cDNA insert was released from the pGEM-T vector by 
carrying out a restriction digestion with the enzyme BamHI, utilising the sites that had 
been introduced in the PCR primers at both the 5’ and 3’ ends of the sequence (Figure 
4.8). The pIRESbla vector was linearised by digestion in the same way to create a 
compatible site for ligation, and both digestion products were electrophoresed in 
separate tracks of an agarose gel. The 1.35 kb BMP-7 insert band and the 4.85 kb 
pIRESbla vector band were then carefully excised from the gel and purified from the 
gel slice using a QIAquick Gel Extraction Kit (Qiagen). To prevent the BamHI 
digested vector from recircularising in the absence of a DNA insert, the vector was 
treated with alkaline phosphatase. After quantifying the DNA, a ligation reaction was 
carried out to insert the BMP-7 cDNA fragment into the prepared pIRESbla vector, 
via the BamHI site within its multiple cloning site. 1 µl of the ligation reaction 
mixture was transformed into competent DH5α E. coli cells and six colonies were 
picked from the agar plate and grown up in 5 ml liquid cultures. Recombinant plasmid 
DNA was isolated by carrying out DNA mini-preps, and a BamHI digestion was 
carried out, which confirmed the presence of a BMP-7 insert in the plasmid DNA 
isolated from each of the six clones of transformed cells (data not shown). 
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Figure 4.8 Cloning the BMP-7 cDNA into pIRESbla 
(A) The BMP-7 cDNA insert was released from the pGEM-T vector by carrying out a 
digestion with the BamHI restriction enzyme. (B) The pIRESbla expression vector 
was also digested with BamHI within its multiple cloning site, to produce compatible 
ends for ligation with the digested BMP-7 cDNA. (C) The digestion products were 
run on a 1 % agarose gel in separate tracks. Digestion of the pGEM-T vector that 
contained the BMP-7 insert produced two bands of 3 kb and 1.35 kb in size 
respectively (lane 1). Digestion of the pIRESbla vector via its single BamHI site 
resulted in a band of 4.85 kb in size (lane 2). (D) A ligation reaction was carried out to 
insert the BMP-7 cDNA into the pIRESbla vector via the prepared BamHI sites. 
 
 
 
4.2.3.3.1 Confirming the orientation of the BMP-7 insert 
 
Because the BMP-7 cDNA was inserted into the pIRESbla vector non-
directionally using a BamHI site at both the 5’ and 3’ ends, it was possible for the 
insert to ligate in either the correct 5’-3’ orientation or the reverse 3’-5’ orientation. 
The CMV promoter drives expression in the pIRESbla vector in a directional manner, 
requiring the ATG start codon at the 5’ end of the sense strand of the inserted cDNA 
to be downstream of the promoter sequence in order for expression to occur. 
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Therefore, it was important to ensure that the BMP-7 cDNA insert was not only 
present in the pIRESbla vector, but also in the correct orientation. 
This was accomplished using a PCR-based approach, where the sense primer 
(pIRESbla-S) was located outside of the BMP-7 insert, adjacent to the 5’ end of the 
multiple cloning site of the pIRESbla vector and directed towards the insert. The 
antisense primer (BMP7WT-A) was located within the BMP-7 cDNA insert, at the 3’ 
terminal end (Figure 4.9). Purified mini-prep DNA isolated from the transformed 
DH5α E. coli cells was used as a template, and the PCR reaction products were 
electrophoresed on 1 % agarose gels (Figure 4.9C). In the case that the BMP-7 cDNA 
insert had ligated into the pIRESbla vector in the correct 5’-3’ orientation, the PCR 
reaction yielded a product of 1.4 kb in size. However, if the insert was in the reverse 
orientation, no amplification product would be produced from the reaction as a result 
of the primers being directed the same way rather than towards each other. Figure 
4.9C shows that both clones 2 and 3 contained a BMP-7 cDNA insert in the correct 
orientation, indicated by the presence of a 1.4 kb PCR product. The plasmid DNA 
from clone 2 was scaled-up in preparation for transfection by carrying out an 
endotoxin-free DNA maxi-prep, and was sent for sequencing using the pIRESbla-S 
and pIRESbla-A primers, which confirmed that the insert DNA was absent of any 
errors. 
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Figure 4.9 Determining the BMP-7 cDNA orientation within pIRESbla 
A PCR reaction was carried out on the plasmid DNA from six clones of transformed 
cells, to determine the orientation that the BMP-7 cDNA insert had ligated into the 
pIRESbla vector. The pIRESbla-S and BMP-7WT-A primers were used, annealing to 
sequences within the pIRESbla vector and BMP-7 insert respectively. (A) The BMP-7 
cDNA insert ligated into the pIRESbla vector in the correct orientation, with the 
primers directed towards each other, produced a 1.4 kb amplification product. (B) The 
BMP-7 cDNA insert ligated into the pIRESbla vector in the reverse orientation, with 
the primers directed the same way, produced no amplification product. (C) Agarose 
gel electrophoresis of the PCR products showed that clones 2 and 3 both contained a 
BMP-7 insert in the correct orientation, producing an appropriately sized 1.4 kb band. 
 
 
 
4.2.4 Detection of the BMP-7 protein by ELISA 
 
When carrying out studies that involve the expression of recombinant proteins, 
it is important that suitable methods are in place to detect the presence and determine 
the quantity of the expressed protein of interest. Therefore, the human BMP-7 DuoSet 
ELISA kit (R&D Systems) was utilised for the detection of the BMP-7 protein in cell 
culture supernatants and cell lysates following transfection experiments. This assay 
was calibrated using highly purified recombinant human BMP-7 produced in CHO 
cells by R&D Systems. To determine the sensitivity of the assay, a standard curve was 
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produced using a range of BMP-7 concentrations from 0 to 1000 pg/ml, with each 
standard loaded in duplicate. Figure 4.10 shows that the assay remained sensitive in 
detecting BMP-7 at concentrations as low as 31.25 pg/ml, and that the background 
absorbance was minimal. 
 
 
 
 
 
 
Figure 4.10 BMP-7 ELISA standard curve 
A standard curve of recombinant human BMP-7 concentrations, from 0 to 1000 
pg/ml, was produced to determine the sensitivity of the R&D Systems BMP-7 DuoSet 
ELISA assay. The assay sensitively detected the BMP-7 at concentrations as low as 
31.25 pg/ml. A minimal amount of background absorbance was seen, and the result 
shown remained consistent throughout. 
 
 
 
4.2.5 Stable transfection of CHO-K1 cells with the pIRESbla/BMP-
7 vector 
 
Adherent CHO-K1 cells were transfected with the pIRESbla expression vector 
containing the cloned BMP-7 cDNA insert (pIRESbla/BMP-7). At the same time, 
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control transfections were also carried out. These were an empty pIRESbla vector 
only transfection without insert DNA, and a sham transfection using the transfection 
reagent alone in the absence of any DNA. Approximately 24 hours post-transfection, 
the stably transfected cells were selected for resistance to the antibiotic blasticidin at a 
concentration of 10 µg/ml. In the presence of blasticidin in the culture media, all of 
the sham transfected cells died within 24-48 hours of its addition, due to the absence 
of the blasticidin resistance gene. However, cells transfected with the pIRESbla/BMP-
7 vector or the pIRESbla vector alone, which both contained the blasticidin resistance 
gene, survived and began to divide. This indicated that the CHO-K1 cells had been 
successfully transfected. 
Once the transfected cells were growing consistently after passaging and 
considered to be established, 25 cm2 and 75 cm2 flasks were seeded with 0.25 x 106 
cells and 0.75 x 106 cells respectively. After 3 days, when the cells were 
approximately 80 % confluent, the media was aspirated and replaced with fresh media 
containing blasticidin. To determine the time at which expression of the BMP-7 
protein was optimal, 0.5 ml (25 cm2 flasks) or 1 ml (75 cm2 flasks) samples of the cell 
culture supernatants were taken daily for 14 days. A cocktail of protease inhibitors 
was added to the samples immediately after collection, and the supernatants were 
clarified by centrifugation to remove whole detached cells and cell debris, before 
being stored at -20 ºC prior to analysis. To ensure that the total volume in the flask 
remained the same throughout the 14-day time period, a volume of fresh media equal 
to that of the sample removed was added each day. 
Although the stably transfected cells were blasticidin-resistant, and therefore 
expressing the blasticidin S deaminase gene transcript and translating its protein 
product, analysis of the collected supernatant samples by ELISA and Western blotting 
showed that they were not producing and secreting detectable levels of the BMP-7 
protein into the cell culture media at any time during the 14 days. There were no 
discernible differences between the ELISA background absorbance readings and those 
that were obtained from the supernatants of cells transfected with the pIRESbla/BMP-
7 vector or the pIRESbla vector alone. The BMP-7 protein was still undetectable after 
carrying out a twenty-fold concentration of the supernatants using Vivaspin sample 
concentrators (GE Healthcare UK Ltd), and increasing the concentration of blasticidin 
in the media to 20 µg/ml over the same 14-day time course also had no effect. 
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Therefore, cell lysates were prepared to check if the BMP-7 protein was being 
produced but retained within the cell rather than secreted. However, the BMP-7 
protein still remained undetectable, either because it was not being produced, or 
because it was present at levels so low that it fell below the detectable threshold of the 
assays used. 
 
4.2.6 Expression of the BMP-7 protein using adherent Spodoptera 
frugiperda (Sf9) insect cells 
 
Our laboratory had previously successfully expressed glial cell line-derived 
neurotrophic factor (GDNF) using the Invitrogen Bac-to-Bac Baculovirus Expression 
System (detailed in Alfano et al., 2007). As GDNF is another TGF-ß superfamily 
member that possesses the characteristic cystine-knot motif, and is therefore 
structurally similar to BMP-7, an attempt was made to express the human BMP-7 
protein using this system. 
The Bac-to-Bac Baculovirus Expression System provides an efficient and safe 
method to generate recombinant baculoviruses, enabling the expression of proteins in 
the eukaryotic Sf9 insect cell line. The method is based on the site-specific 
transposition of a gene of interest from a pFastBac donor plasmid into a baculovirus 
shuttle vector (bacmid). This occurs via the Tn7 transposon, thereby producing a 
recombinant bacmid, which is produced and propagated in DH10Bac E. coli cells 
(Figure 4.11). There are a number of advantages of using eukaryotic Sf9 insect cells 
for protein expression. These cells are robust and carry out the same post-translational 
modifications that take place in mammalian cells. This ensures that the correct 
disulphide bridges are formed, producing correctly folded proteins. Insect cells also 
utilise the same glycosylation sites as mammalian cells, adding mannose-rich glycans, 
and are able to secrete expressed proteins into the culture media, therefore aiding 
protein recovery. 
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Figure 4.11 The Bac-to-Bac Baculovirus Expression System 
The Bac-to-Bac Baculovirus expression system (Invitrogen) provides a convenient 
method for producing a recombinant baculovirus that can be used for the expression 
of proteins in insect cells. The gene of interest is cloned into the pFastBac 1 donor 
plasmid (A), and transformed into competent DH10Bac E. coli cells that contain the 
baculovirus shuttle vector, also known as the bacmid (B). Once transformed, site-
specific transposition of the gene of interest from the donor plasmid to the bacmid 
occurs inside the DH10Bac cells, producing a recombinant bacmid (C). The high 
molecular weight recombinant bacmid DNA is extracted and purified by carrying out 
a DNA maxi-prep (D). (Image adapted from that presented in the Invitrogen Bac-to-
Bac product manual). 
 
 
 
4.2.6.1 Generation of the recombinant bacmid 
 
For expression in Sf9 cells, the BMP-7 cDNA was cloned into the pFastBac 1 
donor plasmid following the procedures described in section 4.2.3. Other pFastBac 
donor plasmids are also available as part of this expression system, but pFastBac 1 
was selected as it allows the expression of proteins without the addition of a tag. The 
recombinant pFastBac 1/BMP-7 plasmid was then transformed into DH10Bac E. coli 
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cells, which contained both the baculovirus shuttle vector (bacmid) and a helper 
plasmid. Once transformed, directional transposition occurred between the mini-Tn7 
element on the pFastBac 1 vector and the mini-attTn7 target attachment site within the 
bacmid DNA, assisted by the pMON7124 helper plasmid that encodes the necessary 
transposase enzyme and confers resistance to the antibiotic tetracycline. This resulted 
in the production of a recombinant bacmid. Colonies of DH10Bac cells that had 
successfully carried out this transposition step were identified after approximately 48 
hours with the aid of blue/white selection. As expression of the LacZα peptide within 
the bacmid was disrupted upon insertion of the mini-Tn7 element into the mini-attTn7 
attachment site, colonies that contained the recombinant bacmid were white, whilst 
colonies that contained the unaltered bacmid were blue. White colonies were picked 
from the agar plate and the recombinant bacmid DNA was isolated and purified by 
carrying out a DNA maxi-prep. The presence of the BMP-7 cDNA in the recombinant 
bacmid was confirmed by DNA sequencing with the primers pFastBac1-S and 
pFastBac1-A, located at the 5’ and 3’ ends respectively of the multiple cloning site 
within the pFastBac 1 vector. 
 
4.2.6.2 Production of the recombinant baculovirus 
 
To produce a recombinant baculovirus, 9 x 105 Sf9 insect cells were 
transfected with 1 µg of purified bacmid DNA, containing the transposed BMP-7 
cDNA, in wells of a 6-well plate. This was carried out in duplicate alongside a 
positive control of a bacmid containing GDNF, and a negative control containing just 
the Cellfectin transfection reagent without DNA. The control transfections were 
carried out in separate plates to minimise the chance of cross-contamination 
occurring. Following transfection, the cells were incubated in a 27 ºC humidified 
incubator for approximately 72 hours. At this time, signs of late viral infection were 
observed in the cells that had been transfected with bacmid DNA containing the BMP-
7 cDNA or the GDNF positive control. The cells transfected in this way had ceased 
growing, started to detach from the plate, and many appeared lysed upon visual 
inspection with a microscope. However, the cells that had been transfected with the 
Cellfectin reagent alone remained unaffected. This indicated that the visual changes 
observed in the transfected cells were a result of viral infection. The media containing 
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the virus, and the negative control transfected media, was collected from each well 
and transferred to sterile 15 ml centrifuge tubes. The media was then clarified by 
centrifugation at 500 x g for 5 minutes, before being stored at 4 ºC protected from 
light and labeled as the P1 baculoviral stock. The titre of the P1 baculoviral stock, 
calculated in plaque forming units (pfu)/ml, was determined by carrying out a viral 
plaque assay. This stock was amplified to produce a high-titre P2 baculoviral stock, of 
which the titre was also determined. The results from the viral plaque assays are 
displayed in Table 4.1, where it can be seen that the titres of both the P1 and P2 
baculoviral stocks lie towards the higher end of the expected ranges suggested by 
Invitrogen in their product manual. It was therefore decided that these viral titres were 
sufficient to be used for the infection of Sf9 cells to express the BMP-7 protein. 
 
 
 
Baculoviral 
stock 
Baculoviral titre 
(pfu/ml) 
Supplier’s (Invitrogen) expected 
baculoviral titre range (pfu/ml) 
P1 0.69 x 107 1 x 106 to 1 x 107 
P2 0.76 x 108 1 x 107 to 1 x 108 
 
 
Table 4.1 Titres of the P1 and P2 baculoviral stocks 
The titres of the P1 and P2 baculoviral stocks were determined by carrying out a viral 
plaque assay. The results obtained showed that the titres obtained were towards the 
higher end of the supplier’s expected range. 
 
 
 
4.2.6.3 Infection of Sf9 insect cells with the recombinant baculovirus 
 
On the recommendation of the Invitrogen Bac-to-Bac Baculovirus Expression 
System product manual, a small-scale baculoviral infection of the Sf9 cells was 
initially carried out in order to optimise the conditions for protein expression. 6 x 105 
Sf9 cells were seeded in wells of a 24-well plate and infected at varying multiplicities 
of infection (MOI, pfu/cell) ranging from 1 to 5. However, at this scale of infection 
for all MOIs tested, the BMP-7 protein was not detectable by ELISA in the cell 
culture supernatants or cell lysates (data not shown). The same remained true after 
producing repeat batches of the bacmid and the recombinant baculovirus. However, it 
should be noted that the Sf9 cells did show all the expected signs of late-stage 
infection (cessation of cell growth, granular appearance, detachment and cell lysis), 
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indicating that the baculovirus was otherwise functional. Also, the GDNF positive 
control infection worked as it had done previously to produce the GDNF protein (later 
detailed in Alfano et al., 2007). 
To ensure that the lack of detectable BMP-7 protein was not just a result of the 
infections initially being carried out on a small scale, the infections were repeated on a 
larger scale. To prepare for baculoviral infection, 1.8 x 107 Sf9 cells were seeded in 
100 mm diameter dishes in 12 ml of growth media, and allowed to attach for 1 hour. 
After this time, the media was aspirated, the cells were rinsed once with fresh growth 
media, and 12 ml of fresh media was added to the dishes. To express the BMP-7 
protein, the seeded cells were infected with the P2 baculoviral stock at a MOI of 2, 
which had previously worked well for the expression of GDNF in these cells. This 
was again carried out alongside a positive control of an infection using a GDNF-
expressing recombinant baculovirus, and a negative control infection using media 
collected from cells that were transfected with the Cellfectin transfection reagent 
alone. 
When the Sf9 cell culture supernatants and lysates from the second round of 
baculoviral infections described above were subjected to ELISA (data not shown), the 
BMP-7 protein was once again undetectable despite the cells showing the expected 
signs of late-stage infection. This finding therefore suggested that the BMP-7 protein 
was not being expressed or was only being expressed at very low and undetectable 
levels. The same supernatants and cell lysates were also subjected to SDS-PAGE 
under reducing conditions and Western blotted (Figure 4.12). 
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Figure 4.12 BMP-7 protein expression using Sf9 insect cells 
Sf9 insect cells were infected with recombinant baculoviruses containing cDNA 
sequences that encoded for the BMP-7 protein. After approximately 72 hours, the 
supernatants were collected and whole-cell lysates were produced. The proteins were 
separated by SDS-PAGE under reducing conditions on a 15 % polyacrylamide gel and 
then Western blotted. Lane 1: 5 ng rhBMP-7 standard (R&D). Lane 2: unconditioned 
cell culture medium. Lane 3: uninfected conditioned cell culture medium. Lane 4: 2.5 
ng rhBMP-7 standard diluted in uninfected conditioned cell culture medium. Lane 5: 
uninfected cell lysate. Lane 6: BMP-7 clone 1-infected supernatant. Lane 7: BMP-7 
clone 1-infected cell lysate. Lane 8: frameshifted BMP-7 clone 2-infected supernatant. 
Lane 9: frameshifted BMP-7 clone 2-infected cell lysate. 
 
 
 
A study carried out by Jones et al. (1994) showed that the human BMP-7 
protein is initially synthesised in the form of a monomeric 50 kDa pro-protein. This 
pro-protein is dimerised, glycosylated and then proteolytically cleaved at its arginine-
X-X-arginine maturation site, before being secreted by the cells into the culture 
medium. The secreted mature protein consists of 34-38 kDa disulphide-linked 
homodimers, which migrate upon reduction as 17-23 kDa monomers depending on 
the extent of glycosylation. If the BMP-7 protein was present in the infected Sf9 cell 
supernatants and lysates, one would have expected the pattern of bands observed on 
the developed Western blot to closely resemble those on the polyacrylamide gel 
images that were published by Jones et al. (1994). However, Figure 4.12 shows that 
this was not the case. 
The developed Western blot shown in Figure 4.12 shows that the recombinant 
BMP-7 protein is either absent or at such low levels in secreted form in the culture 
supernatant that it is undetectable. This is apparent due to there being no 
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immunoreactivity difference between the lanes containing the supernatants collected 
from cultured Sf9 cells that were infected with BMP-7 cDNA-containing 
baculoviruses (lanes 6 and 8) and the unconditioned and conditioned medium-
containing negative control lanes (lanes 2 and 3); no immunoreactivity whatsoever 
was observed in any of these lanes. This finding therefore appears to support the 
aforementioned ELISA data. To ensure that the presence of other proteins in the 
culture supernatants was not hindering the detection of BMP-7, 2.5 ng of rhBMP-7 
was diluted in conditioned medium and electrophoresed in lane 4, where it remained 
detectable. 
It can also be seen in Figure 4.12 that immunoreactivity was observed in lanes 
7 and 9. In these lanes, the lysates of Sf9 cells that were infected with baculoviruses 
containing the cDNA of BMP-7 clones 1 and 2 respectively had been electrophoresed. 
Initially, it appeared that the presence of immunoreactivity in these lanes contradicted 
the ELISA data by suggesting that the BMP-7 protein was expressing at detectable 
levels, albeit remaining within the cells rather than being secreted. However, upon 
further inspection and consideration of the pattern of bands displayed within these 
lysate lanes, this no longer seems to be the case. The reasons for this are as follows: 
Firstly, if the BMP-7 protein was responsible for the bands in these lanes, one would 
have expected to have seen a pro-protein monomer band of approximately 50 kDa in 
size [based on the findings of Jones et al. (2004)]. A band of this size is notably 
absent. Secondly, although bands are present in these lysate lanes at approximately 36 
kDa in size, which is the size of the mature BMP-7 protein dimer, it is unlikely that 
the BMP-7 protein is responsible for these bands. This is because under reducing 
conditions, one would instead expect to see 17-23 kDa mature monomer bands, as was 
the case in the control lanes 1 and 4 that contained reduced commercial recombinant 
human BMP-7 derived from CHO cells. Depending on the time-scale between 
cleavage of the pro-protein and the secretion of the mature protein, one might not even 
expect to observe bands corresponding to the mature protein in the cell lysates. 
One explanation for the absence of the BMP-7 protein in the supernatants and 
the absence of a 50 kDa pro-protein monomer band in the lysates, as well as the 
presence of alternative unexpected bands between 36 kDa and 22 kDa in size in the 
lysates, is that the protein was not being correctly processed by the cells. It is possible 
that this may have led to the degradation of the protein within the cells prior to 
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secretion, which may have also been responsible for the presence of low molecular 
weight bands of around 6 kDa in size. 
However, a later finding following further DNA sequence analysis of BMP-7 
clones 1 and 2 casts further doubt over this theory and provides more evidence to 
suggest that the BMP-7 protein is not responsible for the presence of the 
immunoreactivity seen in lanes 7 and 9. The sequence analysis revealed that clone 2 
contained a single nucleotide base insertion, which caused a frameshift to occur. This 
led to the creation of a very early stop codon only 18 bases downstream of the 
insertion point, and approximately one third of the way through the sequence portion 
that encodes the mature component of the BMP-7 protein. Although this would have 
resulted in clone 2 containing only a short section of the mature BMP-7 protein that 
would have a lower molecular weight than the full mature protein that would be 
produced by clone 1, it is apparent from Figure 4.12 that there are no differences 
between the molecular weights of the bands seen for clones 1 and 2. Therefore, the 
BMP-7 protein is unlikely to be responsible for producing the bands in these lanes. 
Instead, it appears likely that the bands were produced by a non-specific antibody-
antigen interaction. Furthermore, it can be seen that these bands are clearly not present 
in the negative control lysate lane (lane 5), which contained a lysate prepared from 
cells that were mock infected with supernatants that did not contain any baculovirus. 
This immunoreactivity therefore cannot have been produced by a protein found 
natively within the Sf9 cells. Thus, it is more probable that the immunoreactivity 
displayed was the result of a non-specific interaction of the polyclonal anti-BMP-7 
antibody with baculoviral proteins in the infected cell lysates, which one would expect 
to be in abundance. 
In hindsight, a more appropriate negative control for the Western blot would 
have been a lysate produced from cells infected with the GDNF-expressing 
baculovirus. This may have assisted with the interpretation of the bands, perhaps 
shedding light on the origin of the immunoreactivity and possibly enabling firmer 
conclusions to be drawn about whether or not it was the result of a non-specific 
antibody-antigen binding interaction. 
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4.2.7 Optimisation of the pIRESbla/BMP-7 expression vector 
 
After stably transfecting CHO cells with the pIRESbla/BMP-7 plasmid 
construct, the BMP-7 protein was undetectable in supernatants and cell lysates, as 
described earlier in section 4.2.5. However, the cells survived and grew in the 
presence of the antibiotic blasticidin, so they were stably expressing the blasticidin 
resistance gene and translating its protein product. Because the BMP-7 cDNA was 
cloned upstream of the blasticidin resistance gene, separated by an IRES element, and 
the expression of both genes was driven from a single CMV promoter, it is unlikely 
that the mRNA transcript for the blasticidin resistance gene would have been present 
without the mRNA for the BMP-7 gene. It was therefore a possibility that a lack of 
efficiency during the translation stage of protein synthesis might have been 
responsible for the absence of a detectable level of the BMP-7 protein. As a result of 
this, the decision was made to modify the original pIRESbla/BMP-7 expression 
cassette in order to optimise the translation of the protein. 
Whilst investigating ways in which BMP-7 protein translation could be 
improved, it was noticed that some of the commercial cytokine companies, such as 
R&D Systems and Sigma Aldrich, express many of their BMP recombinant proteins 
in CHO cells, but as chimeras. In this situation, the mature sequence of the BMP of 
choice is fused onto the pre-pro sequence of BMP-2 (Figure 4.13). When contacted, 
the companies were unable to divulge the reason that this approach was adopted due 
to it being proprietary information, and have since removed the small amount of 
information they had previously provided from the product datasheets. However, a 
publication by Hammonds et al. (1991) may provide some insight as to why this 
method for protein expression was used. The authors of this paper have shown that by 
using the pre-pro region of BMP-2, fused to the mature region of BMP-4, the 
expression of the mature BMP-4 protein in mammalian cells was “dramatically 
improved”. It is purely speculative, but quite plausible, that the commercial suppliers 
saw the considerable benefit that could be gained from this, and adapted this method 
for the production of the mature protein forms of other BMP family members. 
Although Hammonds et al. (1991) provide no explanation of the reason why 
the BMP-2 pre-pro domain had such an effect on increasing the expression of the 
mature BMP-4 protein that was fused to it, this is a very interesting phenomenon that 
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might be taken advantage of, and which provoked much thought. It is quite possible 
that the enhanced translation of BMP-2 mRNA into protein could be a consequence of 
a regulatory difference, which may have developed during the evolution of the BMP 
family. To explore this avenue of thought at the simplest level, a brief analysis was 
carried out on the mRNA sequences of some of the BMP family members. 
To initiate the translation of protein from mRNA in eukaryotic cells, the small 
ribosomal subunit scans for specific sequences on the transcribed mRNA strand. 
These short translation initiation sequences begin several nucleotide bases upstream of 
the translation start site, and incorporate the required AUGStart triplet codon within 
them (Kozak, 2002 and references within). In mammals, the optimal context for 
recognition of the AUGStart codon is (GCCGCC)A/GCCaugG, with the A or G at 
position –3, and the G at position +4 (both highlighted in bold), being the most 
conserved and functionally important bases (Kozak, 2002). The bases with less 
importance are enclosed within brackets. Sequences in this optimal context are 
generally referred to as Kozak consensus sequences, named after Marilyn Kozak who 
is the author that first described them (Kozak, 1981). A comparison of the translation 
initiation sequences of some of the BMP family members (Figure 4.14), shows that 
BMP-2 mRNA contains a complete match of the most important core component of 
the optimal Kozak consensus sequence. However, it can also be seen that BMPs -4, -5 
and -7, which the commercial suppliers produce in mature form using the BMP-2 pre-
pro sequence, show an obvious variation in this region. Therefore, the strong Kozak 
sequence that BMP-2 possesses may be responsible for its enhanced expression 
compared to other BMP family members. If this is the case, because the BMP-7 
translation initiation sequence appears to be weaker than that of BMP-4, one might 
expect the BMP-2 pre-pro domain to have an even greater effect on the production of 
the mature BMP-7 protein than was seen for BMP-4.  
In light of these findings and observations, an attempt was made to optimise 
the translation of the BMP-7 protein by the addition of an ideal Kozak consensus 
sequence at the 5’ end of the BMP-7 cDNA. Although other elements might exist in 
the mRNA or protein sequences of the pre-pro domain of BMP-2, which might be 
responsible for its favourable expression, this approach provided a convenient starting 
point without the added complexity of producing a chimeric protein. 
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Figure 4.13 Commercial recombinant BMP-2/7 chimeric protein 
It has been noted that a few of the commercial suppliers express some of their 
recombinant BMPs as chimeras. In this case, the mature component of the BMP-7 
protein is fused to the C-terminal end of the pre-pro region of BMP-2, and is released 
by proteolytic cleavage at the indicated RXXR dibasic site. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.14 BMP translation initiation sequences 
A comparison of the 5’ mRNA sequences of some of the BMP family members. The 
core component (-3 to +4) of the translation initiation sequences is highlighted in 
yellow, and the AUGStart codon (+1 to +3) is underlined. BMP-2 can be seen to 
contain a particularly strong core sequence, matching the optimal Kozak consensus of 
ACCaugG. 
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4.2.7.1 The production and cloning of a BMP-7 cDNA insert containing an 
optimised Kozak consensus sequence 
 
To try to increase the efficiency of BMP-7 protein translation, a modified 
BMP-7 cDNA insert that contained an optimal Kozak consensus sequence at the 5' 
end was produced by carrying out a PCR reaction. The original pIRESbla/BMP-7 
vector was used as a template, and the sequence was amplified using the BMP7WT2-
S and BMP7WT-A forward and reverse primers respectively. The BMP7WT2-S 
forward primer incorporated the complete Kozak consensus sequence of 
GCCGCCACCatgG within it, as well as the same BamHI restriction site that the 
reverse primer contained to aid the subsequent cloning of the insert. The addition of 
the Kozak sequence resulted in the first base following the start codon (position +4) to 
be changed from a C to a G, which in turn led to the substitution of the second amino 
acid in the signal peptide from a histidine residue to an aspartic acid residue. In the 
same way as described earlier in section 4.2.3, the resulting PCR product was purified 
and cloned into the pIRESbla expression vector via its BamHI restriction site (Figure 
4.15) to produce the pIRESbla/Kozak-BMP-7 vector. 
 
 
 
 
 
 
 
Figure 4.15 Addition of a Kozak consensus sequence to the BMP-7 cDNA 
In an effort to increase the efficiency of BMP-7 protein translation, an optimised 
Kozak consensus sequence (GCCGCCACCatgG) was introduced by PCR at the 5’ 
end of the BMP-7 cDNA. This modified insert was then cloned into pIRESbla via its 
BamHI site to produce the pIRESbla/Kozak-BMP-7 vector. The 5’ region of this 
vector is shown. 
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4.2.8 Stable transfection of CHO-K1 cells with the 
pIRESbla/Kozak-BMP-7 vector 
 
CHO-K1 cells were stably transfected with the pIRESbla/Kozak-BMP-7 
vector using the same procedure that was described in section 4.2.5. The same control 
transfections were also carried out, with the addition of another transfection using the 
pIRESbla/BMP-7 vector that had previously failed to produce a detectable level of 
BMP-7 protein for comparison. In order to determine the effect that the addition of an 
optimal Kozak consensus sequence had on the production of the BMP-7 protein, a 
time-course experiment was conducted. Supernatant samples were collected daily 
from the flasks containing the transfected cells over a 10-day time period, and their 
BMP-7 content was determined by ELISA. 
As before, the BMP-7 protein was undetectable in the supernatants from the 
cells stably transfected with the pIRESbla/BMP-7 vector, producing absorbance 
readings at background levels, as did the pIRESbla vector only transfected 
supernatants. However, in contrast to these findings, Figure 4.16 shows that the 
addition of a Kozak consensus sequence to the BMP-7 cDNA had a positive impact 
on protein expression. It can be seen that the CHO cells that were stably transfected 
with the pIRESbla/Kozak-BMP-7 vector produced and secreted detectable levels of 
the BMP-7 protein. Under normal growth conditions, in 10 % foetal bovine serum 
(FBS), the amount of BMP-7 protein in the culture supernatant peaked after 2 days at 
a concentration of 22.4 ng/ml. After 4 days, the concentration of secreted protein 
decreased to 15.8 ng/ml before stabilising in the region of 13-14 ng/ml, with the 
exception of a temporary drop to 12 ng/ml after 7 days. 
Although this was the first time that detectable levels of protein had been 
achieved, the levels were relatively low in comparison to the quantities that were 
required to carry out heparin-binding studies. The supernatants also contained a lot of 
extraneous protein due to the presence of the 10 % FBS, which may have interfered 
with such studies. It was therefore apparent that the supernatants would need to be 
both concentrated and at least partially purified before further use. To assist with the 
removal of the serum proteins, the CHO cells were adapted to growth in media 
containing 2 % FBS. Samples were collected again over a 10-day time period to 
determine the effect that the five-fold reduction in FBS had on BMP-7 protein 
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expression. It can be seen in Figure 4.16 that under these conditions the concentration 
of BMP-7 in the media was considerably lower, at a maximum of 9.5 ng/ml on day 1 
and minimum of 1.03 ng/ml on day 8. A similar experiment was also carried out in 
serum-free conditions using CHO-S-SFM II medium (Invitrogen), but the 
concentration of BMP-7 in the supernatant was even lower than that found in the 
presence of 2 % FBS, not exceeding 2 ng/ml (data not shown). The decrease in BMP-
7 production that was observed as the concentration of FBS in the media was reduced 
was most likely a result of the growth conditions no longer being optimal for the cells, 
even after adaptation. It is also possible that the secreted protein became more 
susceptible to being degraded when the concentration of extraneous serum proteins in 
the media was reduced. 
 
 
 
 
 
 
Figure 4.16 Expression of BMP-7 in stably transfected CHO-K1 cells 
CHO-K1 cells were stably transfected with the pIRESbla/Kozak-BMP-7 vector, and 
grown in media containing 10 % or 2 % FBS. Supernatant samples were collected 
daily over a 10-day period and their BMP-7 content was determined by ELISA. 
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4.2.9 Site-directed mutagenesis 
 
4.2.9.1 C-terminal point mutations 
 
Having successfully expressed detectable levels of the wildtype recombinant 
human BMP-7 protein, attention was turned to producing mutant DNA constructs to 
be used for the expression of mutant BMP-7 protein variants. The molecular docking 
simulations described in Chapter 3 predicted the C-terminal basic amino acids lysine 
419, arginine 421 and arginine 426 to be the key contact residues in the binding 
interaction between BMP-7 and heparin/HS. Depending on whether the BMP-7 
protein dimer possesses two independent heparin/HS-binding sites - one on each 
monomer - or a single bridged cooperative binding site, either 3 or 6 basic residues in 
total may take part in the binding interaction based on the results of these simulations. 
To maximise the chance of reducing the heparin/HS-binding affinity of BMP-
7, whilst hopefully maintaining the structural integrity of the protein, the decision was 
made to carry out point substitutions of these predicted key residues for alanine in 
pairs (section 3.2.3.5). Based on either of the two binding scenarios described above, 
this would result in a reduction of the number of predicted basic contact residues in 
the C-terminal region by two-thirds. Only one of the predicted key basic residues 
would remain on each monomer, which would be insufficient to form a heparin/HS-
binding site, even if the protein monomers were to bind cooperatively to a single GAG 
chain. 
As explained in Chapter 3 (section 3.2.3.5), the first pair of amino acids 
selected for substitution to alanine were lysine 419 and arginine 421. To produce these 
two amino acid changes (K419A and R421A) in the translated BMP-7 protein, it was 
necessary to make a total of four nucleotide base substitutions in the corresponding 
cDNA sequence. As shown in Figure 4.17A, these point mutations and their positions 
were as follows: a1255g, a1256c, a1261g and g1262c. The resulting amino acid 
changes in the C-terminal region are shown in Figure 4.17B. To introduce these point 
substitutions into the BMP-7 cDNA sequence, the Stratagene QuikChange II Site-
Directed Mutagenesis Kit was used. The QuikChange II kit provides a fast and 
convenient three-step method for making site-specific mutations in DNA inserts 
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within double-stranded plasmids, therefore eliminating the need for sub-cloning 
(Figure 4.18). 
During the first step of the procedure, in which thermal cycling was carried 
out, 20 ng of the double-stranded pIRESbla/Kozak-BMP-7 vector template was 
denatured at 95 ºC for 30 seconds. This vector was selected as the template so that the 
K419A/R421A mutant would also contain the optimal Kozak consensus sequence, 
which was shown in section 4.2.8 to increase the production of recombinant human 
BMP-7 in CHO-K1 cells. After denaturing the template, the mutagenic sense and 
antisense primers were annealed to the template at 55 ºC for 1 minute. These primers, 
named BMP7K419A/R421A-S and BMP7K419A/R421A-A respectively, both 
contained the desired mutations and were complementary to opposite strands of the 
same BMP-7 cDNA region. The annealed primers were then extended without 
displacement at 68 ºC for 6 minutes (1 minute/kb of plasmid length) using PfuUltra 
high-fidelity DNA polymerase, generating a mutated plasmid containing staggered 
nicks. The temperature cycle was repeated 18 times. 
Although the first thermal cycling step was very similar to a typical PCR 
reaction, it differed due to the template amplification taking place in a linear manner 
rather than logarithmically. This occurred as a direct result of the location of the 
staggered nicks, positioned immediately upstream of the 5’-termini of both primers. 
These were the points where the PfuUltra DNA polymerase had completed 
synthesising the mutated circular plasmid strands, and detached once it returned to the 
5’ end of the primer that it started extending from. Because of the nicks, the primers 
could only be extended when annealed to the parental DNA template strands, and not 
when annealed to the newly synthesised mutant strands as would normally be 
permitted during a typical PCR reaction. Along with using a lower number of thermal 
cycles, this has the benefit of reducing the chance of any unwanted second-site errors 
from occurring. 
After producing the mutant plasmids, the wildtype parental template DNA was 
removed from the reaction mixture. The parental DNA was differentiated from the 
newly synthesised mutant DNA due to it being isolated from DH5α E. coli cells, and 
therefore Dam (DNA adenine methylase) methylated. Unlike the mutant DNA, this 
made it susceptible to digestion by the DpnI endonuclease. The DpnI treatment was 
carried out in a water bath at 37 ºC for 2 hours, after which time 1 µl of the mixture 
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was transformed into XL-1 Blue supercompetent E. coli cells. Single colonies were 
picked from transformation plates, and the mutated plasmid DNA was isolated by 
carrying out DNA mini-preps. In preparation for transfection, this DNA was scaled-up 
by carrying out an endotoxin-free DNA maxi-prep. Finally, the purified plasmid DNA 
was sent for sequencing, confirming the presence of the desired mutations, and that 
the mutant BMP-7 cDNA insert was free of any unwanted errors. This mutant vector 
construct was given the name pIRESbla/BMP-7-K419A/R421A. 
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Figure 4.17 The BMP-7 K419A and R421A C-terminal point substitutions 
In an attempt to reduce the heparin-binding affinity of BMP-7, efforts were made to 
produce a mutant protein containing a pair of C-terminal point substitutions, termed 
K419A/R421A (B). To introduce these mutations, it was necessary to make at total of 
4 nucleotide base changes in the cDNA sequence (A). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.18 An overview of the Stratagene QuikChange II site-directed 
mutagenesis method 
The three-step QuikChange method allows point-specific mutations to be made 
directly in DNA inserts located within double-stranded plasmids. After generating the 
mutant strands using suitable primers, the methylated parental template DNA is 
eliminated by digestion with the DpnI enzyme. The remaining mutated plasmid DNA 
is then transformed into XL-1 Blue supercompetent cells, to repair nicks and produce 
sufficient quantities of the plasmid for transfection. (Image adapted from that 
presented in the Stratagene QuikChange II Site-Directed Mutagenesis Kit product 
manual). 
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Figure 4.17 The BMP-7 K419A and R421A C-terminal point substitutions 
Please refer to the figure legend on the opposite page. 
 
 
 
 
 
 
Figure 4.18 An overview of the Stratagene QuikChange II site-directed 
mutagenesis method 
Please refer to the figure legend on the opposite page. 
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4.2.9.2 N-terminal deletion 
 
As discussed above (section 4.2.9.1), the molecular docking simulations 
carried out in Chapter 3 predicted the C-terminal basic amino acids lysine 419, 
arginine 421 and arginine 426 to be the key contact residues in the binding interaction 
between BMP-7 and heparin/HS. However, a limitation of the published BMP-7 
crystal structures used to carry out these simulations was that they were missing 27 to 
35 of the 37 amino acids in their N-terminal regions, upstream of the first cysteine 
residue. This missing portion of the structure remains unresolved as a result of it being 
disordered (Griffith et al., 1996; Greenwald et al., 2003), but contains either 6 or 7 
(depending on the structure) of the 15 basic residues in total found within the mature 
BMP-7 protein. Therefore, when considering elements of the BMP-7 protein that may 
have the potential to act as heparin/HS-binding sites, this region cannot be 
disregarded. 
To determine the importance of the unresolved N-terminal region for 
heparin/HS-binding, the decision was made to produce a truncated BMP-7 mutant that 
was absent of this region, directly mimicking the available crystal structures. In doing 
so, all 7 of the basic lysine and arginine residues located within this structural 
component would be removed. A diagrammatic representation of the proposed N-
terminal deletion can be seen in Figure 4.19. In case the initial amino acids at the N-
terminus of the mature BMP-7 protein were important for cellular recognition of the 
RXXR dibasic cleavage site, situated at the C-terminal end of the pre-pro-protein, the 
first three residues (STG) were left in place. As a result of the deletion, these residues 
were shifted towards the first cysteine of the TGF-β domain. It was thought that this 
would also provide some distance between the cleavage site and the cystine-knot 
motif, therefore reducing the chance of any cleavage problems due to steric hindrance. 
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Figure 4.19 The BMP-7 N-terminal deletion 
To help determine the importance of the unresolved N-terminal region for 
heparin/HS-binding, a truncated BMP-7 mutant was prepared. 32 amino acids were 
removed upstream of the first cysteine residue of the mature protein (ΔS296-R327, 
shown in red), consequently eliminating 7 basic arginine and lysine residues 
(highlighted in bold text and underlined). 
 
 
 
To produce the N-terminal deletion (ΔS296-R327) shown in Figure 4.19, it 
was necessary to delete 96 nucleotide bases from the BMP-7 cDNA (Δ886-981) 
(Figure 4.20A). This was achieved using a PCR-based technique known as overlap 
extension PCR (OE-PCR), requiring a total of three independent PCR reactions to be 
carried out. The first of these reactions utilised the primer pair pIRESbla-S and 
BMP7ΔS296-R327-A, as shown in Figure 4.20B, producing a 999 bp product (Figure 
4.21 lane 2). In the second reaction, the primer pair BMP7ΔS296-R327-S and 
pIRESbla-A were used, producing a 457 bp amplicon (Figure 4.21 lane 1). For both of 
these reactions, the pIRESbla/Kozak-BMP-7 vector was used as a template to once 
again include the optimal Kozak consensus in the cDNA of the truncated mutant. The 
BMP7ΔS296-R327-S and BMP7ΔS296-R327-A sense and antisense primers annealed 
to the BMP-7 cDNA sequence at opposite sides of the deleted region. However, to 
produce an overlap that was used to fuse the two PCR products shown in Figure 
4.20C together, both of these primers incorporated non-annealing sequence 
overhangs. These overhanging sequences were complimentary to the flanking regions 
on opposite sides of the deleted section of cDNA.  
To reconnect the two cDNA fragments generated by the previous PCR 
amplifications, a third and final PCR reaction was performed. In this reaction, equal 
amounts (20 ng each) of the purified 999 bp and 457 bp amplicons were used as a 
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template. An initial denaturation step was carried out, which separated the double-
stranded fragments into their composite strands. The two previous products were then 
able to anneal to one another, combining via their complementary flanking sequences 
that were introduced in the primer overhangs (Figure 4.20D). Once annealed, the 
proofreading Platinum Pfx DNA polymerase (Invitrogen) was able to fill-in the 
missing parts of each strand in the 5’ to 3’ direction. The result of this was a 1408 bp 
product, which contained the complete 1221 bp truncated BMP-7 mutant cDNA insert 
(Figure 4.20E). As the overlap formed by the template fragments shown in Figure 
4.20D also acted as a primer for the polymerase in both directions, no additional 
primers were required to initially fill-in the missing nucleotides. However, after the 
first five thermal cycles of the reaction, the pIRESbla-S and pIRESbla-A primers were 
added to amplify the 1408 bp product (Figure 4.21 lane 3). 
The final stage in producing the truncated BMP-7 ΔS296-R327 mutant 
expression construct was to clone the newly generated cDNA sequence into the 
pIRESbla vector. To remove the extraneous vector DNA and prepare the 1221 bp 
insert for ligation, the 1408 bp PCR product was digested with the BamHI restriction 
enzyme (Figure 4.20E). Due to the presence of the excess vector DNA either side of 
the BamHI cut-site, the PCR product could be cut efficiently without first requiring it 
to be sub-cloned into the pGEM-T vector. The digested DNA was then separated on a 
1 % agarose gel. After gel extracting and purifying the required 1221 bp band, the 
ΔS296-R327 mutant cDNA insert was ligated into the BamHI site of the pIRESbla 
vector, and sequence verified. The resulting mutant BMP-7 expression construct was 
given the name pIRESbla/BMP-7-ΔS296-R327. 
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Figure 4.20 Production of the BMP-7 ΔS296-R327 mutant cDNA sequence 
The truncated BMP-7 ΔS296-R327 cDNA sequence was generated using a PCR-
based method known as overlap extension PCR (OE-PCR). Three PCR reactions were 
required in total. (A) The pIRESbla/Kozak-BMP-7 template, with the 96 bp region to 
be deleted highlighted in red and its flanking regions coloured yellow and green. (B) 
The first two PCR reactions were carried out to produce the overlapping 999 bp and 
457 bp fragments shown in (C). These overlaps were introduced by including non-
annealing sequences in the BMP7ΔS296-R327-S and BMP7ΔS296-R327-A primers. 
These overhangs were complementary to the flanking sequences on opposite sides of 
the deleted region. (D) The overlapping fragments shown in (C) were utilised in a 
final PCR reaction to fill-in the missing nucleotides. The product of this reaction was 
the complete truncated product shown in (E). The additional vector DNA was 
removed by digesting the 1408 bp PCR product with the BamHI restriction enzyme. 
The 1221 bp BMP-7 ΔS296-R327 cDNA insert was then purified and cloned into 
pIRESbla. 
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Figure 4.20 Production of the BMP-7 ΔS296-R327 mutant cDNA sequence 
Please refer to the figure legend on the opposite page. 
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Figure 4.21 Overlap extension PCR (OE-PCR) 
The DNA fragments produced when creating the BMP-7 ΔS296-R327 mutant cDNA 
sequence were analysed on 1 % agarose gels. Lane 1: The 457 bp amplicon generated 
by the reaction using the primer pair BMP7ΔS296-R327-S and pIRESbla-A. Lane 2: 
The 999 bp amplicon generated by the reaction using the primer pair pIRESbla-S and 
BMP7ΔS296-R327-A. Lane 3: The complete 1408 bp amplicon generated by the 
overlap extension PCR reaction. This reaction utilised both the 457 bp and 999 bp 
DNA fragments, and amplification was achieved using the primer pair pIRESbla-S 
and pIRESbla-A. 
 
 
 
4.2.10 Stable transfection of CHO-K1 cells with the mutant BMP-7 
expression constructs 
 
To express the mutant BMP-7 proteins, the pIRESbla/BMP-7-K419A/R421A 
and pIRESbla/BMP-7-ΔS296-R327 vector constructs were individually stably 
transfected into CHO-K1 cells. This was carried out following the same procedures 
described in section 4.2.5, using blasticidin as the selective antibiotic. These 
transfections were performed alongside a positive control using the pIRESbla/Kozak-
BMP-7 vector, an empty pIRESbla vector negative control and a sham transfection 
using the transfection reagent alone in the absence of any DNA. As before, a time-
course experiment was then conducted to monitor the production of the BMP-7 
mutant proteins over a 10-day period. Supernatant samples were collected daily and 
their BMP-7 content was determined by ELISA. A summary of the ELISA data can be 
found in Figure 4.22. 
The results obtained from all three of the control transfections were as 
expected, and as seen previously. This indicated that the transfections were successful. 
Briefly, the CHO-K1 cells that were sham-transfected died within 48 hours after the 
addition of the selective antibiotic, due to them being absent of the blasticidin 
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resistance gene. Also, the cells that were stably transfected with the empty pIRESbla 
vector - as a negative control - survived but did not produce any BMP-7 protein due to 
the absence of the required BMP-7 cDNA sequence. Finally, the positive control - in 
which the cells were stably transfected with the pIRESbla/Kozak-BMP-7 vector - 
produced similar levels of the BMP-7 protein to those observed before, at 21.1 ng/ml 
compared with the 22.4 ng/ml obtained previously. 
Following transfection with the BMP-7 mutant cDNA constructs, the CHO-K1 
cells survived in the presence of blasticidin and grew stably. However, despite this 
and the success of the control transfections, neither of the mutant BMP-7 proteins 
were detectable in the culture supernatants at any time during the 10-day period. This 
was also true when the scale of expression experiments was increased by growing the 
CHO cells in larger 150 cm2 flasks. Therefore, cell lysates were produced to check if 
the proteins were accumulating within the cell rather than being secreted. The BMP-7 
content of these lysates was also determined by ELISA. Whilst the pIRESbla/Kozak-
BMP-7 vector control-transfected cell lysate contained 2.25 ng/ml of recombinant 
BMP-7 protein/1 x 106 cells, the mutant variants were again undetectable. This 
suggested that no protein was being synthesised. The same results were observed 
when the stable transfections were repeated. In case the mutant proteins were present 
but only at very low levels, the proteins in the supernatants were concentrated twenty-
fold using Vivaspin sample concentrators. However, when the concentrated 
supernatants were analysed by ELISA, the mutant proteins still remained undetectable 
(data not shown). This again suggested that there was a lack of mutant protein 
production taking place. The same result was also obtained after attempting to 
partially purify and concentrate the supernatants by carrying out both cation- and 
anion-exchange chromatography (data not shown). 
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Figure 4.22 Expression of the mutant BMP-7 DNA constructs using CHO-K1 
cells 
Adherent CHO-K1 cells were stably transfected with either the mutant BMP-7 
pIRESbla/BMP-7-K419A/R421A or pIRESbla/BMP-7-ΔS296-R327 vector 
constructs. At the same time, positive and negative control stable transfections were 
also carried out using the wildtype BMP-7 pIRESbla/Kozak-BMP-7 DNA construct 
and empty pIRESbla vector respectively. (A) Supernatant samples were collected over 
a period of 10 days and the BMP-7 content of these samples was determined by 
ELISA. The maximum concentration of BMP-7 that was detected in the samples 
during this time period is shown. (B) Cell lysates were also produced from 1 x 106 
CHO-K1 cells and their BMP-7 content was also determined by ELISA. It can be seen 
in (A) and (B) that the mutant BMP-7 proteins were undetectable in both the 
supernatants and lysates. 
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Figure 4.22 Expression of the mutant BMP-7 DNA constructs using CHO-K1 
cells 
Please refer to the figure legend on the opposite page. 
 151 
4.2.11 Reverse transcription polymerase chain reaction (RT-PCR) 
 
The experiments described in section 4.2.10 above showed that the stably 
transfected CHO-K1 cells were not generating detectable levels of the BMP-7 mutant 
proteins, but the reason for this was unclear. One possibility was that the mutations 
that were introduced might have caused complications during either the production or 
post-translational modification of the muteins. This may have resulted in the cells 
degrading any protein that they had produced, rendering it undetectable. Another key 
process from which the expression problems may potentially have arisen was the 
transcription of the mutant mRNA sequences, an essential prerequisite of protein 
translation. However, the stably transfected cells clearly demonstrated resistance to 
blasticidin. As an IRES element was utilized in the expression cassette, the BMP-7 
mutant and blasticidin sequences would have been expressed from the same promoter 
and been present on the same mRNA transcript. Therefore, the occurrence of any 
transcriptional irregularities was unlikely, but needed to be ruled out before any 
conclusions could be drawn. 
To confirm the presence of the mutant mRNA transcripts, a reverse 
transcription polymerase chain reaction (RT-PCR) experiment was performed. The 
RNA was extracted from 7.5 x 106 stably transfected cells using a Qiagen RNeasy kit, 
and any residual DNA was eliminated by digestion with DNase I. The reverse 
transcription step was then completed using random primers to synthesise cDNA from 
the purified RNA. To detect the presence of the BMP-7 mutant mRNA transcripts, a 
PCR reaction was carried out using the BMP7WT2-S and BMP7WT-A sense and 
antisense primers. These primers annealed to regions at the termini of the reverse 
transcribed cDNA sequences, outside of the mutation sites. They were therefore 
suitable for use in the PCR amplification of both the wildtype and mutant BMP-7 
sequences. A number of control RNA extractions and RT-PCRs were also conducted.  
As a positive control for the extraction, reverse transcription and PCR steps, 
RNA was also extracted from the CHO-K1 cells that were producing detectable levels 
of the wildtype BMP-7 protein, and RT-PCR was again performed using the same 
primers. To ensure that the BMP-7 PCR amplification was working correctly, a 
further PCR control was included in which the pIRESbla/Kozak-BMP-7 vector was 
used as the template. The same procedure was also followed for the negative control, 
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using RNA that was purified from the CHO-K1 cells that were stably transfected with 
the empty pIRESbla vector. Finally, actin control amplifications were incorporated 
using the Actin-S and Actin-A primers, to ensure that the whole procedure remained 
consistent throughout. A CHO cell cDNA library, previously produced and kindly 
provided by Chris Ball at NIBSC, was used as an actin positive control template. 
The results from the RT-PCR experiment described above can be seen in 
Figure 4.23. The pIRESbla/Kozak-BMP-7 vector control PCR reaction in lane 1 
shows that the BMP-7 cDNA amplification was successful, producing a band of the 
expected 1.3 kb size. No product was generated when the actin primers were used 
with this template, as an actin negative control, due to the absence of any actin cDNA. 
The opposite result was seen in lane 6, when BMP-7 or actin primers were paired with 
the actin positive control template. The actin primers produced a correctly sized 208 
bp product, whilst no amplification product was obtained when using the BMP-7 
primers. The pattern of results from the reactions in lanes 1 and 6 confirmed that the 
PCR reactions were specific, only producing an amplicon when the appropriate 
template and primer combination were present. Lane 2 shows the result obtained when 
the cDNA produced from the cells stably transfected with the empty pIRESbla vector 
was used as a template. As one would expect, no BMP-7 product was obtained due to 
the absence of the BMP-7 cDNA insert. However, the actin cDNA did amplify, 
confirming that the reverse transcription step was successful. 
Most importantly, Figure 4.23 clearly showed that the CHO-K1 cells that were 
stably transfected with either the pIRESbla/BMP-7-K419A/R421A (lane 4) or 
pIRESbla/BMP-7-ΔS296-R327 (lane 5) mutant vector constructs, were expressing the 
respective mRNA transcripts. The cDNA template from the cells that were stably 
transfected with the pIRESbla/Kozak-BMP-7 vector (lane 3) - which were also 
secreting detectable levels of the wildtype BMP-7 protein - produced a 1.3 kb PCR 
amplification product. The same size product was obtained from the cDNA template 
that was derived from the cells transfected with the pIRESbla/BMP-7-K419A/R421A 
vector (lane 4). It can be seen that the ΔS296-R327 amplification product in lane 5 
was shorter at 1.2 kb because of the truncation. Overall, this experiment confirmed 
that the lack of mutant protein production was not a result of any transcriptional 
defect, suggesting that the problems lied at the protein level. 
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Figure 4.23 Detection of the mutant BMP-7 mRNA in CHO-K1 cells by RT-PCR 
The mRNA was isolated from CHO-K1 cells that were stably transfected with the 
wildtype and mutant BMP-7 expression constructs, and reverse transcribed. To detect 
the presence of the reverse transcribed BMP-7 cDNA, PCR reactions were carried out 
using the BMP7WT2-S and BMP7WT-A sense and antisense primers. Actin control 
amplifications were also carried out using the same samples with the Actin-S and 
Actin-A primers. The cDNA template samples were as follows: Lane 1: 
pIRESbla/Kozak-BMP-7 vector positive control. Lane 2: cDNA from cells transfected 
with the empty pIRESbla vector. Lane 3: cDNA from cells transfected with the 
wildtype pIRESbla/Kozak-BMP-7 vector. Lane 4: cDNA from cells transfected with 
the mutant pIRESbla/BMP-7-K419A/R421A vector. Lane 5: cDNA from cells 
transfected with the mutant pIRESbla/BMP-7-ΔS296-R327 vector. Lane 6: CHO cell 
cDNA actin positive control. 
 
 
 
4.2.12 Expression of the BMP-7 protein variants using suspension 
cultures of Freestyle CHO-S cells 
 
It remained unclear whether the lack of detectable mutant BMP-7 protein 
production resulted from an underlying protein processing difficulty (caused by the 
mutations themselves), or was a side-effect of generally low levels of protein 
expression overall. As efforts had been made to concentrate cell culture supernatants 
twenty-fold, and the mutant proteins were also undetectable in cell lysates, the later 
was unlikely but not implausible. Therefore, a final attempt was made to express the 
BMP-7 mutant variants using Invitrogen’s FreeStyle MAX CHO Expression System. 
This system utilises high density CHO-S cell suspension cultures to allow large-scale 
transient transfection and recombinant protein expression. It was thought that if the 
overall level of protein production could be increased, there would be a greater chance 
of detecting the mutant proteins if present at all, and their quantity was also 
consequently increased. Unfortunately, there was no published data to suggest that 
this expression method would enhance the production of the BMP-7 protein compared 
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to those used previously. However, communications with Chris Ball at NIBSC 
indicated that favourable increases had been obtained when expressing other proteins 
using this system. 
To express the wildtype and mutant BMP-7 variants, 3 x 107 CHO-S cells 
were transfected in suspension with 37.5 µg of either the pIRESbla/Kozak-BMP-7, 
pIRESbla/BMP-7-K419A/R421A or pIRESbla/BMP-7-ΔS296-R327 vector 
constructs. The transfected cell cultures were then incubated at 37 ºC with 8 % CO2 on 
an orbital shaker platform rotating at 135 rpm. Approximately 72 hours post-
transfection, the medium from the cultures was collected and clarified by 
centrifugation. The BMP-7 content of the supernatants was determined by ELISA.  
In comparison to the results obtained from the stable transfections (section 
4.2.8), Figure 4.24 shows that a 4.7 fold increase in the production of the wildtype 
BMP-7 protein was achieved when using the FreeStyle MAX CHO Expression 
System. Despite this wildtype protein expression increase, from 22.4 ng/ml to 104.94 
ng/ml, the mutant BMP-7 proteins remained undetectable. It was therefore concluded 
that the mutations themselves were having a negative impact on the production of the 
proteins, most likely causing folding or processing complications. 
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Figure 4.24 Expression of the mutant BMP-7 DNA constructs using FreeStyle 
CHO-S cells 
Suspension Freestyle CHO-S cells were transiently transfected with either the mutant 
BMP-7 pIRESbla/BMP-7-K419A/R421A or pIRESbla/BMP-7-ΔS296-R327 vector 
constructs. At the same time, positive and negative control transfections were also 
carried out using the wildtype BMP-7 pIRESbla/Kozak-BMP-7 DNA construct and 
empty pIRESbla vector respectively. Supernatants were collected approximately 72 
hours post-transfection and their BMP-7 content was determined by ELISA. Whilst it 
can be seen that the mutant BMP-7 proteins were undetectable, the level of the 
wildtype BMP-7 protein that was obtained (104.94 ng/ml) was 4.7-fold higher than 
the level previously obtained when the same pIRESbla/Kozak-BMP-7 DNA construct 
was expressed using stably transfected adherent CHO-K1 cells (22.4 ng/ml – shown 
for comparison). 
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4.2.13 Transient transfection of CHO-K1 cells with mutant BMP-7 
expression constructs produced by Centocor Inc 
 
During the later stages of the mutagenesis work described previously, a 
recombinant BMP-7 expression study was published by a group from Centocor Inc, 
PA, USA (Swencki-Underwood et al., 2008). This group had also recognised that the 
production of recombinant BMP-7 in mammalian cells presented a number of 
challenges: 
 
“Specifically, the expression level of recombinant mature BMP-7 
protein in mammalian cells is very low, the molecule has poor 
solubility at neutral pH, and intracellular proteolytic processing events 
result in a secreted BMP-7 having multiple amino-termini, creating a 
heterogeneous mixture of proteins.” 
 
The authors of this publication suggested that these difficulties were caused by 
a few main factors. They explain that electrostatics calculations show that the mature 
BMP-7 protein has a strongly bi-polar charge distribution, which may be unfavourable 
for its folding, stability and solubility. In comparison, the mature BMP-2 protein has a 
more even charge distribution. By N-terminal sequencing, the authors also identified 
that the BMP-7 precursor protein contains multiple sites at which it is proteolytically 
cleaved during the prodomain removal step. This differential processing results in the 
production of a mixture of incorrectly processed truncated BMP-7 isoforms. 
Using the available BMP-7 structural information, Swencki-Underwood et al. 
(2008) counteracted these difficulties by designing and generating a number of mutant 
BMP-7 variants, containing point substitutions in the N- and C-terminal regions of the 
mature protein. These substitutions increased the expression level of the recombinant 
BMP-7 protein in CHO cells by approximately eight- to ten-fold when compared to 
the levels obtained for the wildtype protein. This was accomplished by reducing the 
overall charge of the mature protein and removing the alternative cleavage sites. 
These findings were in contrast to those described in this study, where the 
introduction of mutations in the same regions resulted in either a lack of, or substantial 
decrease in protein production. Either way, the mutant proteins were undetectable. 
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However, the mutations that were made by Swencki-Underwood et al. (2008) were 
either of a different type (i.e. substitutions in the N-terminus rather than a deletion), or 
were in different positional combinations. The substitutions that they made in the C-
terminal region were also of a different chemical nature to those in this study, with 
basic amino acids being replaced with negatively charged acidic residues rather than 
alanine, which is neutral and has a much smaller side chain. Despite these differences, 
the mutations described were located in the same C- and N-terminal target regions of 
the mature BMP-7 protein as those in the K419A/R421A and ΔS296-R327 mutants, 
which were produced in section 4.2.9 of this study. Therefore, the Centocor mutants 
were of particular interest, and were requested for use in heparin-binding experiments 
as part of this project. Centocor kindly provided these mutants (Table 4.2) in the 
forms of both DNA expression constructs and clarified conditioned cell culture 
supernatants. 
 
 
Construct identifier Description of point substitutions 
3255             C-terminal:      R421E/N422D/R426E 
3267 N- and C-terminal:      R299S/R314S, R421E/N422D/R426E 
3281             N-terminal:      R299S/R314S 
 
 
Table 4.2 Centocor mutant BMP-7 expression constructs 
The identifications of the mutant BMP-7 constructs produced by Centocor (Swencki-
Underwood et al, 2008), and a description of the substitutions that each contained. 
 
 
 
The mutant constructs and proteins provided by Centocor were identified by 
the unique numbers that they had been given (Table 4.2). Mutant 3255 contained the 
C-terminal substitutions R421E/N422D/R426E, and mutant 3281 contained the N-
terminal substitutions R299S/R314S. All of these point substitutions were combined 
to produce the mutant identified as 3267 (R299S/R314S, R421E/N422D/R426E). 
Notably, the amino acids R421 and R426 were two of the residues - along with K419 - 
that were predicted by the molecular docking simulations in Chapter 3 to be important 
for heparin-binding. To express these mutants, which also contained optimised Kozak 
consensus sequences, 1 x 107 CHO-K1 cells were transiently transfected with the 
supplied constructs using the procedure described in Swencki-Underwood et al. 
(2008). A transfection was also carried out using the pIRESbla/Kozak-BMP-7 
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wildtype construct in this expression system for comparison. Four days post-
transfection, the supernatants were collected from the cell cultures and clarified by 
centrifugation. The BMP-7 content of both these supernatants and those provided by 
Centocor was determined by ELISA (Figure 4.25). 
 
 
 
 
 
Figure 4.25 Expression of the Centocor mutant BMP-7 proteins 
Adherent CHO-K1 cells were transiently transfected with the Centocor 3255 
(R421E/N422D/R426E), 3267 (R299S/R314S, R421E/N422D/R426E) and 3281 
(R299S/R314S) mutant BMP-7 DNA constructs in our own laboratory (panel labeled 
RHUL) and in the laboratory of Swencki-Underwood et al. (2008) at Centocor (panel 
labeled Centocor). Transfections that were carried out in our own laboratory were 
conducted alongside positive and negative control transfections using the wildtype 
BMP-7 pIRESbla/Kozak-BMP-7 DNA construct and empty pIRESbla vector 
respectively. Transfections that were carried out by the Centocor group were 
conducted alongside a negative control using an empty pCEP4 vector (Invitrogen). 
Approximately 72 hours post-transfection, supernatants were collected from the 
transfected cell cultures and their BMP-7 content was determined by ELISA. 
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It can be seen in Figure 4.25 that the supernatants that were provided by the 
Centocor group (labeled Centocor) contained 79.0 ng/ml, 89.0 ng/ml and 158.5 ng/ml 
of the 3255, 3267 and 3281 BMP-7 mutant proteins respectively. In comparison, the 
supernatants that were collected from CHO cells that had been transfected with the 
same mutant BMP-7 expression constructs in our own laboratory (labeled RHUL) 
contained lower concentrations of the respective mutant BMP-7 proteins, at 45.5 
ng/ml (3255), 52.2 ng/ml (3267) and 66.4 ng/ml (3281). It is clear from these results 
that the levels of the mutant BMP-7 proteins that were produced by the CHO cells 
following all of these transfections were greater than the 27.0 ng/ml of wildtype BMP-
7 protein that was produced under the same conditions. However, these concentrations 
were still somewhat lower than the concentrations that were previously published by 
Centocor (Swencki-Underwood et al., 2008), which were in the range of 
approximately 230-260 ng/ml. It is therefore apparent that the expression level of the 
BMP-7 protein remains variable from one transfection to another despite the 
considerable effort that has been put into optimising its biochemical characteristics. 
This once again serves to highlight the challenge that expressing consistent levels of 
the BMP-7 protein presents. It is also noteworthy that in almost all instances, the 
levels of the optimised BMP-7 mutant proteins that were produced by both Centocor 
and ourselves using this expression approach were lower than the level of the wildtype 
BMP-7 protein that was produced by the suspension-cultured CHO-S cells when using 
the Invitrogen FreeStyle MAX CHO Expression System in our own laboratory 
(104.94 ng/ml, as discussed in section 4.2.12). This shows that for the purpose of 
increasing the yield of the BMP-7 protein alone, such optimisation of its biochemical 
characteristics is not necessary when similar gains in production can be obtained by 
simply adopting an alternative expression method. Even so, this work provided us 
with sufficient quantities of mutant proteins that could be used to determine whether 
or not certain basic residues in the N- and C-terminal ends of the BMP-7 protein play 
a key part in BMP-7-HS/heparin interactions. This was assessed by subjecting these 
muteins to heparin-affinitiy chromatography, as discussed in Chapter 5. 
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Chapter 5: Heparin-binding studies 
 
5.1 Introduction 
 
As described in Chapter 4, the efforts made to express the BMP-7 
K419A/R421A and ΔS296-R327 mutants did not result in the production of detectable 
levels of protein. However, the Centocor mutants discussed in section 4.2.13 
(Swencki-Underwood et al, 2008) were both expressed and supplied in sufficient 
quantities that their heparin-binding properties could be investigated. As explained 
previously, these proteins contained similar mutations to those attempted in this study, 
which were located in the same regions of interest. To study the heparin-binding 
properties of the wildtype and mutant BMP-7 proteins, heparin affinity 
chromatography was employed in this chapter, just as it was previously to uncover the 
heparin-binding site of GDNF (Alfano et al., 2007). The BMP-7 protein variants were 
applied to heparin columns at physiological ionic strength and pH, and the relative 
affinities of the protein-heparin interactions were determined by the concentration of 
NaCl required to elute the proteins from the columns. 
 
5.2 Results and discussion 
 
5.2.1 Heparin affinity chromatography 
 
5.2.1.1 Heparin affinity chromatography of wildtype recombinant human BMP-
7 
 
The CHO-K1 cells that were transfected to express the Centocor mutants 
secreted the recombinant proteins into CD CHO medium (Invitrogen). CD CHO 
medium is a chemically defined serum-free and protein-free medium, which also 
contains no peptide components of animal, plant or synthetic origin. The clarified 
supernatants containing the mutant proteins (section 4.2.13) were therefore deemed to 
be of a sufficient quality to be used directly in initial heparin affinity chromatography 
experiments after dialysis, without prior purification. Any mutant that demonstrated a 
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favourable reduction in its ability to bind heparin after the initial screen could then be 
purified and investigated further. 
Before being able to determine the affect, if any, that the mutations made by 
Centocor had on the heparin-binding ability of BMP-7, it was first necessary to 
determine the NaCl concentration at which the wildtype protein eluted from heparin 
affinity columns. For consistency, the commercially produced wildtype recombinant 
human BMP-7 protein (R&D Systems) was diluted in conditioned CD CHO medium 
taken from cells that were transfected with the empty pCEP4 vector alone. This BMP-
7-containing supernatant was then dialysed against PBS to ensure that the protein was 
applied to the heparin affinity column at physiological pH and ionic strength. After 
equilibrating a 1 ml Heparin HiTrap HP column (GE Healthcare UK Ltd) with PBS, 
500 ng of the wildtype BMP-7 protein was applied to the column in a 5 ml volume, at 
a flow rate of 0.5 ml/min. The column was washed with 5 ml of PBS, and the protein 
was eluted by applying a linear gradient of NaCl in PBS (0.14 to 1.2 M). The whole 
procedure was conducted at 4 ºC and 1 ml fractions were collected throughout. The 
BMP-7 content of the fractions was determined by ELISA, and their NaCl 
concentration was determined by carrying out conductivity measurements and 
standardising against a series of solutions of known concentration. 
With the exception of a minor pass-through peak, it can be seen in Figure 5.1 
that the wildtype recombinant human BMP-7 bound to the heparin column at 
physiological pH and ionic strength. To elute the protein from the column, 
approximately 0.5 M NaCl was required. This represented a modest affinity ionic 
interaction with heparin when compared with the higher affinity interactions observed 
for the GDNF-family ligands, which required at least 0.8 M NaCl for elution from the 
column (Alfano et al., 2007). 
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Figure 5.1 Heparin-affinity chromatography of the wildtype BMP-7 protein 
500 ng of wildtype recombinant human BMP-7 (R&D Systems) was applied to a 
Heparin HiTrap HP column (GE Healthcare UK Ltd) in 5 ml of conditioned CD CHO 
medium at physiological pH and ionic strength. The column was washed with 5 ml of 
PBS and the bound protein was eluted by applying a linear gradient of NaCl in PBS. 1 
ml fractions were collected throughout. The BMP-7 content of the fractions was 
determined by ELISA and their NaCl concentration was determined by carrying out 
conductivity measurements and standardising against a series of solutions of known 
concentration. It can be seen that approximately 0.5 M NaCl was required to elute the 
wildtype BMP-7 protein from the column. 
 
 
 
5.2.1.2 Heparin affinity chromatography of the Centocor 3255 BMP-7 mutant 
 
Having established the relative affinity of the wildtype BMP-7 protein for 
heparin, attention was diverted to investigating the heparin-binding properties of the 
Centocor mutants. The first of these mutants to be studied was that denoted 3255, 
containing the C-terminal substitutions R421E/N422D/R426E. From the molecular 
docking simulations carried out in Chapter 3, the amino acids R421 and R426 were 
two of the three C-terminal residues that were predicted to be important for heparin-
binding. If the predicted models of the interaction between BMP-7 and HS/heparin 
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presented in Chapter 3 were correct, it would be expected that a pronounced decrease 
would be observed in the heparin-binding affinity of the BMP-7 3255 mutant, 
compared to that of the wildtype protein. To test this hypothesis, heparin affinity 
chromatography was again utilised in the same way as described in section 5.2.1.1 
above. 
The clarified supernatant containing the 3255 mutant protein was dialysed 
against PBS, and a volume containing 500 ng of the mutant protein was applied to a 1 
ml Heparin HiTrap HP column. As shown in Figure 5.2, the result obtained was not as 
hypothesised. Like the wildtype BMP-7 protein, the 3255 mutant also required 
approximately 0.5 M NaCl for elution from the column, indicating that its heparin-
binding affinity was unaltered. As the 3255 mutant was missing half of the basic 
residues in the C-terminal region of the BMP-7 protein - and two-thirds of those 
predicted to be key for binding to heparin - this data suggests that the heparin-binding 
site of BMP-7 is not located in the C-terminal region. This meant that the prediction 
made by the molecular docking simulations was incorrect, most probably resulting 
from the limitation of the missing N-terminus in the available BMP-7 crystal 
structures. Based on the uneven distribution of basic residues in the mature BMP-7 
protein sequence, and the lack of any alternative clusters of positive charge in the 
folded three-dimensional structure, it is likely that the heparin-binding site of BMP-7 
lies within its N-terminal region. As mentioned previously, this region contains 
approximately half of the basic residues found within the mature BMP-7 protein. 
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Figure 5.2 Heparin-affinity chromatography of the Centocor 3255 mutant BMP-
7 protein 
500 ng of the Centocor 3255 mutant BMP-7 protein was applied to a Heparin HiTrap 
HP column (GE Healthcare UK Ltd) in 5 ml of conditioned CD CHO medium. The 
column was washed with 5 ml of PBS and the bound protein was eluted by applying a 
linear gradient of NaCl in PBS. 1 ml fractions were collected throughout. It can be 
seen that approximately 0.5 M NaCl was required to elute the 3255 mutant BMP-7 
protein from the column. 
 
 
 
5.2.1.3 Heparin affinity chromatography of the Centocor 3281 BMP-7 mutant 
 
As explained in section 5.2.1.2, it appears likely that the heparin-binding site 
of BMP-7 is situated in its unstructured N-terminal sequence. However, as detectable 
levels of the BMP-7 ΔS296-R327 mutant could not be produced, it was not possible to 
study the heparin-binding ability of the whole N-terminal region of BMP-7 
experimentally. Even still, the BMP-7 3281 mutant provided by Centocor contained 
two N-terminal mutations of interest; the basic arginine residues at positions 299 and 
314 had been substituted with serine residues (R299S/R314S). Either one, or both, of 
these residues may potentially play a part in the heparin-binding site of BMP-7. 
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Heparin affinity chromatography was carried out to determine if these two 
point mutations had any affect on the heparin-binding affinity of the BMP-7 protein. 
The supernatant containing the 3281 mutant was dialysed against PBS, and 500 ng of 
the mutant protein was applied to a 1 ml heparin column. It can be seen in Figure 5.3 
that the R299S/R314S double substitution failed to alter the heparin-binding affinity 
of BMP-7. Again, approximately 0.5 M NaCl was required for its elution from the 
column. Despite this finding, it remains possible that the heparin-binding site of BMP-
7 is situated in its N-terminal region. This is because there are a number of alternative 
basic residues located within this region, which also have the potential to form a 
suitable binding site. 
 
 
 
 
 
 
Figure 5.3 Heparin-affinity chromatography of the Centocor 3281 mutant BMP-
7 protein 
500 ng of the Centocor 3281 mutant BMP-7 protein was applied to a Heparin HiTrap 
HP column (GE Healthcare UK Ltd) in 5 ml of conditioned CD CHO medium. The 
column was washed with 5 ml of PBS and the bound protein was eluted by applying a 
linear gradient of NaCl in PBS. 1 ml fractions were collected throughout. It can be 
seen that approximately 0.5 M NaCl was required to elute the 3281 mutant BMP-7 
protein from the column. 
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5.2.1.4 Heparin affinity chromatography of the Centocor 3267 BMP-7 mutant 
 
Although neither the Centocor 3255 mutant nor the 3281 mutant individually 
demonstrated a reduction in their affinities for heparin compared to the wildtype 
protein, it remained to be seen if combining the mutations would have any affect. 
Therefore, the heparin-binding ability of the Centocor 3267 BMP-7 mutant 
(R299S/R314S, R421E/N422D/R426E) was studied using heparin affinity 
chromatography. 
Figure 5.4 shows that combining the N-and C-terminal mutations also had no 
affect on the heparin-binding affinity of BMP-7. The 3267 mutant eluted from the 
column with a NaCl concentration of approximately 0.5 M, just as the wildtype 
protein and other mutants had previously. However, as the N-terminal mutations in 
the 3267 mutant were by no means comprehensive, the possibility of a N-terminal or 
cooperative N- and C-terminal heparin-binding site cannot be ruled out completely. 
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Figure 5.4 Heparin-affinity chromatography of the Centocor 3267 mutant BMP-
7 protein 
500 ng of the Centocor 3267 mutant BMP-7 protein was applied to a Heparin HiTrap 
HP column (GE Healthcare UK Ltd) in 5 ml of conditioned CD CHO medium. The 
column was washed with 5 ml of PBS and the bound protein was eluted by applying a 
linear gradient of NaCl in PBS. 1 ml fractions were collected throughout. It can be 
seen that approximately 0.5 M NaCl was required to elute the 3267 mutant BMP-7 
protein from the column. 
 
 
 
5.2.1.5 Further investigation of the heparin column elution profiles of the BMP-
7 protein variants 
 
Although the Centocor mutants failed to demonstrate any change in their 
heparin-binding affinities compared to the wildtype BMP-7 protein, some small 
differences were observed between the column elution profiles that were obtained 
whilst carrying out this investigation. In particular, it can be seen that in the cases of 
the wildtype and Centocor 3267 mutant proteins (Figures 5.1 and 5.4 respectively), 
the minor pass-through peaks were more pronounced in relation to the major peak 
when compared to the profiles of the other BMP-7 variants. Also, following the minor 
peak in the profile of the 3267 mutant, the levels of BMP-7 in the fractions preceding 
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the major peak remained higher than those in the other profiles. These findings were 
consistently true and were observed irrespective of the protein loading (data not 
shown). It was thought that the pronounced peaks consistently obtained for the 
unbound BMP-7 protein might suggest that two forms of the protein were in 
existence. If this was the case, the increased level of protein between the two peaks in 
the chromatographic profile of the 3267 mutant might represent an intermediate state. 
To test this theory, some further investigation was conducted. The component 
fractions from both the minor and major peak in the profile of the BMP-7 3267 mutant 
were pooled separately and dialysed against PBS. This ensured that the eluates were 
returned to physiological ionic strength and pH. The two fraction pools were then 
applied to separate heparin columns, and eluted by applying a linear gradient of NaCl 
in PBS as before. The same procedure was also followed using the component 
fractions from both peaks of the profile of the wildtype BMP-7 protein. The eluted 
fractions were then assayed for BMP-7 content by ELISA. 
When the pooled fractions that formed the major peak of the 3267 mutant were 
re-subjected to heparin affinity chromatography, the same pattern of results was seen 
as previously described in section 5.2.1.4 above. It can be seen in Figure 5.5 that two 
peaks were produced once again, with the minor peak representing the unbound 
protein. The BMP-7 protein in the major peak eluted as before at a NaCl concentration 
of approximately 0.5 M. Furthermore, when the fraction pool that formed the 
previously observed minor peak of the 3267 mutant was applied to another heparin 
column, only a single peak was obtained (Figure 5.6). This peak solely contained 
material that had passed through the column without binding, as did the minor peak in 
Figure 5.4 that the pooled sample was obtained from. However, these findings were 
not unique to the 3267 mutant, as exactly the same results were obtained when the 
pooled fractions from the previous wildtype BMP-7 profile were re-subjected to 
heparin affinity chromatography (data not shown). 
Together, these data show that at some point during the dialysis or heparin 
chromatography procedures, a portion of the BMP-7 protein underwent a 
transformation. The nature of this transformation was not clear but it was 
unidirectional and resulted in the protein being unable to bind to heparin. As the 
resulting BMP-7 protein could still be detected using two independent monoclonal 
antibodies in the sandwich ELISA assay, it is unlikely that it had been proteolytically 
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fragmented. Instead, one possibility is that the protein had become structurally 
denatured during the process, with the degree of denaturation varying from one BMP-
7 variant to another. Another possibility, although it is purely speculative at this stage, 
is that a small component of the protein encompassing the heparin-binding site had 
been clipped off by a protease, leaving the rest of the protein intact. As the heparin 
affinity chromatography experiments suggest that the heparin-binding site of BMP-7 
probably lies within its unstructured N-terminal extension, this explanation is quite 
feasible but would require further investigation before any firm conclusions could be 
made. 
 
 
 
 
 
 
Figure 5.5 Heparin-affinity chromatography of the BMP-7 3267 mutant pooled 
major peak 
The component fractions of the major peak in the elution profile of the BMP-7 3267 
mutant were pooled and dialysed against PBS. The pooled fractions were then applied 
to a Heparin HiTrap HP column (GE Healthcare UK Ltd). The column was washed 
with 5 ml of PBS and the bound protein was eluted by applying a linear gradient of 
NaCl in PBS. 1 ml fractions were collected throughout. It can be seen that the 3267 
mutant BMP-7 protein that was present in the previous major peak once again eluted 
from the column with approximately 0.5 M NaCl. 
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Figure 5.6 Heparin-affinity chromatography of the BMP-7 3267 mutant pooled 
minor peak 
The component fractions of the minor peak in the elution profile of the BMP-7 3267 
mutant were pooled and dialysed against PBS. The pooled fractions were then applied 
to a Heparin HiTrap HP column (GE Healthcare UK Ltd). The column was washed 
with 5 ml of PBS and the bound protein was eluted by applying a linear gradient of 
NaCl in PBS. 1 ml fractions were collected throughout. It can be seen that the 3267 
mutant BMP-7 protein that was present in the previous minor peak once again passed 
through the heparin column without binding. 
 
 
 
5.2.2 Protection of recombinant human BMP-7 from proteolysis by 
Endoproteinase Lys-C 
 
It has been previously found that binding to heparin can serve to protect a 
protein from proteolysis (Lortat-Jacob et al., 1996). This can be demonstrated using 
Endoproteinase Lys-C (Mummery and Rider, 2000; Mummery et al., 2007; Rickard et 
al., 2003). Lys-C is a serine endopeptidase isolated from Lysobacter enzymogenes, 
which hydrolyses peptide bonds specifically at the carboxyl side of lysine residues. 
Proteins generally bind to heparin via the basic side chains of lysine and arginine 
residues. When lysine residues are involved in the interaction, they become masked 
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by the heparin and inaccessible to Lys-C, therefore preventing proteolysis occurring. 
An experiment was carried out to determine if this was also true for the BMP-7 
protein, and to demonstrate the binding of BMP-7 to heparin by yet another method 
independent of the aforementioned heparin affinity chromatography and previous 
heparin-binding ELISA (C. Rider et al, unpublished data). 
25 µl reaction mixtures were assembled containing 50 ng recombinant human 
BMP-7 (R & D Systems) in the presence and absence of 5 µg/ml heparin (Sigma). 
The mixtures were incubated for 30 minutes at room temperature before 1 ng 
Endoproteinase Lys-C (Sigma) was added to each tube. The digestion mixtures were 
then incubated in a 37 ºC water bath for the specified time, after which Laemmli 
sample buffer was added and they were boiled immediately. Following digestion, the 
samples were analysed by carrying out SDS-PAGE and Western blotting. 
Figure 5.7 shows that under these conditions, the recombinant human BMP-7 
protein was almost completely degraded in the absence of heparin. This was 
demonstrated by an almost complete loss of BMP-7 immunoreactivity after a 120 
minute digestion with Lys-C, with a decrease being apparent after only 30 minutes. 
BMP-7 peptide fragments were not detectable, suggesting that the epitopes necessary 
for detection were removed upon cleavage. In the presence of heparin, very little 
proteolysis of the BMP-7 protein occurred, if any, over the same time interval. This 
indicated that by binding to heparin, the BMP-7 protein was protected from digestion 
by Lys-C. It is quite possible that by interacting with heparin-related 
glycosaminoglycans, the BMP-7 protein might be similarly protected from proteolytic 
degradation in vivo.
 172 
 
 
 
 
Figure 5.7 Digestion of human BMP-7 with endoproteinase Lys-C 
In the presence and absence of 5 µg/ml heparin (Sigma), 50 ng quantities of the 
recombinant human BMP-7 protein (R&D Systems) were subjected to proteolytic 
digestion with endoproteinase Lys-C for the indicated time intervals. Following 
digestion, the samples were analysed by carrying out SDS-PAGE and Western 
blotting. It can be seen that in the absence of heparin, the BMP-7 protein was almost 
completely degraded after 120 minutes. In the presence of heparin, the BMP-7 was 
protected from proteolysis by endoproteinase Lys-C. 
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Chapter 6: General discussion 
 
Prior to commencing this investigation, it was clear that BMPs -2 and -4 bind 
to HS and heparin GAGs via a small cluster of basic amino acids in their short N-
terminal extensions (Ruppert et al., 1996; Ohkawara et al., 2002). It had also been 
demonstrated that BMP-7 has the ability to bind to HS/heparin (Irie et al., 2003; Rider 
et al., unpublished data). However, BMP-7 belongs to a different BMP sub-group 
from BMPs -2 and -4 and it differs from them considerably in its N-terminal region. 
Consequently, it remained unclear as to where its HS/heparin-binding site is situated. 
The aim of this study was therefore to determine the location of the HS/heparin-
binding site of human BMP-7. This goal was approached using a combination of 
predictive computational molecular docking calculations, site-directed mutagenesis 
techniques and heparin-affinity chromatography. 
The findings from a series of predictive docking calculations that were carried 
out using published BMP-7 and heparin structures suggested that BMP-7 binds to 
HS/heparin through three basic residues close to the C-terminal ends of each of its 
constituent monomers (K419, R421 and R426). Although difficulties were 
encountered in expressing both wildtype and mutant BMP-7 protein variants 
(discussed later on in this chapter), a mutein that was suitable for testing the validity 
of the above prediction experimentally was kindly provided by Centocor Inc (PA, 
USA). In this mutein, two of the three C-terminal basic residues that had been 
predicted to play a key part in BMP-7-HS/heparin interactions (R421 and R426) had 
been removed from each monomer by substituting them for glutamic acid residues, 
leaving only K419 unchanged. In addition, N422 had been substituted for an aspartic 
acid residue. Based on the aforementioned prediction, it was expected that when this 
particular BMP-7 mutant was subjected to heparin-affinity chromatography it would 
either not bind to the heparin column or its heparin-binding affinity would be 
markedly reduced. This is because the two remaining K419 residues (one on each 
monomer) would not be sufficient to bind a HS/heparin chain either independently or 
in cooperation with each other. Also, it was thought likely that the introduction of 
acidic residues in place of the basic arginine residues (and N422) would alter the 
overall charge of this particular stretch of C-terminal sequence and perhaps even serve 
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to repel like-charged acidic HS/heparin chains. One would expect either of these 
occurrences to have a negative effect on HS/heparin-binding affinity. However, the 
result obtained from this experiment was not as expected. Instead, the removal of 
R421 and R426 from each BMP-7 monomer was demonstrated to have no affect on 
the heparin-binding affinity of BMP-7. 
The fact that the removal of R421 and R426 failed to decrease the heparin-
binding affinity of BMP-7 whatsoever indicates that these residues do not play a 
critical part in BMP-7-HS/heparin interactions. This finding (and the demonstration 
that the introduction of acidic residues was without effect) also suggests that the 
prediction that was made by the docking calculations was incorrect and casts 
considerable doubt on the hypothesis that the key HS/heparin-binding regions of the 
BMP-7 protein are situated close to the C-terminal ends of its two constituent 
monomers. Even so, at this point in time, no firm conclusions can be made regarding 
this matter. This is because the interpretation of the findings described above is 
complicated by the fact that two C-terminal K418 basic residues also remain in the 
R421E/N422D/R426E mutant. It was explained in Chapter 3 that the results from the 
molecular docking calculations suggested that the basic side chain of K418 is not 
oriented in a way that would be conducive to it cooperating with K419, R421 and 
R426 to bind a HS/heparin chain. However, there are two reasons why one cannot rule 
out the possibility that K418 may play a part in BMP-7-HS/heparin interactions based 
on these predictions. Firstly, experimental data now appears to show that the 
predictions made by the docking calculations are incorrect and cannot be relied upon. 
Secondly, during the docking process, the BMP-7 protein entity was treated as a rigid 
body with no flexibility in the structure being allowed for. This was due to a limitation 
of the Autodock 2.4 software that was used to carry out the calculations and was a 
reason why it was always the case that the predictions made by the docking 
predictions would need to be treated with caution. It therefore remains a possibility 
that there may be enough flexibility in the BMP-7 protein structure for the side chains 
of the two K418/K419 residue pairs (one pair on each monomer) to cooperate in 
binding a HS/heparin chain between them. Consequently, before any firm conclusions 
can be made about the role that the C-termini of BMP-7 may or may not play in BMP-
7-HS/heparin interactions, it needs to be determined whether or not BMP-7 will still 
bind to HS/heparin with the same relative affinity after the two K418/K419 residue 
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pairs that remain in the R421E/R426E mutant are also removed. This will require 
further site-directed mutagenesis studies to be carried out. 
Because the results obtained during this investigation appear to show that the 
HS/heparin-binding ability of BMP-7 is unlikely to be solely dependent on the 
predicted C-terminal basic residues, one may hypothesise that the key HS/heparin-
binding residues are located within either or both of the two alternative basic residue 
clusters that BMP-7 possesses. As explained previously in Chapter 1, these clusters 
are situated in the N-terminal extension of BMP-7 and the sequence stretch that lies 
immediately downstream of it. Because other closely related BMP family and TGF-β 
superfamily members, such as BMPs -2 and -4 (Ruppert et al., 1996; Ohkawara et al., 
2002) and GDNF (Alfano et al., 2007) have already been shown to bind to HS/heparin 
via basic residues in their N-terminal extensions, it would not be completely 
unexpected for BMP-7 to do the same, albeit through basic residues in different 
positions within these sequences. There is also still a possibility that residues from 
these N-terminal clusters could cooperate with some of the C-terminal basic residues 
to bind HS/heparin chains. Unfortunately, due to the protein expression problems that 
were encountered during this investigation, suitable mutants were not available to test 
these hypotheses comprehensively. As a result, further investigation is required in 
order to fulfill the aim of this project. 
The inconsistency between the results obtained from the computational 
docking predictions and the experimental data seems to have been caused by a 
limitation of all of the BMP-7 structures that have been published to date and which 
were used in these docking calculations. These structures are missing the majority of 
their N-terminal extensions. It is likely that this component of the structure remained 
unresolved as a result of it being disordered (Griffith et al., 1996; Greenwald et al., 
2003). Because this missing region contains almost half of the fifteen basic residues 
that can be found within the mature BMP-7 protein, a number of potentially important 
N-terminal basic residues could not be taken into consideration during the molecular 
docking calculations. It was therefore not possible to predict the extent to which the 
missing residues are (or are not) involved in BMP-7-HS/heparin interactions. As a 
result, it appears that the Autodock 2.4 software incorrectly predicted that the C-
terminal basic residues of BMP-7 would form the most suitable site for a HS/heparin 
chain to bind to. 
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As mentioned above and outlined in detail in Chapter 4, a number of problems 
were encountered during this investigation when attempting to express both the 
wildtype and mutant recombinant human BMP-7 proteins. Firstly, difficulties were 
experienced when trying to produce the wildtype recombinant human BMP-7 using a 
CHO cell expression system. These problems appeared to be caused not only by 
complexities in the BMP-7 protein structure (Swencki-Underwood et al., 2008) but 
also by the presence of a weak translation initiation sequence in the BMP-7 mRNA 
transcript. These difficulties were overcome by replacing the native BMP-7 translation 
initiation sequence with an optimised Kozak consensus sequence, and by switching to 
another CHO cell-based expression system in which transfections were carried out on 
a larger-scale. 
Secondly, problems were encountered when attempting to express BMP-7 
proteins in Sf9 insect cells using the Invitrogen Bac-to-Bac Baculovirus Expression 
System. This was surprising as another close TGF-β superfamily member, GDNF, had 
previously expressed well using this system in our own laboratory. Without carrying 
out a full investigation into this matter, it is not possible to draw any firm conclusions 
on the reasons why detectable levels of the BMP-7 protein were not produced by the 
Sf9 cells. However, a key difference between GDNF and BMP-7 is that while GDNF 
contains a short signal peptide upstream of its mature protein domain, BMP-7 contains 
both a signal peptide and a large pro-protein sequence. It is possible that the additional 
bulk (compared to GDNF) and the extra processing step that is required to liberate the 
mature domain of BMP-7 from its pro-protein region caused complications that 
prevented it from expressing properly and perhaps promoted its breakdown instead. It 
is also plausible to suggest that the structural complexities highlighted by Centocor 
Inc. (Swencki-Underwood et al., 2008) may have been at least partly to blame for 
these difficulties, as they were when using mammalian cells. 
Thirdly, great difficulty was experienced when trying to express two different 
mutant BMP-7 proteins. One of these mutants contained a double substitution close to 
its C-terminus (K419A/R421A), and the other had a large section of sequence 
removed from its N-terminal extension (ΔS296-R327). The reason that detectable 
levels of these mutant proteins could not be expressed is still unclear. Even so, reverse 
transcription PCR experiments have provided us with some insight into this matter. 
These experiments showed that the mRNA transcripts that encoded for these mutant 
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proteins were present in the cells. It therefore appears that any problems arose during 
their translation or post-translational processing/modification. Further insight into 
some potential causes of the problems encountered with both of the aforementioned 
mutants can be gained from the BMP-7 expression study that was carried out by 
Swencki-Underwood et al. (2008). 
In contrast to the findings from this study, Swencki-Underwood et al. (2008) 
demonstrated that the expression level of BMP-7 increased when substitution 
mutations were introduced into the regions of the protein that lie close to the C-
terminal ends of each of its constituent monomers. However, Swencki-Underwood 
and colleagues substituted different combinations of residues compared to the residues 
that were substituted in our own laboratory (R421, N422 and R426 rather than K419 
and R421). Also, the replacement amino acids that Swencki-Underwood and 
colleagues inserted in place of those that were removed were either aspartic acid or 
glutamic acid residues rather than alanine, which has a smaller, neutral side chain. 
Based on this comparison of the findings from these two studies alone, it appears that 
the problems that were encountered when trying to express detectable levels of the 
K419A/R421A mutant in our laboratory may have been caused by one or more of the 
following factors: the positions/combinations of the substituted residues, the chemical 
nature of the replacement residues, and the size of the side chains of the replacement 
residues. Swencki-Underwood et al. (2008) have also shed some light on the potential 
reasons why detectable levels of the ΔS296-R327 N-terminal deletion mutant could 
not be expressed by demonstrating that mutants containing shorter N-terminal 
deletions (7-23 residues) were poorly expressed due to both processing and secretion 
problems. Based on this finding, it is apparent that deletion mutations should be 
avoided when carrying out any future mutagenesis studies that necessitate the 
expression of BMP-7 protein variants. 
Despite the difficulties that have been experienced during this investigation, 
the use of site-directed mutagenesis techniques may still prove to be important during 
the ongoing study of BMP-7-HS/heparin interactions. Not only will a site-directed 
mutagenesis approach enable the location of the HS/heparin-binding site of BMP-7 to 
be resolved, but it will also yield non-HS/heparin-binding mutant proteins that can be 
used in functional studies that may help to determine the biological significance of 
these interactions. However, using such an approach to test the effect that all the 
 178 
possible combinations of basic residue substitutions have on the HS/heparin-binding 
ability of the BMP-7 protein is likely to be a laborious task. Therefore, alternative 
approaches must also be considered. 
One idea for an alternative approach that could be employed to identify the 
key HS/heparin-binding residues of the BMP-7 protein arises from the results that 
were obtained from studies conducted by Ruppert et al. (1996) and Choi et al. (2010). 
As mentioned previously, Ruppert and colleagues demonstrated that the HS/heparin-
binding site of BMP-2 is situated close to its N-terminus, residing within its flexible 
N-terminal extension. In addition, their data suggests that a peptide containing the first 
17 residues of the BMP-2 protein, which includes its complete N-terminal extension 
and key HS/heparin-binding residues, is able to bind to heparin independently of the 
rest of the mature protein. Similarly, Choi et al. (2010) have recently shown that a 
peptide containing ten amino acids from the N-terminal region of BMP-4, which 
included its key basic HS/heparin-binding residues (Ohkawara et al., 2002), is able to 
bind to HS/heparin. As it now appears that the HS/heparin-binding site of BMP-7 is 
also likely to be situated within or immediately downstream of its flexible N-terminal 
extension, there is a possibility that a peptide-based approach could be employed in 
the future to identify its key HS/heparin-binding residues. 
Before commencing a full peptide-based investigation, it would first be 
necessary to determine if a peptide containing the N-terminal sequence of BMP-7 will 
bind to HS/heparin. This could be achieved by synthesising this peptide and 
subjecting it to heparin-affinity column chromatography (as described in Chapters 2 
and 5). To aid the detection of the peptide in fractions following its elution from 
heparin columns, a fluorescent label could be added during its synthesis. If it were to 
be found that this wildtype peptide does indeed bind to heparin, a number of mutant 
peptides that contain different deletions or basic residue substitutions could then be 
produced, and their heparin-binding abilities could be determined in a similar manner. 
One would expect any mutant peptides that were missing key HS/heparin-binding 
basic residues to exhibit a reduction in their heparin-binding affinity compared to that 
of the wildtype peptide. 
However, this approach is by no means guaranteed to be successful and has a 
number of potential limitations. Firstly, if the BMP-7 protein has a combined N- and 
C-terminal HS/heparin-binding site, attempts to identify its key HS/heparin-binding 
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residues using N-terminal peptides alone will either be unsuccessful or only partially 
informative. Secondly, it is possible that the binding of BMP-7 to HS/heparin chains 
may require the participation of both its N-terminal extensions (one from each 
monomer). If this is the case, the two N-terminal extensions may need to be held in 
close proximity and/or in an appropriate orientation by the rest of the mature protein 
structure. Under such circumstances, this approach of investigating the binding of free 
peptides to immobilised heparin chains will be unsuitable. Thirdly, this approach 
could potentially be very expensive. This is because peptides can be costly and there 
are a wide variety of possible deletions and combinations of basic residue 
substitutions that can be made in this N-terminal region. 
During the time in which this investigation has been underway, a limited 
number of alternative studies relating to BMP-HS/heparin interactions have been 
conducted. These studies have been confined to the Dpp-type BMPs, and the findings 
from them have generally been in agreement with those reported by Ruppert et al. 
(1996) and Takada et al. (2003). As explained previously (Chapter 1, section 1.4), 
Ruppert, Takada and colleagues demonstrated that the addition of exogenous heparin 
potentiated the activity of BMPs -2 and -4 in two different in vitro cell-based assays. 
Takada et al. (2003) also showed that the addition of exogenous heparin reduced the 
amount of BMP-2 that accumulated in the cell layer and prolonged both its half-life 
and activity in the culture media. Since then, similar findings have been published by 
Fisher et al. (2006), Zhao et al. (2006) and Jiao et al. (2007). Furthermore, Jiao et al. 
(2007) reported that an increase in BMP-2 activity was observed when the 
extracellular surfaces of C2C12 cells were depleted of HS by heparinase III treatment, 
or when the sulphation of cell surface HS chains was inhibited by chlorate treatment. 
In another study, Hu et al. (2009) have shown that in the lungs of knockout mice 
lacking NDST1 - one of the N-acetylglucosamine N-deacetylase/N-sulfotransferase 
enzymes that participates in synthesising HS chains - the binding of BMPs -2 and -4 
to endogenous cell surface HS was decreased. As a consequence, the internalisation of 
these proteins was impaired and their signaling activity was enhanced. This caused 
abnormalities during lung development due to defective cell differentiation and an 
increase in cell proliferation. More recently, Johnson et al. (2011) have demonstrated 
that when delivered precomplexed with heparin, the ability of BMP-2 to promote the 
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repair of challenging bone defects and restore long bone mechanical function in vivo 
was increased. 
Based on the collection of findings described above, it would appear that 
endogenous cell surface HS GAGs modulate the signaling activities of BMPs -2 and -
4 by limiting their effective extracellular concentration, and that they do this by 
sequestering them close to the cell surface and mediating their internalisation. If this is 
the case, it is likely that exogenous heparin potentiates the activity of BMPs -2 and -4 
by competitively inhibiting their binding to endogenous HS, therefore preventing 
them from being internalised, and instead, maintaining them in the extracellular 
environment. However, at the present time, it is not possible to draw any firm 
conclusions as to the role that HS/heparin GAGs play in the cellular processes that 
take place under the control of BMPs -2 and -4. This is because there have been some 
inconsistencies in the published findings, which may or may not have occurred as a 
result of the different experimental approaches and conditions that have been 
employed. For example, in contrast to the results described above, Khan et al. (2008) 
reported that the addition of exogenous heparin had a negative effect on BMP-4 
signaling in human osteosarcoma SaOS-2 cells. Also, Kuo et al. (2010) demonstrated 
that the treatment of C2C12 and PC12 cells with heparitinase or chlorate markedly 
reduced their response to BMP-2 or BMP-4 stimulation. In addition, Kuo et al. (2010) 
have provided evidence to suggest that cell surface HS may serve to promote the 
signaling activities of BMPs -2 and -4 by acting as a co-receptor and catalysing the 
formation of their signaling complexes. Specifically, the experimental data that has 
been published by Kuo and colleagues indicates that HS might fulfill this role by 
enhancing the recruitment of type II receptor subunits to the tetrameric BMP-type I 
receptor assemblies that form initially. 
Unlike the interactions that take place between the Dpp-type BMPs and 
HS/heparin, BMP-7-HS/heparin interactions have remained little studied and there 
have been no additional publications relating to them and their biological significance 
since this investigation commenced. Even so, it was explained previously in section 
1.4 that the findings from in vitro studies that were performed in both our own 
laboratory (unpublished data) and that of Irie et al. (2003) have shown that the 
response of C2C12 and ROS 17/2.8 cells to BMP-7 stimulation was greatly reduced in 
the absence of cell surface HS or in the presence of exogenous heparin. Irie et al. 
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(2003) also showed that the binding of BMP-7 to the surfaces of ROS 17/2.8 cells was 
markedly decreased when the cells were treated with heparitinase or chlorate. Based 
on these findings, it appears that cell surface HS plays a part in BMP-7-mediated 
processes, although the exact function of HS in these processes remains unclear. It is 
possible that HS GAGs may facilitate BMP-7 signaling by sequestering the BMP-7 
protein close to the cell surface where its transmembrane receptors are situated, 
therefore increasing the chance of ligand-receptor interactions taking place. Irie and 
colleagues have also suggested that HS may catalyse or stabilise BMP-7-receptor 
interactions by directly binding to both BMP-7 and its receptor(s). In order for BMP-7 
to simultaneously interact with its receptor(s) and HS without any steric obstruction 
occurring, the HS/heparin-binding site(s) of BMP-7 would need to be independent of, 
and perhaps distant from, its receptor binding site(s), which are located in the wrist 
and knuckle regions of the cystine-knot domains of each BMP-7 monomer (Chapter 1, 
section 1.1.6). It is not yet clear whether this is the case or not, but as the results from 
this study now suggest that BMP-7 is likely to interact with HS/heparin via basic 
residues in its long, flexible N-terminal sequences, which could extend away from the 
cystine-knot domains of the structure, this is a feasible possibility and the formation of 
such complexes may be permitted. However, further investigation is required before 
any firm conclusions can be drawn on this matter. 
Overall, it can be said that the findings from this study and those described 
herein have furthered our understanding of BMP-HS/heparin interactions. It is now 
known that BMPs -2, -4 and -7 have the ability to interact with HS/heparin, and there 
is evidence to suggest that such interactions influence the activity of these BMPs. In 
addition, it has been demonstrated that BMPs -2 and -4 bind to HS/heparin via a small 
cluster of basic amino acids in their N-terminal regions. Furthermore, the results 
obtained from this investigation suggest that BMP-7 is also likely to bind to 
HS/heparin through basic residues in its N-terminal region. However, despite this 
progress, much work is still to be conducted and a great deal more to be learned 
before our understanding of these interactions is anything like the level of 
understanding that we already have of FGF-HS/heparin interactions and their 
biological significance. With this level of understanding, it should become apparent 
whether or not heparin mimetics have a part to play in therapeutic interventions that 
involve the application of recombinant BMPs. 
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